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Abstract  
Regulation of skeletal muscle development and regeneration is critical to all metazoans 
and also of clinical relevance as muscle wasting is manifested in a variety of disorders.  The 
events contributing to development and regeneration of skeletal muscle are primarily controlled 
by members of the myogenic regulatory factors (MRF) and myocyte enhancer factor 2 (MEF2) 
transcription factor families. Secondary factors also exert effects on myogenesis such as the 
activator protein 1 (AP-1) transcription factor which has a complex role in the differentiation 
process.  The AP-1 subunit Fra-2 has a role in skeletal muscle development and regeneration but 
it is less defined.  Here, the role of Fra-2 in skeletal myogenesis was investigated thereby 
extending the study of AP-1 in muscle.  It was determined that Fra-2 is regulated by the ERK 1/2 
MAPK pathway via phosphorylation at S320 which is important for Fra-2 protein stability.  Gain 
of function studies exploiting stability of Fra-2 achieved by phosphomimetic mutations impacted 
differentiation negatively.  Conversely, loss of function using siRNAs resulted in precocious 
differentiation suggesting an overall inhibitory role for Fra-2 in myogenic cells.  Intriguingly, it 
was observed that AP-1 is differentially expressed in a differentiated culture of C2C12 myogenic 
cells in that Fra-2 expression is restricted to monomucleated reserve cells and not in the 
differentiated myotubes.  Furthermore, it was determined that Fra-2 is expressed in Pax7 positive 
satellite cells in a single muscle fibre culture model and that it binds to the promoter of the 
mustn1 gene which, in turn, is also a novel satellite cell marker.  In conclusion, Fra-2 protein 
stability is regulated by phosphorylation of ERK 1/2 in myogenic cells and its expression in 
quiescent reserve cells and in satellite cells suggests a possible role for Fra-2 in maintaining the 
undifferentiated state in myogenic progenitor cells.  
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Chapter I: Review of literature 
 
Embryonic skeletal muscle development 
 
1.1 Somitogenesis and the development of skeletal muscle 
 
During embryogenesis, the process of skeletal muscle development termed 
myogenesis, is initiated in structures known as the somites (Buckingham, 2001; 
Buckingham et al. (2003)).  Somites are highly condensed blocks of paraxial mesoderm 
that form rostral to caudal and run parallel along either side of the neural tube during 
embryogenesis (figure 1).  As development progresses, signals from nearby tissues 
induce the somites to compartmentalize into the sclerotome and the dermomyotome 
(Buckingham et al., 2003; Pownall et al., 2002; Wagner et al., 2000).  The ventromedial 
section of the somite becomes the sclerotome due to the signaling molecule sonic 
hedgehog (Shh), which emanate from the notochord and neural tube.  The 
dermomyotome is specified by Wnt signaling from the overlying epidermis, which 
undergoes an epithelial to mesenchymal transition (EMT) when neurotrophin-3 (NT3) 
and Wnt1 signals are received from the neural tube.  Cells from the dorsal medial part 
of the somite migrate under the dermomyotome and form the myotome, which is 
specified by Wnt signals from the neural tube, epidermis and lateral plate mesoderm 
(figure 1, figure 2).  Cells of the dermomyotome responding to Wnt1 and Wnt3 have 
increased levels of Myf5, where as Wnt6 and Wnt7a increase MyoD expression. In 
contrast, BMP4 from the lateral mesoderm repress myogenic gene expression, thereby 
preventing premature activation on MyoD (figure 2) (Tajbakhsh et al., 1998).  Taken 
together, the expression of Shh, Wnts and BMP molecules control expansion and 
differentiation of skeletal muscle during development.  
Figure 1.  Compartmentalization of somites during embryogenesis.   
Epithelial somitic segmentation occurs from rostral to caudal and parallel to the neural 
tube and notochord in the developing embryo.  The somite gives rise to the  
dermomyotome and the sclerotome.  The myotome forms under the dermomyotome 
and gives rise to muscle progenitor cells. 
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Figure 2.  Signaling mediating myotome specification in the somites.   
Wnt1 and Wnt3 signaling from the neural tube induce Myf5 expression in the dorsal 
somite.  Wnt 4, 6, and 7a signaling from the dorsal ectoderm activates MyoD 
expression.  Inhibitory signals such as sonic hedgehog (Shh) from the notochord  
repress Myf5 expression.  Bone morphogenic protein 4 (BMP4) and fibroblast growth 
factors (FGF) from the lateral plate mesoderm inhibit expression of myogenic genes in 
the ventral somite. 
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These signaling events define specific sections within the somite, allowing for 
different tissue types to arise from somatic mesoderm.  Ultimately, the sclerotome will 
give rise to cartilage of vertebral column and ribs, while dermomyotome will become 
dermis, brown fat and trunk muscles.  The dermomyotome further divides into the 
dermatome and myotome, which can be further divided into epaxial and hypaxial 
sections that will generate muscle precursor cells.  Cells from the dorsal myotome 
become epaxial (back) muscles, while cells from the lateral myotome contribute to the 
hypaxial (limb) muscles (figure 3) (Pownall et al., 2002).  
 
1.2 Limb development in the embryo 
 
Limb formation is initiated in the somites when Pax3 expressing cells 
originating from the myotome delaminate and express c-met, a tyrosine kinase receptor 
for hepatocyte growth factor (HGF), which along with Lbx1 are expressed in migrating 
cells.  As migration continues, Pax3 and Six1 transcription factors activate the 
myogenic commitment genes MyoD and Myf5.  MyoD and Myf5 expressing cells are 
committed myogenic cells, termed myoblast, that continue to migrate to the limbs axial 
structures and dorsal regions of the embryo, where they proliferate, fuse and terminally 
differentiate into multinucleated myotubes that express differentiation factors, such as 
Myogenin (figure 4) (Buckingham et al., 2003; Molkentin and Olson, 1996b; Williams 
and Ordahl, 2000).  Terminally differentiated myotubes (myocytes) are the subunits of 
skeletal muscle and possesses the capacity to self repair following injury by 
reactivating the myogenic program in muscle stem cells, called satellite cells.  These 
events collectively encompass skeletal muscle differentiation, which is a complex 
process that has been extensively studied and has provided considerable insight into  
Figure 3.  Somite segmentation and tissue derivatives.   
Cells of the somite segregate into the dermatome , myotome and sclerotome.  Brown 
fat, dermis and truck muscles are derived from the dermatome.  The myotome gives 
rise to back (epaxial), body wall (hypaxial), and limb muscles.  The vertebrae and 
cartilage originate from the sclerotome. 
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Figure 4.  Muscle precursor cell migration and differentiation into limb muscles.  
Muscle precursor cells originating from the myotome express transcription factor 
Pax3.  Pax3 induces the expression of a receptor c-met as these cells delaminate.  The 
muscle precursor cells delaminate and begin to migrate.  Hepatocyte growth factor 
(HGF) activates the c-met receptor and induces expression of Lbx1.  During migration 
these cells proliferate and Pax3 and Six1 mediate expression of Myf5 and MyoD.  The 
muscle precursor cells reach the limb bud and express the myogenic determination 
factors Myf5 and MyoD which activate the expression of  the differentiation marker, 
Myogenin. 
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cell lineage commitment and differentiation (Buckingham et al., 2003; Gerber et al., 
1997).  
 
Molecular regulation of embryonic skeletal muscle development 
 
Skeletal muscle development is an intricate process regulated by skeletal muscle 
specific transcription factors in co-ordination with other non muscle specific regulatory 
proteins.  The mechanisms involved in these processes are well understood.  The 
regulatory molecules involved in generation of skeletal muscle can be divided into 
specification, determination, differentiation, and maintenance factors and will be 
discussed in the subsequent sections. 
 
2.1 Specification by Pax3 and Pax7 
 
The paired homeobox (Paxton et al.) transcription factors Pax3 and Pax7 are 
involved in lineage specification of skeletal muscle during development.  Pax3 is 
initially expressed in the presomitic paraxial mesoderm before segmentation of the 
somites; it is detected in the epithelial of the somites before being restricted to the 
dermomyotome.  Pax3 is required for hypaxial muscle of the trunk and for 
delamination and migration of myogenic precursor cells.  Cells in the dermomyotome 
that are specified by Pax3, give rise to Pax7 positive cells, which will become the 
embryonic and fetal muscle cells (Kuang et al., 2006).  Embryonic progenitor cells 
expressing Pax3 and Pax7 contribute to satellite cells in the trunk and limb muscles.  
Pax3 is expressed in both muscle and non-muscle cells and its regulation is determined 
by Six1 and Six 4, which are transcription factors that also regulate MyoD, MRF4 and 
Myogenin (Grifone et al., 2005).  Interestingly, only Pax3 is expressed in myogenic cell 
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migrating to limb structures.  Pax3 is important during embryonic myogenesis, since 
the Pax3 mutant mice called splotch do not express MyoD and lack limb muscles, due 
to lack of migration of muscle precursor cells (Franz and Kothary, 1993). 
Pax7 is involved in postnatal skeletal muscle growth and maintenance.  Pax7 is 
expressed in the somite, but is restricted to the dermomyotome and activates MyoD and 
Myf5.  The Pax7 knockout mouse was generated by Mansouri et al., (Mansouri et al., 
1996) and it was reported that these mice had abnormalities in facial structures (maxilla 
and nose) due to cephalic neural crest defects and could not detect any obvious effects 
on central nervous system and skeletal muscle.  However, Seale et al, 2000 connected 
Pax7 to skeletal muscle when they collaborated with the group that made the Pax7 
knockout and reported that Pax7 was important for satellite cell specification, since loss 
of Pax7 resulted in satellite cell depletion (Seale et al., 2000), demonstrating that Pax7 
knockout mice are deficient in satellite cells and cannot regenerate muscle post injury, 
thus Pax7 is more important for postnatal myogenesis. Interestingly, Olguin et al., 
suggested that the MRFs, namely Myogenin affects Pax7 levels and Pax7 effects MyoD 
stability, which suggest autoregulatory loop for Pax7 expression (Olguin et al., 2007). 
 
2.2 Determination and differentiation by the myogenic regulatory factors 
 
Skeletal myogenesis requires co-ordinated expression and regulation of the 
myogenic regulatory factors (MRFs), MyoD, Myf-5, MRF4 and Myogenin (Molkentin 
and Olson, 1996b; Pownall et al., 2002; Tapscott et al., 1990).  MyoD was the initial 
muscle specific transcription factor determined from a screen for transcripts 
upregulated in a fibroblast conversion assay (Lassar et al., 1986).  The MRFs are basic 
helix-loop-helix (bHLH) transcription factors that are temporally and spatially 
10 
 
expressed during embryonic development and are the primary regulators of muscle 
progenitor cell specification and differentiation (Bergstrom and Tapscott, 2001; 
Molkentin and Olson, 1996b; Pownall et al., 2002).  The MRFs contain a conserved 
muscle recognition site defined by ATK in the basic domain, which specifies activation 
of muscle specific genes (Davis et al., 1990).  During somitogenesis, MyoD and Myf5 
expression regulates commitment of pluripotent mesodermal cells into the myogenic 
lineage (Asakura et al., 1995; Pownall et al., 2002; Williams and Ordahl, 2000).  MRF4 
and Myogenin transcription is dependent on MyoD and Myf5 and are up-regulated 
during muscle differentiation and required in vivo for normal muscle differentiation 
(figure 5) (Bergstrom and Tapscott, 2001; Cheng et al., 1995; Pownall et al., 2002).  
The critical role for MRF expression during development is demonstrated by 
aberrant muscle formation in targeted gene ablation studies performed in mice (Arnold 
and Winter, 1998).  Both myoD (-/-) and myf5 (-/-) mice are viable, however, mice with 
gene disruptions for both myoD and myf5 do not form skeletal muscle and die at birth 
(Kablar et al., 1997; Rawls et al., 1995; Sabourin et al., 1999).  Consistent with roles in 
muscle cell determination compound gene targeted mice (myod-/-, myf5-/-) have no 
muscle, but single knockouts are minimally affected suggesting that myoD and myf5 
can compensate for each other (Kablar et al., 1997).  The myogenin (-/-) and mrf4 (-/-) 
null mice have myoblasts that express myoD and myf5, but differentiated muscle is 
absent, demonstrating that these factors are required for differentiation but likely not 
commitment (Arnold and Braun, 1996; Rawls et al., 1995; Zhang et al., 1995a).  In 
view of the fact that the MRFs have such an important role in myogenesis, it has been 
of interest to study how these transcription factors are regulated. 
Figure 5.  Transcription factor expression during myogenesis.   
Muscle precursor cells express Pax3 and Pax7 transcription factors which activate the 
myogenic commitment factors MyoD and Myf5.  Cells committed to the myogenic 
lineage, termed myoblasts, become myocytes  and express MyoD, Myf5 and MEF2 
transcription factors that regulate expression of Myogenin, an early differentiation 
marker.  Differentiating myocytes  fuse together forming multinucleated myofibres 
that express markers such as muscle creatine kinase (MCK) and myosin heavy chain 
(MyHC).  Myofibres contain adult muscle stem cells called satellite cells that express 
Pax7 and Myf5.  Once activated satellite cells may repair injured fibres, form a new 
fibre, or self-renew. 11 
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2.3 Transcriptional control by MyoD 
 
 The MRFs are muscle specific transcription factors that are required for 
skeletal myogenesis, however, they co-operate with other factors that aid in augmenting 
gene expression.  The MRFs can physically interact with the ubiquitously expressed E-
box proteins (E2, E12/E47, HEB), which are also members of the bHLH family (Abe et 
al., 2004; Becker et al., 2001; Berkes and Tapscott, 2005; Conway et al., 2004; Lluis et 
al., 2005; Parker et al., 2006).  Such interactions with E proteins allows MRF to bind to 
E-boxes defined by 5’CANNTG’3 consensus sequence and activate muscle specific 
gene transcription (Berkes and Tapscott, 2005).  Other bHLH proteins, such as Id, 
MyoR, Twist and Mist-1, also interact with MRFs, but are inhibitory to muscle gene 
expression as they interact with E-protein preventing them from interacting with the 
MRFs (Lemercier et al., 1998; Neuhold and Wold, 1993; Spicer et al., 1996). 
Myocyte enhancer factor 2 (MEF2) family of transcription factors are MADS 
(MCMI, agamous, deficiens, serum response factor) box proteins that bind to AT rich 
sites identified by 5’C/TTA(AT)4TAG/A’.  Of the four isoforms, MEF2A, C and D are 
found in skeletal muscle (Buchberger and Arnold, 1999; Dodou et al., 2003; Puri and 
Sartorelli, 2000; Wang et al., 2001).  MEF2 synergistically regulates muscle-specific 
gene expression in co-operation with the MRFs, specifically MyoD (Berkes and 
Tapscott, 2005; Dodou et al., 2003).  However, MEF2 proteins may act repressively 
with MyoD, as they are known to interact with HDAC4 and HDAC5, both class II 
HDACS which repress gene expression. 
Besides the bHLH, MyoD has other functional domains that are important for 
its’ function.  A transactivation domain is found in the N-terminus, and it has a 
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histidine and cysteine rich domain, as well as a helix III domain involved in chromatin 
remodelling (Gerber et al., 1997).  MyoD is known to interact with histone 
acetyltransferase (HATs) and histone deacetlyases (HDACs).  Two HATs involved in 
expression of muscle specific genes are p300 and PCAF, which both interact with 
MyoD as coactivators (Puri et al., 1997).  MyoD recruits p300 to the promoter to 
acetylate histones followed by PCAF recruitment that acetylates MyoD.  Both 
acetylation events increase DNA binding and transcription, leading to positive 
expression of muscle specific genes, such as Myogenin (figure 6) (Dilworth et al., 
2004). Although MyoD positively regulates gene expression, it can interact with Class I 
histone deacetylaes (HDAC1) to negatively regulate muscle genes (Puri et al., 2001). 
Muscle specific target genes regulated by the MyoD include myogenin and muscle 
creatine kinase (MCK) (Lassar et al., 1989; Qin et al., 1998) and myosin heavy chain 
(MyHC) (Allen et al., 2001), which are markers of terminal differentiation. 
 
2.4 Signaling mechanism in myogenesis 
 
 In the embryo, signals received from the notochord, neural tube and lateral plate 
mesoderm specify Pax3, Myf5 and MyoD in the somite.  The pathways involved in 
mediating specification are the canonical and non-canonical Wnt (Tajbakhsh et al., 
1998), Shh (Borycki et al., 1999), BMP (Reshef et al., 1998) and Notch pathways 
(Hirsinger et al., 2001).  Wnt1, Wnt3 and Shh mediate Myf5 expression, while Wnt 4, 
Wnt6 and Wnt7a along with BMP4 (figure 7) and Notch regulate MyoD (figure 8).  
Wnt 1 and Wnt3a signal via the canonical Wnt signaling pathway (figure 7).  In the 
canonical pathway, Wnt signals via the Fzd receptor activating Dsh, which inhibits 
GSK3-β from phosphorylating β-Catenin, thus preventing it targeted degradation.   
Figure 6.  Molecular regulation of myogenesis and transcriptional control by  
MyoD.   
MyoD  mediates chromatin remodelling on the myogenin gene by recruiting the 
histone acetyl transferase, p300 to DNA.  Once recruited, p300 acetylates histones 
along with PCAF.  Together with p300, PCAF actelylates histones promoting gene 
transcription. 
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Stabilization of β-Catenin allows it to translocate into the nucleus and interact with 
TCF to activate Myf5 and Pax3 transcription.  Additionally, Shh binds to the Patched 
receptor resulting in the dissociation of an inhibitory protein termed smoothened, which 
leads to the activation of the Gli transcription factor that also mediates Myf5 expression 
(figure 7) (Gustafsson et al., 2002).  The BMPs activate R-Smads, which translocate 
into the nucleus and together with Smad4, inhibit MyoD expression while not affecting 
Pax3 (figure 7).  The non-canonical Wnt signaling pathway is initiated in the 
dermomyotome by Wnt7a, which activates the PKA pathway leading to the 
phosphorylation of CREB that induces expression of the myogenic commitment factors 
MyoD, Myf5 and Pax3, and also the specification of the myotome (figure 9) (Chen et 
al., 2005).  Conversely, PKA also represses transcriptional activity of Myf5, MyoD and 
Myogenin independently of direct phosphorylation (Winter et al., 1993).  However, 
PKA can directly phosphorylate MEF2, inhibiting its activity (Du et al., 2008) and 
preventing myogenic differentiation.  
 In committed proliferating myoblasts, cyclins and cyclin dependent kinases 
(CDK) regulate cell cycle progression through G1 to S phase and entry into mitosis.  
CyclinD/CDK4 and cyclinE/CDK2 inhibit transcriptional activity of MyoD, thereby 
repressing transcription of muscle specific genes (Rao et al., 1994).  Cyclin E also 
activates CDK2, which phosphorylates Rb preventing interaction with E2F, thus 
allowing cell cycle progression.  Phosphorylation of Rb also prevents interaction with 
MyoD, leading to inhibition of S phase entry and no differentiation (Gu et al., 1993).  
Additionally, cyclinE/CDK2 can directly phosphorylate MyoD on S200 targeting it for 
protein degradation in G1, inhibiting differentiation (figure 10) (Kitzmann et al., 1999).  
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These events collectively regulate cell cycle progression, and promote MB proliferation 
and expansion.  For differentiation to proceed, CDK inhibitors (CKIs) are elevated 
leading to inhibition of cell cycle mediators. CKIs are members of the inhibitor of 
CDK4 (INK4) family, which include p16, p18 and p19, and are also members of cyclin 
dependent kinase-interacting protein/kinases inhibitor protein (CIP/KIP) that include 
p21, p27 and p57.  CKIs lead to a repression of CDK activity, which decreases Rb 
phosphorylation and promotes cell cycle exit and an increase in MyoD protein 
(Knudsen et al., 1998).  MyoD can induce muscle gene expression leading to 
differentiation.  Non cell cycle cyclin and CDKs are also involved in regulating 
differentiation.  P35/CDK5 can phosphorylate Nestin, which regulates the rate of MB 
differentiation and cyclin T/CDK9 promotes MyoD activity (Simone et al., 2002). 
ERK 1/2 signaling is active in many cell types including skeletal muscle. ERK 
1/2 signaling has a role in different stages of skeletal muscle development including 
proliferation (figure 10) (Jones et al., 2001) and later stages of differentiation (Adi et 
al., 2002).  Growth factors, such as Fibroblast growth factors (FGF) and Insulin like 
growth factor (IGF), are involved in activation of the ERK 1/2 pathway that stimulate 
proliferation of MB possibly inhibiting expression of p21 and MyoD.  Although ERK 
1/2 targets are uncharacterized, it has been demonstrated that MEK 1/2, which is 
activated by the same cytokines and growth factors stimulating ERK 1/2, can physically 
interact with MyoD preventing its ability to transactivate myogenin (Miyake et al., 
2009). The Akt pathway is also activated by IGF and acts a positive regulator of 
proliferation. Signaling initiated by IGF-I activates PI3 kinase that activates Akt and 
inhibits ERK 1/2, thus promoting myogenesis (Kaliman et al., 1996; Milasincic et al., 
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1996; Minami et al., 2011).  Once phosphorylated, Akt inhibits FoxO1 from stimulating 
transcription of p27, a cell cycle inhibitor (figure 11) (Machida et al., 2003). 
Another member of the MAPK family, p38 is important for regulation of 
differentiation.  The p38 MAPK has four isoforms (α, β, γ, δ), two of which (α and β) 
have been shown to phosphorylate molecules that positively regulate myoblast 
differentiation (Cuenda and Cohen, 1999; Zetser et al., 1999).  The extracellular 
components of the p38 pathway are undefined, but it is known that transforming growth 
factor-β activated kinase 1 (TAK1) phosphorylates MKK3/6, which phosphorylates p38 
(Bhatnagar et al., 2010).  One other mechanism involving cell to cell contact has been 
investigated.  N-cadherin on adjacent cells activates Cdo that complexes with other 
proteins including Cdc42 (a GTPase), which phosphorylates p38 (Lu and Krauss, 
2010).  Activated p38 can phosphorylate MEF2, which recruits Ash2L to the promoter 
leading to activation.  Phosphorylation of E47 by p38 allows interaction with MyoD, 
also promoting expression of muscle specific genes (figure 12) (Lluis et al., 2005).  
MEF2A and MEF2C are also MyoD interacting partners that are phosphorylated by the 
p38 MAPK regulating its transcriptional activity (Cox et al., 2003; Zetser et al., 1999).  
Additionally, p38 also promotes differentiation by repressing gene expression of Pax7 
via phosphorylation of chromatin repressors (Palacios et al., 2010).  Thus, activation 
and repression of genes dependent on p38 phosphorylation is required for myogenic 
differentiation. 
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Figure 7.  Signaling mechanisms in the somite that regulate muscle specific gene 
expression.   
Canonical Wnt signaling is activated by interaction of Wnt1/3 with the Frizzled (Fzd) 
receptor resulting in activation of Dishevelled (Dsh). Sonic hedgehog (Shh) binds to 
the Patched receptor activating Gli proteins. and Bone morphogenic proteins (BMPs) 
stimulate activation of type I and II receptor leading to activation of Smads 2/3 which 
can interact with Smad 4 and regulate  Myf5 expression. 
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Figure 8.  Notch  signaling in somites and satellite cells.   
The Notch receptor and its Delta ligand interact causing the Notch intracellular domain 
(NICD) to be cleaved.  The NICD can be endocytosed or  targeted for degradation.  
The NICD may also enter the nucleus and interact with CSL to turn on genes that have 
been shown to inhibit MyoD.  Numb and Dishevelled (Dsh) can inhibit the Notch 
signaling pathway. 
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Figure 9.  Mechanism of Wnt signaling in mesodermal cells.  
Non-canonical Wnt signaling is involved in commitment to the myogenic lineage.  
Wnt 1 or 7a bind to the frizzled receptor and activate G-coupled receptor proteins.  
GTP is used to activate adenylate cyclase which converts ATP to cAMP.  cAMP binds 
to the regulatory (R) subunit of PKA resulting in dissociation from the catalytic 
subunit.  The catalytic subunit of PKA enters the nucleus and phosphorylates the 
transcription factor, CREB.  CREB mediates transcription of Pax3 and the myogenic 
commitment genes, Myf5 and MyoD.  The catalytic subunit of PKA can directly 
phosphorylate the MEF2D transcription factor which represses its activity. 20 
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Figure 10.  Activation of proliferation and cell cycle progression in myoblasts by 
growth factors and cyclins.   
Fibroblast growth factor (FGF) activates the MEK 1/2-ERK 1/2 pathway.  ERK 1/2 
targets are not well understood but activation of this kinase promotes proliferation and 
inhibit differentiation in myoblasts.  CyclinD/CKD4 and cyclinE/CDK 2 
phosphorylate Rb, preventing interaction with E2F and MyoD.  E2F can activate cell 
cycle progression genes while MyoD can not activate differentiation genes, thus 
promoting proliferation.  CyclinE/CDK2 can also directly phosphorylate MyoD on 
S200, which targets it for protein degradation. 
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Figure 11.  IGF signaling in myogenesis inhibits differentiation.   
IGF binds to its receptor and activates the insulin receptor substrate (IRS) which 
recruits PI3K.  PI3K is converted to PIP3 which is involved in the phosphorylation of  
Akt1.  Phosphorylated Akt2 enters the nucleus and phosphorylates the FoxO1 
transcription factor.  FoxO1 exits the nucleus and is degraded in the cytoplasm.  
FoxO1 can not activate the cell cycle inhibitor p27, thus, inhibiting differentiation. 
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Figure 12.  Mechanism of p38 signaling in skeletal muscle differentiation.   
The extracellular signals that activate the MKK 3/6-p38 pathway are unknown.  Cell 
to cell contact and activation of the Cdo receptor via N-Cadherin is one mechanism 
of activation of p38 signaling.  p38 can phosphorylate and activate MEF2 and E47 
proteins.  MEF2, MyoD and E47 form a complex with RNA pol II, which is 
activated by phosphorylation by cyclinT/CDK9.  This complex promotes activation 
of muscle  differentiation genes. 
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Skeletal muscle regeneration 
 
3.1 Characterization and identity of satellite cells 
 
Satellite cells are located between the basal lamina and the sarcolemma (plasma 
membrane) of muscle fibres and were initially observed in 1961 by use of electron 
microscopy.  These cells were observed due to their atypical peripheral location in the 
muscle fibre (Mauro, 1961) (figure 13). Also noted were their large nuclei to cytoplasm 
ratio and condensed chromatin. Satellite cells are thought to originate from the 
dermomyotome and account for approximately 30% of the nuclei in postnatal muscle 
and decreases to roughly 5% in adult muscle. These cells are committed myogenic 
progenitor cells that are distinct from myoblasts. They are mitotically quiescent, but 
may enter multiple rounds of proliferation in response to injury to generate myoblasts 
or myogenic precursor cells, which will contribute to repair of the muscle fibre or 
generation of new fibres.  In 1969, Reznik demonstrated that satellite cells contribute 
their nuclei to growing and damaged muscle fibres (Reznik, 1969).  This observation 
was later corroborated by others (Bischoff, 1975). The regenerating potential of satellite 
cells was observed early, but research continues to unravel how they work.   
Satellite cells are thought to originate during development. Satellite cells of the 
trunk originate in the dermomyotome determined by chick-quail grafting experiments 
(Gros et al., 2005).  Limb muscle satellite cells are derived from hypaxial 
dermomyotome (Schienda et al., 2006).  Satellite cells are composed of a 
heterogeneous group with differential expression of markers.  All satellite cells express 
Pax7 while there is a decrease in Pax3 some express Pax3 at low levels as well as 
MyoD (Kuang et al., 2006).  In response to injury, satellite cells become activated and  
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Figure 13.  Anatomical location of satellite cells in muscle fibre.   
In a single muscle fibre, satellite cells reside between the basal lamina and 
sarcolemma.  Satellite cells are distinct from the myonuclei of the muscle fibre.  In a 
cross section through a bundle of muscle fibres, the number of satellite cells are few an 
located on the periphery of fibres. 25 
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proliferate (figure 14).  Daughter cells can either down regulate Pax7 and proceed to 
myogenic differentiation, or maintain Pax7 and remain quiescent and still have the 
ability to re-enter the cell cycle (Zammit et al., 2004).  Satellite cell activation is 
controlled by Notch signaling. Notch is activated in satellite cells in transition from 
quiescent to activated or proliferative. An inhibitor of Notch signaling, Numb, is 
localized asymmetrically in dividing cells.  In one cell it down regulates Notch 
mediated cell proliferation and these cells can differentiate (Conboy and Rando, 2002).  
Numb has become the marker for asymmetric satellite cell division.  It was determined 
that Numb co-segregates with labelled DNA template into cell expressing Pax7 (Shinin 
et al., 2006).  Two populations of satellite cells have been defined; one that are 
Pax7+Myf5+ and one Pax7+Myf5-. Additionally it had been observed that Pax7+Myf5- 
cells give rise to Pax7+Myf5+ and divide in a apical-basal manner (Kuang et al., 2007). 
In most apical-basal divisions, Pax7+Myf5- cells are on the basal surface, while that 
Pax7+Myf5+ cells are on the apical side, which is adjacent to the muscle fibre (figure 
14).  Additionally, Pax7+Myf5- cells can contribute to satellite cell reserve when 
transplanted in Pax7-/- mice (Kuang et al., 2007) (figure 15).  
 
3.2 Molecular regulation of satellite cells 
 
Satellite cells express distinct molecular and surface markers. During 
quiescence, satellite cells express transcription factors such as Pax3, Pax7 and Myf5. 
Pax7 is a marker for quiescent and activated satellite cells. Membrane proteins such as 
M-Cadherin, CD34, c-Met, syndecan3/4 and nuclear envelope proteins laminin A and 
C are also expressed.  It is thought that the adhesion marker N-cadherin allows the 
satellite cell to communicate with the adjacent myocyte (Irintchev et al., 1994). While  
Figure 14.  Symmetric and asymmetric satellite cell division.   
Satellite cells can be divided into satellite myogenic cells (Pax7+, Myf5+) and satellite 
stem cells (Pax7+).  Satellite myogenic cells (Pax7+, Myf5+) undergo symmetric 
division, producing other satellite myogenic cells (Pax7+, Myf5+), which can form 
new fibres or repair existing ones.  Satellite stem cells (Pax7+) can self-renew by 
symmetric division  or may generate satellite myogenic cells (Pax7+, Myf5+) by 
asymmetric cell division. 
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Figure 15.  Satellite cell activation and self-renewal.   
Quiescent satellite cells express Pax7 and Myf5.  Once activated, satellite cells express 
MyoD, which activates Myogenin.  Cells expressing Myogenin that are derived from 
satellite cells down regulate Pax7 and can form either a new fibre or contribute to an 
existing one.  Activated satellite cells also self-renew, continuing to express Pax7. 28 
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Pax3 and Pax7 are involved in the activation of the myogenic program as they bind to 
and regulate elements in the myod gene. Following activation due to injury or damage 
satellite cells express Myf5 and MyoD which turns on Myogenin causing the myogenic 
program to be initiated resulting in repair of the fibre or generation of a new one. At the 
time of activation, satellite cells may also self-renew an attribute that allows 
classification of these cells as stem cells, since they display lineage specific 
differentiation and self-renewal (Buckingham and Montarras, 2008).  Fate choices and 
balance between self-renewal and differentiation are characteristic of stem cells, and of 
satellite cells. 
 
3.3 Signaling mechanism in satellite cells 
 
Extracellular signaling pathways affect satellite cell self-renewal and 
differentiation, and involve the canonical and non-canonical Wnt signaling pathway 
(Otto et al., 2008) and the Notch pathway (Conboy and Rando, 2002; Mourikis et al., 
2012).  Activation of canonical Wnt signaling by Wnt 1a, 3a and 5a has been shown to 
increase satellite cell proliferation.  β-catenin can increase Pax7+ cells, thus inhibiting 
differentiation. Conversely, silencing of β-catenin decreases self renewal of satellite 
cells and increases their activation (Otto et al., 2008).  While the non-canonical 
pathway activated by Wnt7a was found to determine satellite cell polarity activating 
symmetric expansion of satellite cells via planar cell polarity pathway (PCP) (figure 16) 
(Le Grand et al., 2009; von Maltzahn et al., 2012).   
Notch signaling may play an important role in regeneration, as reduced Notch 
signaling leads to precocious differentiation of skeletal muscle progenitor cells 
promoting renewal of muscle progenitor cells (Buckingham and Vincent, 2009).  
Figure 16.  The canonical and non-canonical Wnt signaling pathways in satellite 
cells.   
When phosphorylated by GSK3-β, β-Catenin is targeted for degradation.  Wnt 
signaling mediates activation of Dishevelled (Dsh) which prevents GSK3-β from 
phosphorylating β-Catenin.  Β-Catenin can enter the nucleus and interact with 
TCF/LEF  to activate Myf5.  The non-canonical Wnt pathways involve activation of 
G-protein coupled receptors, which activate the PLC, JNK, ROCK, and Akt pathways.  
Activation of PLC increases extracellular calcium stimulating calcineurin (CN) to 
activate NFAT.  The JNK and ROCK pathways mediate changes in cytoskeleton while 
the Akt pathways promotes protein synthesis via mTOR. 
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Figure 8 illustrates the notch signaling pathway. The Notch intracellular domain 
(NICD) is cleaved and enters the nucleus where it interacts with CLS to turn on genes, 
such as Hes1, which repress myogenic genes. In addition, conditional knock outs of the 
Notch intracellular domain (NICD) interacting protein RBPJ (or CLS) results in 
precocious differentiation of skeletal muscle and a decrease in satellite cell number. 
Thus, suggesting that Notch signaling prevents premature differentiation of myogenic 
stem cells and progenitor cell during development.  In contrast, Notch activation in 
adult satellite cells activated satellite cells and sustained Notch signaling inhibits 
satellite cell differentiation.  Inhibition of cleavage of NICD by γ-secretase does not 
cause satellite cell activation as there is a reduced number of Pax7-, MyoD+ cells 
(Mourikis et al., 2012).  ERK1/2 signaling may be involved in regulating satellite cells.  
Pax7 is involved in satellite cell self renewal and Myostatin may regulate this by ERK 
1/2 signaling (McFarlane et al., 2008).  
 
 
3.4 Non-skeletal muscle cell types with regenerative potential 
 
Satellite cells are the primary source of cells that regenerate skeletal muscle.  
However, other cells of mesodermal origin that are Pax7-, but reside in muscle may 
have myogenic potential.  Pericytes (Dellavalle et al., 2011; Dellavalle et al., 2007), 
mesoangioblast and CD133+ cells have been shown to give rise to myogenic cells.  Side 
population (SP) cells were identified in bone marrow, but later found to be in muscle 
and can differentiate into adipocytes and osteogenic cells. Muscle side population (SP) 
cells are found within skeletal muscle and have similar markers to mesoangioblasts and 
muscle derived stem cells.  They can contribute to muscle repair after injury and 
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vascular regeneration. The majority are CD31+ and some are defined as CD31-, CD45- 
and this subset has been shown to contribute to new fibres post injury (Uezumi et al., 
2006). Additionally, in transplantation experiments SP CD31-, CD45- enhanced 
myoblast proliferation in fibres (Motohashi et al., 2008).  Muscle derived stem cells 
(MDSC) and myo-endothelial cells also have myogenic lineage potential.  These multi-
potential progenitor cells are found outside or within muscle and have been shown to 
differentiate into skeletal muscle. A subset of interstitial cells called PW1+  interstitial 
cells (PICs) express PW1, which is also expressed in satellite cells (Mitchell et al., 
2010; Pannerec et al., 2013). Although PW1 is expressed in satellite cells and 
interstitial cells, PICs express genes similar to mesenchymal stem cells and have the 
potential to become smooth, skeletal muscle and fat (Pannerec et al., 2013). 
 
Models used to investigate skeletal myogenesis 
 
A variety of model systems have been exploited in order to unravel the 
phenotypic and molecular events that define the differentiation program in skeletal 
muscle.  The chick and quail embryos have been one of the primary animal model 
systems used as well as the mouse, Drosophlia, and zebra fish model systems. The 
C2C12 cell line is the most widely accepted ex-vivo model for differentiation while the 
rat L6 skeletal muscle cell line is also used but does not express Myf5.  Preparation of 
primary myoblast cultures from skeletal muscle as well as isolation of primary single 
fibres are well established and have been useful in continuing skeletal muscle research.  
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4.1 The C2C12 cell line  
 
The C2C12 mouse myoblast cell line is a subclone of the C2 myoblast line 
derived from a satellite cell and originally made by Yaffe et al, has been the classic cell 
culture model to study myogenic differentiation outside of the animal and has provided 
a useful model for elucidating skeletal myogenesis (Yaffe and Saxel, 1977). 
Mononucleated myoblasts can be cultured in high serum conditions (10% FBS in 
DMEM) where they are highly proliferative and then can be induced to differentiate 
upon serum withdrawal (2% HS in DMEM) and cell-to-cell contact. In low serum 
conditions and about 70% density, myoblasts withdraw from the cell cycle, align, fuse 
and form multinucleated myotubes (figure 17). Thus, the C2C12 cell culture system has 
proven useful in effectively recapitulating the myogenic process ex-vivo. Consequently, 
use of C2C12 cells has allowed for investigation of the processes that constitute 
myogenesis, namely the MRFs, and the factors regulating them. Interestingly, 
mononuclated cells that coexist in differentiated cultures of myotubes have been 
observed.  These quiescent cells, termed reserve cells do not express myogenic 
differentiation markers and may be similar to satellite cells (Yoshida et al., 1998). 
 
4.2 Primary single fibre cultures 
 
Skeletal muscle fibres have been isolated for over 25 years (Bischoff, 1986; 
Rosenblatt et al., 1995) and this method has continued to be altered and enhanced 
(Anderson et al., 2012; Pasut et al., 2013).  Single fibres from a variety of skeletal 
muscle such as the tibialis anterior (TA) and the more widely used  extensor digitorum 
longus (EDL) can be dissected from mice and studied in culture (Pasut et al., 2013).  
Isolation of single muscle fibres allow for manipulation of satellite cells in culture.  
Figure 17.   Culture models for skeletal muscle.   
In the C2C12 cell model , myoblasts (MB) proliferative in high serum conditions.  In 
differentiation conditions (low serum and cell contact), MB form multinucleated 
myotubes (MT).  In a differentiated culture multinucleated MT and quiescent 
mononucleated cells, called reserve cells coexist.  In primary single myofibre cultures, 
the fibre contains many myonuclei, indicated by DAPI staining.  Satellite cells, 
indicated by Pax7 immunofluorescence expression, are located  on the periphery of the 
muscle fibre. 
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This model does not replace in vivo models, but does provide a useful tool for 
investigating satellite cells in their natural niche in an intact muscle fibre.  Fluorescence 
microscopy is routinely used for identifying satellite cells that are Pax7+ (figure 17) on 
single muscle fibres and fluorescence activated cell sorting (FACS) can be used to 
isolate large amounts of Pax7 positive satellite cells. 
 
The Activator Protein-1 transcription factor complex 
 
 These ubiquitously expressed transcription factors are involved in a great 
variety of cellular processes.  AP-1 are classical oncogene that have roles in 
proliferation (Shaulian and Karin, 2001) and tumourgenesis (Shaulian and Karin, 
2002), but have other regulatory functions.  Although its’ members functions may seem 
redundant, they have specific development functions.  
 
5.1 Structural, physical and biological properties 
 
Activator protein-1 (AP-1) is a transcription factor complex consisting of 
immediately early gene products of the Jun and Fos families (figure 18) (Angel and 
Karin, 1991). AP-1 components belong to the basic leucine zipper (b-ZIP) family of 
transcription factors, which also include members of activating transcription factor 
(ATF), musculoaponeurotic fibrosarcoma (Maf) and CREB binding protein (C/EPB) 
(Chinenov and Kerppola, 2001). Proteins that comprise the Jun family include c-Jun, 
JunB and JunD and may form homodimers with its members or heterodimers with 
members of the Fos family (Halazonetis et al., 1988; Milde-Langosch, 2005; Smeal et 
al., 1989). Members of the Fos family of proteins are c-Fos, FosB, Fra-1 and Fra-2, 
which can only heterodimerize with Jun proteins (Milde-Langosch, 2005; Smeal et al., 
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1989). Heterodimerization with Fos members increases Jun activity more than binding 
with other Jun proteins (Allegretto et al., 1990). Dimerization occurs via hydrophobic 
interactions of leucine residues in the leucine zipper domain (Angel and Karin, 1991). 
The AP-1 complex was found to be induced by TPA (12-O-tetradecanolyphorbol 13-
acetate) allowing binding to the TPA responsive element (TRE) (Angel et al., 1987; 
Lamph et al., 1988), which is identified by its 5’ TGAC/GTCA 3’ consensus sequence 
found in promoter and enhancer regions of many genes (Angel and Karin, 1991; Angel 
et al., 2001; Lee et al., 1987b; Milde-Langosch, 2005). AP-1 components may also 
interact with other b-ZIP members and weakly bind cAMP response element (CRE), 
which is recognized by 5’ TGACGTCA 3’ (Chinenov and Kerppola, 2001). Of the first 
promoters that AP-1 was found to interact with were human metallothionein IIa 
promoter and simian virus 40 (SV40) (Lee et al., 1987a), thus AP-1 was found to 
regulate both cellular and viral genes. Activation occurs in response to growth factors, 
cytokines, stress and oncogenic stimuli. Classically, AP-1 was primarily implicated in 
proliferation and tumourgenesis, however, ongoing research has expanded its role 
determining that AP-1 proteins are ubiquitously expressed and regulate gene expression 
and modulate a variety of cellular functions in addition to cell proliferation such as 
differentiation, apoptosis inflammation, cell migration and wound healing (Shaulian 
and Karin, 2001). 
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Figure 18.   Comparison of functional domains in AP-1 family members.   
AP-1 transcription factors form a complex of JUN homodimers or JUN-Fos 
heterodimers.  All AP-1 proteins, except Fra-1 and Fra-2, contain a transactivation 
domain (TAD) that mediates gene expression.  The AP-1 proteins have a DNA 
binding domain (DBD) and a leucine zipper domain (LZD) used for dimerization. 37 
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5.2 The Jun and Fos family of transcription factors 
 
The c-Jun (or Jun) and c-Fos (or Fos) transcription factors are one of the most 
well characterized AP-1 proteins of its members and has roles in cell proliferation and 
transformation. C-Jun is the most patented activator of transcription. A protein, v-Jun, 
was isolated from the Avian sarcoma virus 17 (Maki et al., 1987), whose sequence was 
found to have similar DNA binding domains to the yeast transcription factor GCN4 
leading to the identification of c-Jun as they recognize the same sequence on DNA 
(Bohmann et al., 1987; Vogt et al., 1987). The cellular version of Fos was also 
identified based on similarity to its viral counterpart found in the Finkel-Biskis_Jinkins 
(FBJ) murine sarcoma virus (van Straaten et al., 1983). Some AP-1 proteins have 
transformation potential, for example, c-Jun has the ability to transform cells in 
conjunction Ras (Johnson et al., 1996; Vandel et al., 1996).  Similarly, c-fos can also 
transform cells, but its mechanism involves activating DNA methyl transferase1 
(DNMT1) leading to derepression of genes (Bakin and Curran, 1999). The C terminal 
domain of Fos is required for transformation (Wisdon and Verma, 1993). Of the AP-1 
proteins, c-Jun has the highest transcription activity especially in combination with c-
Fos (Ryseck and Bravo, 1991). Interestingly, it was observed that when JunB dimerizes 
with c-Jun it can repress c-Jun activity (Schutte et al., 1989) and was later demonstrated 
using the cyclinD1 promoter, a known target of c-Jun (Bakiri et al., 2000; Carter et al., 
1991). Further studies have determined that members of the Jun and Fos family work 
together in regulating cell cycle progression (Kovary and Bravo, 1991). Biological roles 
for c-Jun and c-Fos are proposed based on transgenic and mutational analyses. The c-
Jun transgenic mouse does not display overt developmental abnormalities phenotype.  
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In contrast, the knockout is embryonic lethal at E12.5 and has liver and heart defects 
(Eferl et al., 1999). Additionally, it was found that cells lacking c-Jun had declined 
proliferation and reduced expression of cyclinD1 (Johnson et al., 1993) that 
corroborated its role as a mediator of proliferation. The c-fos transgenic mouse has an 
osteoblast phenotype and develops osteosarcoma (Grigoriadis et al., 1993), while the 
knockout mouse affects osteoclasts and develops osteopenia (Wang et al., 1992). 
 
5.3 JunB 
 
JunB is essential for embryonic development as mice lacking JunB do not 
survive post E 8.5-10 due to placental defects (Schorpp-Kistner et al., 1999).  JunB may 
also have a role in bone development as the conditional transgenic mice have bone 
defects (Kenner et al., 2004).  In cell cycle progression, unlike c-Jun, JunB is proposed 
to be an inhibitor of cell proliferation.  JunB levels are decreased in quiescent cells, but 
become elevated in G0 to G1 transition and to S phase, while lowering in G2 to M. JunB 
is anti-proliferative, since it induces expression of the CKI, p16 and inhibits cyclinD 
(Passegue and Wagner, 2000).  Although, JunB opposes c-Jun’s pro-proliferation role it 
has been shown to be required for osteoblast proliferation in JunB conditional gene 
targeted mice (Kenner et al., 2004).  
 
5.4 JunD 
 
JunD is not required for embryogenesis as the gene targeted mice are viable, but 
postnatal growth is declined (Thepot et al., 2000).  More interestingly, male animals 
lacking JunD had reproductive abnormalities and are sterile, but females were not 
affected suggesting JunD is required for male appropriate reproduction (Thepot et al., 
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2000).  There are two isoforms of JunD, the full length which is 39 kDa and a truncated 
form that is 34 kDa lacking part of the N-terminus (Okazaki et al., 1998).  JunD may 
also have a role in bone formation as it interacts with multiple endocrine neoplasia type 
1 (MEN1), which is involved in bone differentiation (Naito et al., 2005).  Interestingly, 
JunD, as opposed to c-Jun, can inhibit transformation by Ras (Pfarr et al., 1994). 
 
5.5 FosB 
 
FosB is a 338 amino acid protein with a characterized transcription activation 
domain it has spliced variant delta FosB2.  FosB has transforming potential, which is 
dependent on the C terminal domain (Wisdon and Verma, 1993). Interestingly, FosB 
transgenic mice do not have an overt phenotype nor does its knockout counterpart.  
FosB is largely associated with behavioural effects.  For example, gene targeting mice 
acquire nurturing behaviour defects (Brown et al., 1996). 
 
5.6 Fos like antigen-1  
 
Fra-1 is a 245 amino acid protein that functions as a transcription factor but has 
low transactivation potential as it has no transactivation domain and inability to 
transform cells (Wisdon and Verma, 1993). The model of Fra-1 null mouse is 
embryonic lethal on account of placental defects (Schreiber et al., 2000).  To examine 
the role of Fra-1 during development, a conditional knockout model was generated by 
Eferl et al., (2004), where they found that loss of Fra-1 resulted in low bone mass such 
as in a osteopenia phenotype (Eferl et al., 2004).  The opposite effect of increase bone 
mass was observed in Fra-1 transgenic mice (Roschger et al., 2004). 
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5.7 Fos-like-antigen 2 
 
Fra-2 was isolated by Nishina et al., (1990) based on its ability to be recognized 
by antiserum raised against a Fos peptide (Nishina et al., 1990). Fra-2 shares sequence 
homology to the other Fos proteins (Fra-1, FosB and c-Fos) and has been considered a 
proto-oncogene, since over-expression of Fra-2 transforms chicken embryo fibroblasts 
(Nishina et al., 1990). In addition, it is demonstrated that Fra-2 forms stable dimers 
with c-Jun (Angel et al., 2001). Extensive characterization of the fra-2 gene and its 
promoter regions has provided insight into regulation of Fra-2 expression when induced 
by serum (Nishina et al., 1990; Sonobe et al., 1995). Studies have found that post 
translational modifications (PTMs) of Fra-2 induced by serum are regulated by ERK 
1/2 and causes phosphorylation of Fra-2 (Sonobe et al., 1995; Yoshida et al., 1991). In 
order to map Fra-2 phosphorylation Murakami et al. (1999) constructed Fra-2 deletion 
mutations that were fused to GST at the amino terminal domain (Murakami et al., 
1999).  In as series of in vitro kinase assays they found that subsequent to serum 
stimulation, Fra-2 was highly phosphorylated at its carboxyl terminal domain 
(Murakami et al., 1999). Use of mutants with mutations at serine and threonine residues 
allowed them to conclude that threonine was the primary amino acid targeted for 
phosphorylation (Murakami et al., 1997; Murakami et al., 1999). Phosphorylation of 
Fra-2 in C2C12 cells is most likely due to its known upstream target ERK 1/2, which is 
also active during myoblast proliferation and in late stages of muscle differentiation 
(Sarbassov et al., 1997). Studies have observed slower migrating Fra-2 bands by 
Western blot analysis and have attributed these changes to phosphorylation since the 
motility of these bands change when Fra-2 is immunoprecipitated and treated with calf 
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intestinal phosphatase (Illario et al.) (Alli et al., 2013; Andreucci et al., 2002; 
Murakami et al., 1997). A similar effect on Fra-2 banding pattern is observed upon the 
addition of a MEK 1/2 specific inhibitor (PD 98059 or UO126) (Alli et al., 2013; Cook 
et al., 1999). More recently S320 was found to be an ERK 1/2 specific phosphorylation 
site on Fra-2 that mediates its protein stability (Alli et al., 2013).  
Abnormal muscle phenotypes have not been reported in Fra-2 transgenic or 
knockout mice. Fra-2 trangenic mice have abnormal eye development (McHenry et al., 
1998) and in a separate study it was also reported that they had pulmonary fibrosis 
(Eferl et al., 2008). Fra-2 knockouts have alteration in chondrocytes and osteoclasts 
(Bozec et al., 2010). Fra-2 knockout mice are born and die within one week of birth 
(Eferl et al., 2007).  Interesting it has been reported that they do no grow after birth 
compared to wild-type mice, thus, lacking postnatal development. 
 
5.8 Regulation by MAPK 
 
It has been demonstrated that AP-1 proteins are downstream targets of MAPK 
signaling when activated by extracellular factors (Cook et al., 1999; Eriksson and 
Leppa, 2002; McBride et al., 1993).  Serum and growth factors activate the ERK 1/2 
MAPK pathway, while pro-inflammatory cytokines and stress activated p38 and JNK 
pathways.  The ERK 1/2 MAPK pathway targets Fos family members.  The c-fos 
promoter contains a element termed the serum response element (SRE) when induced 
by serum or growth factors allows serum response factor (SRF) to complex with 
ternary complex factor (TCF) and bind to SRE (Hill et al., 1994).  Fra-1 and Fra-2 are 
also targeted by ERK 1/2 MAPK pathway when induced by serum (Gruda et al., 1994).  
Interestingly, Fos, Fra-1 and Fra-2 share similar C termini and a conserved serine 
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residue that is targeted by phosphorylation by ERK 1/2 (figure 19) (Basbous et al., 
2008), which has been corroborated in further studies and attributed to protein stability 
(Alli et al., 2013).   
The p38 and JNK pathways target Jun proteins.  The Jun N-terminal kinase 
(JNK) was found to phosphorylate c-Jun at S63 and S73 in its activation domain to 
enhance transcriptional activity (Derijard et al., 1994; Hibi et al., 1993).  Additionally, 
JNK can phosphorylate ATF allowing it to interact with c-Jun and autoregulate itself 
(Gupta et al., 1995).   JunB phosphorylation by JNK is unclear but it has been reported 
that Thr102 and Thr104 are target sites (Li et al., 1999).  JNK also targets JunD at S90, 
S100 and Thr117 which enhances its transcriptional activity (Yazgan and Pfarr, 2002).   
The p38 MAPK does not directly phosphorylate Jun protein, but does phosphorylate 
transcription factors such as MEF2C which may regulate the c-Jun promoter (Gordon et 
al., 2009; Han et al., 1997).  Also, p38 can phosphorylate ATF2 leading to the 
dimerization with c-Jun and regulation of the c-Jun promoter (Morooka et al., 1995). 
 
5.9 Activator Protein-1 and Myogenesis 
 
Skeletal muscle regulation by AP-1 has been investigated by several groups that 
determined that AP-1 has an overall negative role in differentiation (Andreucci et al., 
2002; Bengal et al., 1992; Lehtinen et al., 1996; Pedraza-Alva et al., 1994; Thinakaran 
et al., 1993; Trouche et al., 1993).  The inhibitory role of AP-1 can be partially 
attributed to overexpression experiments with either c-Jun or c-Fos that resulted in 
potent inhibition of myogenesis as these proteins can repress DNA binding of MyoD 
(McBride et al., 1993; Trouche et al., 1993).  Additionally, c-Jun was found to 
physically interact with MyoD antagonizing its ability to activate E-box dependent gene  
Figure 19.  Comparison of the C terminal domain of Fos family members.  All  
Fos proteins have a DNA binding domain (DBD) and a leucine zipper domain (LZD) 
for dimerization.  C-Fos and FosB have transactivation domains (TAD) while Fra-1 
and Fra-2 do not.  A conserved MAPK phosphorylation site, SP, is found in all Fos 
members.  The ERK 1/2 docking site is defined by the FTYP sequence and is found in 
c-Fos, Fra-1 and Fra-2. 
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expression enforcing that AP-1 negatively regulated myogenesis (Bengal et al., 1992). 
In contrast, MyoD was determined to down-regulate the c-Fos promoter in 
differentiation conditions (Trouche et al., 1993).  However, these studies were largely 
focused on c-Jun and c-Fos and did not consider the other Jun and Fos proteins, thus 
overlooking the complexity of AP-1 dimer permutations in regulation of gene 
expression.  Subsequent studies have also implicated AP-1 in regulating myogenesis, 
but suggest that its function during differentiation is more complex than has been 
previously reported (Andreucci et al., 2002).  Electophoretic mobility shift assays 
(Semsarian et al.) have shown that AP-1 has DNA binding activity in differentiating 
C2C12 cells and antibody supershifts reveal that c-Fos:c-Jun dimers are dominant in 
myoblasts, while Fra-2 is the primary dimerization partner with either c-Jun or JunD in 
differentiating myoblasts (Andreucci et al., 2002).  C-Jun and c-Fos are known 
regulators of cyclinD1 and regulate proliferation of myoblasts.  The c-Jun dimerization 
protein JDP2 was shown to repress proliferation in C2C12 cells (Ostrovsky et al., 
2002).  These data propose that other AP-1 members, specifically Fra-2 and JunD may 
have a role in myogenesis and AP-1 may directly regulate muscle specific gene 
expression in skeletal muscle.  Also, regulation of Fra-2 may occur via phosphorylation 
as already demonstrated with c-Jun, c-fos and Fra-1 (Whitmarsh and Davis, 1996).  
Furthermore, the Fra-2 containing AP-1 complexes in skeletal muscle are 
transcriptionally active because they can modulate the MyoD enhancer/promoter in 
luciferase reporter assays (Andreucci et al., 2002).   
An AP-1 target gene of interest in skeletal muscle is Vimentin.  Vimentin is part 
of the intermediate filaments IF’s family of protein and is cytosolic.  TGF-β induces 
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vimentin expression as well as phorbol esters (Carey and Zehner, 1995), both of which 
induce TRE dependent gene expression.  AP-1 was found to mediate vimentin 
expression when activated by serum (Rittling et al., 1989) and more recently, it was 
found that AP-1 was required for TGF-β mediated activation of the vimentin gene in 
skeletal muscle (Wu et al., 2007). 
More recently, AP-1 expression was observed in reserve and satellite cells of 
skeletal muscle suggesting a role in regeneration and muscle maintenance (Alli et al., 
2013).  High throughput studies have extended studies into gene targets in skeletal 
muscle.  A MyoD ChIP-seq by Cao et al., (2010) identified promoters bound by MyoD 
that were also associated with histone acetylation (Cao et al., 2010).  Additionally, 
many of the MyoD targets were enriched with AP-1 binding sites (Cao et al., 2010).  
One MyoD target gene enriched for TREs was mustn1.  It was demonstrated that AP-1 
proteins bind to the mustn1 promoter in a region close to the identified MyoD binding 
site (Liu and Hadjiargyrou, 2006).  The Musculoskeletal temporally activated novel 
gene (Mustang) was discovered in a callus fracture screen and was later found to be 
required for chondrogenesis (Gersch and Hadjiargyrou, 2009).  It is expressed in 
mesenchymal cells of the somite during development and becomes more restricted in 
adult tissues.  In the adult, Mustang was only expressed in skeletal muscle and tendon 
(Lombardo et al., 2004).  Loss of function studies utilizing siRNAs against mustn1 in 
skeletal muscle demonstrated that there was inhibition of differentiation in C2C12 cells 
(Liu et al., 2010).  Recently, mustn1 was implicated in muscle regeneration and satellite 
cell activation as determined by a mustn1-GFP reporter mouse (Krause et al., 2013).  
Taken together, Mustang is a potential candidate target gene in skeletal muscle and an 
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AP-1 target.  Therefore, the mechanism by which AP-1 is involved in satellite cell 
regulation may involve Mustang.  
 
Mitogen activated protein kinases pathways 
 
Post-translational regulation of transcription factors is an important level control 
and includes protein: protein interactions and PTMs including phosphorylation, 
acetylation, methylation, ubiquitlyation, glycoslyation, and sumolyation.  In addition to 
genetic regulation by various cell signals, transcription factors may be modified by 
mitogen activated protein kinase (MAPK) pathways (Johnson et al., 2006).  There are 
many MAPK pathways, the most well characterized include the extracellular regulated 
kinase (ERK) 1/2, the c-Jun N-terminal kinase (JNK) and the p38 pathways (figure 20) 
(Cabane et al., 2003; Keren et al., 2006; Sarbassov et al., 1997).  
 
6.1 Mechanism of signal transduction 
 
Extracellular stimuli in the form of growth factors, cytokines or stress interact 
with transmembrane receptors resulting in the activation of the receptor and 
transduction of the signal.  ERK 1/2 signaling is initiated with receptor tyrosine kinases 
dimerization and autophosphorylation at Tyr residues in the cytoplasmic domain occur 
in response to ligand binding.  Phosphorylation at Tyr in the receptor serve as sites of 
interaction for src homology 2 (SH2) domain proteins and phosphotyrosine binding 
(PBT) domain proteins (Whitmarsh and Davis, 1996).  Both SH2 domain proteins and 
PTB domain proteins can interact with adaptor proteins that binds Ras, a small GTP 
binding protein.  Ras activates Raf which is a MAPK kinase kinase which can 
phosphorylate MAPK  
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Figure 20.   MAPK signaling  cascade targeting  AP-1 proteins.  Extracellular 
growth factors, cytokines, and cellular stress activate the mitogen activated kinases 
(MAPK) pathways.  The MAPK utilize a signaling cascade hierarchy that begins with 
mitogen activated kinase kinase kinase (MAPKKK).   The MAPKKK (Raf, Mos, 
Tpl2, MLK3, TAK, DLK, MEKK 1.4, ASK1) activate MAPKK (MEK 1/2, MKK 3/6, 
MKK 4/7), that activate MAPK (ERK 1/2, p38, JNK) which translocates into the 
nucleus and phosphorylate transcription factors. 
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kinases such as MEK 1/2, which phosphorylates ERK 1/2.  ERK 1/2 becomes activated 
when phosphorylated in its activation loop, Thr-Glu-Tyr (TEY) (Roux and Blenis, 
2004).  Once activated, EKR 1/2 can phosphorylate targets such as Elk-1 (Janknecht et 
al., 1993) and c-Fos (Whitmarsh and Davis, 1996).   
The general mechanism of the MAPK signaling cascade for p38 and JNK are 
similar, but the molecules involved are different.  The upstream kinases that activate 
p38 are MKK3 and MKK6.  Activation of p38 occurs via phosphorylation the Thr-Gly-
Tyr (TGY) motif  (Whitmarsh and Davis, 1996) allowing p38 to phosphorylate targets 
such as ATF2 and MEF2.  MKK4 and MMK7 phosphorylate JNK in its Thr-Pro-Tyr 
(TPY) motif (Whitmarsh and Davis, 1996).  Once activated JNK targets substrates 
including ATF2 and c-Jun.  ERK 1/2, p38 and JNK pathways are important in skeletal 
muscle differentiation as they target many transcription factors that are involved in 
muscle specific gene regulation. 
 
Cytokine and growth factor signaling in skeletal muscle differentiation  
 
Key extracellular signaling molecules in skeletal muscle differentiation, such as 
insulin (D'Alessandris et al., 2007; Illario et al., 2009), insulin-like growth factor-I, 
(IGF-I), IGF-II (Adi et al., 2002; Czifra et al., 2006) and basic fibroblast growth factor 
(bFGF) are involved in skeletal myogenesis.  Transforming growth factor-β (TGF-β) 
and Cardiotrophin-1 (CT-1) have inhibitory effects on differentiation but may have a 
function in maintaining satellite cells in adult muscle. 
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7.1 Insulin, Insulin like growth factors, basic fibroblast growth factor and 
transforming growth factor-beta 
 
The peptide hormone, insulin, is primarily produced and secreted from the 
pancreas and it is known to promote myogenesis (Conejo et al., 2001) as well it is the 
minimum necessary factor that must be present in cell culture media for differentiation 
(Haba Gde et al., 1966; Mandel and Pearson, 1974; Smith et al., 1999).  Insulin 
activates the phosphatidylinositol 3 kinase (PI3K) pathway (Tsakiridis et al., 1996) as 
well as the p38 pathway and is involved in regulating myoblast proliferation and 
survival (Conejo and Lorenzo, 2001).  Insulin-like growth factors IGF-I and II are 
similar to insulin and are secreted by the liver and skeletal muscle.  IGF-I has dual role 
in skeletal muscle contributing to both proliferation and differentiation.  IGF-I is 
necessary for proliferation in early stages by regulating FoxO1 and p21 via activation 
of Akt signaling (Machida et al., 2003).  Phosphorylation of p21 by Akt inhibits CDK2 
while phosphorylation of FoxO1 excludes it from the nucleus preventing transcription 
of cell cycle inhibitors (Machida et al., 2003).  Therefore, both of these mechanisms 
allow cell proliferation to occur.  Activation of Akt by IGF-1 also promotes 
differentiation.  Akt can target pituitary homeobox 2 (Pitx2), which complexes with an 
mRNA binding protein called HuR to stabilize cyclinD1.  However, when Pitx2 is 
phosphorylated by Akt complex formation is prevented resulting in cyclinD1 
degradation (Gherzi et al., 2010).  When activated, Akt also targets GSK3-β preventing 
it from phosphorylating β-Catenin thus, promoting expression of muscle specific genes 
(Pansters et al., 2011).  IGF-1 is an important signaling molecule in skeletal muscle 
development as it has roles in both proliferation and differentiation.  IGF-I signaling 
has been shown to contribute to muscle hypertrophy (Coleman et al., 1995).  
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Basic fibroblast growth factor (bFGF) activated the MEK 1/2 ERK 1/2 pathway 
inducing myoblast proliferation (Milasincic et al., 1996).  The mechanism is not well 
defined, but it involved down regulation of MyoD that subsequently hinders 
differentiation by preventing muscle specific gene expression (Spizz et al., 1986).  
Expression of the FGF receptor is down regulated during differentiation thus, signaling 
is turned off (Olwin and Hauschka, 1988). 
TGF-β is another growth factor that activates downstream phosphorylation 
events leading to changes in gene expression.  Two pathways that are activated by 
TGF-β are the Smad and the ERK 1/2 (Yang et al., 2006) pathways both of which are 
activated in skeletal muscle.  It had been observed that TGF-β inhibits skeletal muscle 
differentiation in C2C12 cells (Olson et al., 1986) by hindering expression of MyoD 
and myogenin (Brennan et al., 1991) while Smad7, a TGF-β receptor inhibitor, 
promotes differentiation (Kollias et al., 2006).  More recently, activation of MEK 1/2 
by TGF-β was shown to inhibit MyoD activity independent of the Smad pathway 
(Miyake et al., 2010). 
 
7.2 Interleukin-6 family of cytokines 
 
Members of the IL-6 family are grouped based on structure similarity and 
include IL-6, IL-11, leukemia inhibitory factor (LIF), ciliary neurotrophic factor 
(CNTF), cardiotrophin-like cytokine (CLC), oncostatin M (OSM) and cardiotrophin-1 
(CT-1) (Kishimoto et al., 1995).  All IL-6 cytokines exclusively utilize the gp130 
receptor subunit to transduce signals in the cell.  The signaling receptor can be a gp130 
homodimer which is used by IL-6 and IL-11 complex with gp130 homodimer while 
LIF, CTNF and CT-1 use a hetrodimer of gp130 and LIFR, OSM uses gp130 and 
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OSMR (figure 21) (Kishimoto et al., 1995).  LIF uses the same receptor as CT-1 and 
has similar functions as CT-1.  IL-6, IL-11, CNTF, and CLC also bind a non-signaling 
α receptor but CT-1 α-receptor is predicted but not yet characterized (Robledo et al., 
1997). Downstream signaling cascades are activated following receptor activation via 
tyrosine phosphorylation.  Interleukin-6 (IL-6) family of cytokines are involved in a 
variety of biological processes such as proliferation, differentiation, survival, apoptosis 
and inflammatory response.  
 
7.3 JAK-STAT signaling 
 
In cardiac fibroblast, CT-1 is able to activate the JAK/STAT, PI3K/Akt, p38 
and ERK1/2 MAPK pathways (Freed et al., 2003a).  With the exception of p38, these 
signaling pathways have been shown to have a role in cardiomyocyte hypertrophy 
(Tian et al., 2004).  Following cytokine binding to gp130-LIFR heterodimer, the signal 
is transduced by other downstream signaling molecules.  Janus kinases (JAKs) are 
required for gp130 signaling and interact via a FERM (four-point, Ezrin, rodixin, 
Moesin) domain with proline rich box1 on the receptor (Freed et al., 2003a).  There are 
JAK1, 2, and 2 as well as tyrosine kinases 2 (TYK2) and all are known to associate 
with gp130-LIFR.  Signal transducer and activator of transcription (STAT) are 
downsteam phosphorylation substrates of JAKs (Zhang et al., 1995b).  There are seven 
members of the STAT family STAT 1, 2, 3, 4, 5a, 5b, and 6 and bind via YXXQ motif 
on gp130-LIFR.  STATs contain src homology domain 2 (SH2), which allows it to 
dimerize with other STATs (Taga and Kishimoto, 1995).  Interestingly, 
gp130/LIFR/OSMR signaling also stimulates the MEK1/2-ERK1/2 pathway.  This 
occurs via SH2 domain containing tyrosine phosphatase (SHP2), which interacts with 
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growth factor receptor bound protein (grb2) and grb2 associated binder 1 (Gab1).  Gab1 
interacts with Ras allowing the Ras-Raf-MEK-ERK cascade to become activated 
(figure 22) (Kishimoto et al., 1995). 
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Figure 21.  IL-6 family of cytokines and their receptors.   
The IL-6 family of cytokines share the common receptor subunit gp130.  IL-6 and IL-
11 use a receptor composed of a gp130 homodimer.  LIF, CT-1, CNTF and OSM use 
receptors that comprises a LIF-R-gp130 heterodimer.  OSM can also signal via a 
heterodimer of OSMR and gp130.  IL; Interleukin, LIF; Leukemia inhibitory factor, 
CT-1; Cardtiotrophin-1, CTNF; ciliary neurotrophic factor, OSM; oncostatin M. 54 
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Figure 22.  IL-6  cytokine induced signaling  mechanisms.   
Some IL-6 cytokines such as CT-1 and LIF signal via a receptor composed of gp130 
and LIFR.  Autophosphorylation of the receptor lead to JAK phosphorylation and 
receptor phosphorylation.  STAT3 is recruited to the receptor and phosphorylated.  
Phosphorylated STAS3 can translocate into the nucleus and activate gene 
transcription.   JAK can mediate activation of the MEK 1/2 , ERK 1/2 pathway. 
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7.4 Cardiotrophin-1 
 
Cardiotrophin-1 (CT-1) is a cytokine identified in a screen for cardiac 
hypertrophic factors that were induced from embryoid bodies from mouse embryonic 
stem cells in conditioned media (Pennica et al., 1995).  CT-1 is expressed in the heart 
tube E8.5-E10.5 in myocardial cells and after E12.5 it is found in other tissues such as 
liver, dorsal root ganglia and skeletal muscle.  In addition to being a factor that induces 
cardiac hypertrophy (Pennica et al., 1995), CT-1 is also involved in cardiomyocyte 
survival (Sheng et al., 1996).  CT-1 activates atrial natriuretic peptide (ANP) in cardiac 
cells.  Clinically, CT-1 has been implicated in cardiac related diseases (Celik et al., 
2012; Freed et al., 2005) and more recently,  has been associated with hypertension 
(Gkaliagkousi et al., 2014) and diabetes (Hung et al., 2013).  In addition to cardiac 
cells, various roles for CT-1 in other cell types have been proposed.  For example in 
hepatocytes, CT-1 is involved in the inflammatory process (Peters et al., 1995; 
Richards et al., 1996), and in motorneurons it promotes cell survival (Holtmann et al., 
2005; Oppenheim et al., 2001).  In skeletal muscle, CT-1 signaling has been shown to 
repress MyoD activity by activating MEK1/2 resulting in reduced myotube 
differentiation (Miyake et al., 2009). 
 
7.5  CT-1 and myogenesis 
 
CT-1 is not expressed in the somites or myogenic progenitor cells, but later in 
skeletal muscle tissue.  It is expressed after E 12.5 in skeletal muscle suggesting it may 
have a role in skeletal muscle maintenance.  CT-1 was shown to have a role in 
regenerating and overloaded skeletal muscle and its expression was detected in satellite 
cells (Nishikawa et al., 2005).  Both gp130 and LIFR are expressed in regenerating 
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skeletal muscle (Kami et al., 2000).  LIF, similar to CT-1 impedes differentiation of 
C2C12 myoblasts into myotubes (Jo et al., 2005).  IL-6 induces skeletal muscle 
hypertrophy and satellite cell proliferation using signaling that activates STAT3 
(Serrano et al., 2008).  It was demonstrated that JAK2 and STAT2 and 3 were required 
for myogenic proliferation and differentiation, actually preventing premature 
differentiation (Sun et al., 2007; Wang et al., 2008).  In addition, it was shown that 
JAK1 down regulation accelerated myogenesis causing an increase in MyoD and MEF2 
and decreasing Id1 (Sun et al., 2007).  In a separate study STAT3 was shown to 
increase c-myc and antagonize MyoD via a direct interaction (Kataoka et al., 2003).  
However, it was later demonstrated that MEK1/2 signaling, at least when activated by 
CT-1, was involved in inhibitory effects of myogenesis not STAT3 signaling (Miyake 
et al., 2009). 
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Chapter II:  Statement of Purpose 
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Chapter II:  Statement of Purpose 
 
Skeletal muscle development and regeneration is applicable to numerous 
pathologies, in which muscle wasting is a consequence.  A greater understanding of the 
molecular processes involved in skeletal muscle development and regeneration may 
further clinical applications such as sarcopenia and cancer cachexia.  Regulation of 
skeletal muscle development by the MRFs and MEF2 transcription factors are well 
characterized and documented.  Other more ubiquitous transcription factors are also 
implicated in regulation of skeletal muscle such as the AP-1 family of proteins.  
However, the understanding of AP-1 transcription factors’ role is incompletely 
characterized in skeletal muscle.  Hence, the overall purpose here was to further 
characterize the role of AP-1 in skeletal muscle.  This general purpose was addressed in 
the following specific studies. 
 
 
Chapter III:  CT-1 maintains the undifferentiated state in skeletal myoblasts 
  
During embryogenesis CT-1 is primarily expressed in cardiomyocytes but is 
also expressed in skeletal muscle.  The role of CT-1 as a cardiac hypertrophic factor is 
established, but its’ role in skeletal muscle still remains unknown.  Two signaling 
pathways activated by CT-1 in cardiomyocytes; MEK 1/2/ERK 1/2 and JAK/STAT, 
have an inhibitory effect on skeletal muscle.  In this study the role of CT-1 in skeletal 
muscle was assessed, and the signaling mechanisms constituting its effects were 
investigated. 
 
 
 
60 
 
Chapter IV:  Signal dependent Fra-2 regulation in skeletal muscle reserve and 
satellite cells 
 
Previously, it was demonstrated that components of the AP-1 transcription 
factor complex were present in proliferating and differentiating skeletal muscle.  Some 
components of the AP-1 transcription factor complex, such as Fra-2, were determined 
to be posttranslationally modified.  ERK 1/2, a known upstream kinase of Fra-2, has an 
inhibitory signaling effect upon skeletal muscle differentiation.  In this study, the 
regulation of Fra-2 by ERK1/2 signaling and its’ role in skeletal muscle development 
was investigated. 
 
Overall, these studies were aimed at further elucidating the function of AP-1 in 
skeletal muscle. 
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Chapter III:  Cardiotrophin-1 maintains the undifferentiated 
state in skeletal myoblasts 
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Summary 
  Skeletal myogenesis is potently regulated by the extracellular milieu of growth 
factors and cytokines.  We observed that Cardiotrophin-1 (CT-1), a member of the 
Interleukin-6 (IL-6) family of cytokines, is a potent regulator of skeletal muscle 
differentiation. The normal up-regulation of myogenic marker genes, Myosin Heavy 
Chain (MyHC), Myogenic Regulatory Factors (MRFs), and Myocyte Enhancer Factor 
2s (MEF2s) were inhibited by CT-1 treatment. CT-1 also represses Myogenin (MyoG) 
promoter activation. CT-1 activated two signaling pathways: Signal Transducer and 
Activator of Transcription-3 (STAT3), and Mitogen-Activated Protein Kinase Kinase 
(MEK), a component of the Extracellular Regulated MAP Kinase (ERK) pathway. In 
view of the known connection between CT-1 and STAT3 activation,  we surprisingly 
found that pharmacological blockade of STAT3 activity had no effect on the inhibition 
of myogenesis by CT-1 suggesting that STAT3 signaling is dispensable for myogenic 
repression. Conversely, MEK inhibition potently reversed the inhibition of myotube 
formation and attenuated the repression of MRF transcriptional activity mediated by 
CT-1. Taken together, these data indicate that CT-1 represses skeletal myogenesis 
through interference with MRF activity by activation of MEK/ERK signaling. In 
agreement with these in vitro observations, exogenous systemic expression of CT-1 
mediated by adenoviral vector delivery increased the number of myonuclei in normal 
post-natal mouse skeletal muscle and also delayed skeletal muscle regeneration induced 
by cardiotoxin (CTX) injection. The expression pattern of CT-1 in embryonic and post-
natal skeletal muscle and in vivo effects of CT-1 on myogenesis implicate CT-1 in the 
maintenance of the undifferentiated state in muscle progenitor cells.
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Introduction 
Terminal differentiation of skeletal myogenic cells, termed myogenesis, consists 
of a series of well characterized highly regulated steps that has become a paradigm for 
lineage acquisition and cellular differentiation. Initially, pluripotent mesodermal stem 
cells commit to become myogenic precursor cells. Commitment to the myogenic 
lineage then results in the binary state of either maintenance of proliferative potential 
and pluripotency, or, on appropriate cues, withdrawal from the cell-cycle, activation of 
a  battery of structural, contractile and metabolic genes constituting the differentiation 
programme and ultimately formation of multi-nucleated myotubes (Perry and Rudnick, 
2000).  The field of myogenesis has benefited from the use of well established in vitro 
cell-culture systems which faithfully recapitulate the in vivo differentiation programme. 
During myogenesis, a group of basic helix-loop-helix transcription factors, Myogenic 
Differentiation-1 (MyoD), Myogenic Factor-5 (Myf5), Myogenin (MyoG), and 
Myogenic Regulatory Factor-4 (MRF4), collectively termed the Myogenic Regulatory 
Factors (MRFs), play essential roles in differentiation (Kassar-Duchossoy et al., 2004; 
Pownall et al., 2002; Rudnicki and Jaenisch, 1995). Most  promoter-enhancer regions 
of  muscle specific genes contain  the cognate binding site, E-box (CANNTG),  for the 
MRFs, and the E-box is often essential for the induction of these genes during 
differentiation (Tapscott, 2005; Walsh and Gualberto, 1992). For example, early and 
late muscle specific genes, MyoG and muscle specific Myosin Heavy Chain (MyHC) 
respectively, are transcriptionally regulated by MyoD and other MRFs through E-boxes 
in their proximal promoter regions (Penn et al., 2004; Rudnicki and Jaenisch, 1995). 
The molecular and genetic requirement for the MRFs during myogenesis has been 
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confirmed in many studies both in vitro and in vivo (Edmondson and Olson, 1989; 
Kassar-Duchossoy et al., 2004; Myer et al., 2001). The MRFs also co-operate with 
another class of myogenic transcription factors, comprised of the Myocyte Enhancer 
Factor two family (MEF2) (Naya and Olson, 1999; Olson et al., 1995). MEF2 genes are 
taxonomically part of the MADS-box gene super-family that encode DNA binding 
proteins involved in yeast mating type decisions (MCM1), plant development 
(Agamous and Deficiens), and serum responsivity of mammalian cells (Serum 
Response Factor: SRF) (Jarvis et al., 1989; Norman et al., 1988; Sommer et al., 1990; 
Yanofsky et al., 1990).  
As well as the detailed knowledge of core transcriptional regulatory circuits 
mediated by myogenic transcription factors and their accessory factors, much work has 
contributed to the identification of a number of growth factor and cytokine mediated 
signaling pathways that positively and negatively impact myogenesis (Engert et al., 
1996; Olwin and Hauschka, 1988; Ridgeway et al., 2000; Templeton and Hauschka, 
1992). In some cases, these pathways regulate the decision to differentiate or not, a 
critical regulatory point since differentiation in muscle is terminal and absolutely 
required for viability of all metazoan life. Moreover, negative regulation of 
differentiation is equally important since it underpins the maintenance of the 
proliferative state and pluripotency.  
A number of growth factors and cytokines, such as Insulin like Growth Factors 
(IGFs), insulin, Transforming Growth Factor-β (TGFß), Fibroblast Growth Factor 
(FGF), and Epidermal Growth Factor (EGF), that influence myogenesis have been 
identified (Allen and Boxhorn, 1987; Engert et al., 1996; Olwin and Hauschka, 1988; 
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Templeton and Hauschka, 1992), however, a detailed understanding of their 
corresponding signal transduction pathways and transcriptional network targets is still 
rudimentary. One group of cellular signaling cascades that are known to affect 
myogenesis in a complex manner are the MAPK pathways. For example, p38 MAPK, a 
member of one of the MAPK pathways, directly phosphorylates and activates E47, 
which forms a productive dimer with MyoD (Lluis et al., 2005; Lluis et al., 2006). 
P38MAPK also regulates MEF2 (Cox et al., 2003; Zetser et al., 1999) transcription 
factors as well as being involved in the recruitment of ATP dependent chromatin 
remodelling factors to myogenic loci (de la Serna et al., 2005; McKinsey et al., 2002; 
Serra et al., 2007). Conversely the ERK-MAPK cascade plays a bi-phasic role in 
myogenic cells, being inhibitory in the initial phases of the differentiation program 
while being required for later stage events, such as cell fusion (Bennett and Tonks, 
1997).   
CT-1 is a member of the IL-6 family, which is comprised of IL-11, Leukemia 
inhibitory factor (LIF), Ciliary Neurotrophic Factor (CNTF), and Oncostatin M (OSM). 
These cytokines are structurally related and form a variety of oligomeric ligand – 
receptor complexes. IL-6 and IL-11 form a complex with a homodimer of the 
Glycoprotein-130 (Gp130) receptor or heterodimers of gp130 and leukaemia inhibitory 
factor receptor-β (LIFRß). Gp130/LIFRβ also recognises LIF, CT-1, CNTF, OSM, and 
Cardiotrophin-Like Cytokine (CLC). OSM binds to the Gp130 and Oncostatin M 
receptor (OMR). Upon formation of the requisite complex with the respective cytokine, 
the preponderant view is that the oligomeric receptor complex transduces its signal 
through the Janus kinase (JAK)-STAT signaling pathway (Heinrich et al., 2003).  
68 
 
CT-1 was originally identified in conditioned medium from embryoid bodies 
(Pennica et al., 1995). In developing embryos, CT-1 is expressed in heart, skeletal 
muscle, liver and dorsal root ganglia (Sheng et al., 1996). In adults, human CT-1 
mRNA is detected in the heart, skeletal muscle, ovary, colon, prostate and testis, and in 
fetal kidney and lung (Pennica et al., 1996). The functions of CT-1 in the 
cardiovascular system have been extensively researched. Patients with ischemic and 
valvular heart disease have elevated levels of CT-1 in their sera (Freed et al., 2003b). 
Further study of the role of CT-1 in the heart indicated that it has a cardio-protective 
role by reducing apoptosis (Brar et al., 2001; Sheng et al., 1996) and may be involved 
in regeneration of cardiac muscle after infarction (Freed et al., 2005). Exogenously 
administered CT-1 also induces cardiac hypertrophy in vitro (Sheng et al., 1996). While 
the modulation of cardiomyocyte phenotype by CT-1 has been well documented, the 
underlying signaling pathways are still unclear and the role of CT-1 in skeletal muscle 
has not, thus far, been characterized. 
In this report, we demonstrate that CT-1 is a potent inhibitor of skeletal muscle 
differentiation. In C2C12 cells, CT-1 represses molecular markers of muscle 
differentiation and phenotypic myogenesis. Also, the transcriptional networks involved 
in the induction of key myogenic genes such as the MyoG and MCK genes are 
suppressed by CT-1 signaling. Surprisingly, small chemical inhibitors of MEK, 
PD98059 and U0126, reversed these repressive effects on skeletal myogenesis by CT-1 
whereas inhibition of STAT3 activation was without effect. Collectively, these data 
show that CT-1 interferes with the transcriptional network required for muscle 
differentiation through the activation of the MEK-MAPK signaling module. 
69 
 
Furthermore, in vivo, adenovirus mediated expression of CT-1 increases satellite cell 
number and delays regeneration of damaged muscle by cardiotoxin (CTX) injection.  
These observations indicate that CT-1 represses myogenesis and serves to maintain 
myogenic progenitors in their proliferative, multipotent state in vitro and in vivo. 
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Experimental procedures 
 
Plasmids     MRF expression plasmids were constructed in pEMSV as described 
elsewhere (Davis et al., 1987). An activated (ΔN3 S218D/S222E) human MEK1 
expression construct was a kind gift from A. Natalie (Mansour et al., 1994). The 
reporter construct pMCK-eGFP was a gift from A. Ferrer-Martinez (Universitat de 
Barcelona, Spain). Transcription reporter constructs, pMCK-luc (Donoviel et al., 1996), 
pCMV-β-Galactosidase were described elsewhere (Kollias et al., 2006). The myogenin 
promoter region was excised from pMyoG-luc by SacI /Bgl II digestion. The resultant 
1152bp fragment was inserted at the SacI /Bgl II sites of pGL4-10 vector (Promega). 
The dsRed2-N1 expression construct was purchased from Clontech Laboratories.   
 
Antibodies    The primary antibodies used in this study were obtained from Santa Cruz 
Biotechnology; MyoD (C-20), Myf5 (C-20), Actin (I-19), and ERK1 (C-16), from BD 
Biosciences; MEF2D (610775),  from Cell Signaling Technology; Stat3 (9132), 
Phospho-Stat3 (Tyr705) (58E12; 9135), Phospho-Stat3 (Ser727) (6E4; 9136), MEK1/2 
(9122), Phospho-MEK1/2 (Ser217/221) (9121), Phospho-p44/42 MAPK 
(Thr202/Tyr204) (E10; 9106), from Developmental Studies Hybridoma Bank; 
Myogenin (F5D), and MyHC (MF20), from DakoCytomation; MyoD1 (clone:5.8A; 
M3512).  Polyclonal antibody for MEF2A was prepared as previously described (Cox 
et al., 2003).  Normal mouse (sc-2025) IgG was from Santa Cruz Biotechnology.   
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Cell Culture     C2C12 myoblasts were obtained from American Type Culture 
Collection (CLR-1772) and cultured in growth medium (GM) consisting of 10% Fetal 
bovine serum (FBS) (HyClone) in high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco) supplemented with 1% penicillin-streptomycin (Gibco) at 37 °C and 
5% CO2.  Myotube formation was induced by replacing GM with differentiation 
medium (DM) which consisted of 2% horse serum (Atlanta Biologicals) in DMEM 
supplemented with 1% penicillin-streptomycin. For CT-1 treatment, recombinant 
mouse CT-1 (R&D system; 438-CT) was resuspended with solvent (4 mM HCl, 0.1% 
bovine serum albumin (BSA)) and supplemented into the media. For myotube 
formation assays, DM with CT-1 (10ng/ml) was replenished every 2 days. Inhibitors 
(PD98059 (Cell Signaling Technology; 9900), U0126 (Cell Signaling Technology; 
9903), and P6 (2-(1,1-Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-
f]isoquinolin-7-one; Pyridone 6) (Calbiochem; 420097)) were resuspended with DMSO 
and added into the cell culture media for 30 minutes prior to adding CT-1.  
 
Sacromeric Myosin Heavy Chain Detection    
C2C12 cells were washed with Phosphate buffered saline (PBS) (pH7.4) and fixed with 
90% methanol at -20 °C for 10 min.  After fixation, the cells were incubated in 5% milk 
in PBS for 30 min at 37 °C for blocking.  Cells were incubated at room temperature 
with MF-20 (primary antibody) diluted in blocking buffer (5% milk PBS) for 1 hour.  
After incubation, the cells were washed three times with PBS and incubated for 60 min 
at room temperature with an Horseradish peroxidase (HRP)-conjugated α-mouse 
secondary antibody.  The cells were again washed three times with PBS and incubated 
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in developer (0.6 mg/ml DAB, 0.1 % H2O2 in PBS) to detect MyHC by 
immunocytochemistry. The nuclei were counter-stained with haematoxylin. Images 
were recorded with a microscope (Axiovert 35; Carl Zeiss MicroImaging) with either 
4X NA 0.10 or 10X NA 0.25 Achrostigmat objective lenses with a digital camera 
(Canon, EOS D60).  
 
Proliferation assay    After 72hrs in DM and in the presence of CT-1 (10ng/ml) (or 
solvent), cells were incubated with 100μM of BrdU (Sigma) for 1 hr at 37°C.  Cells 
were washed with cold 1x PBS then fixed with 70% ethanol for 1hr at 4°C.  The cells 
were then washed with 1x PBS and incubated with 2N HCl for 1 h at 37°C to denature 
the DNA.  The cells were blocked in 10% goat serum (Sigma) diluted in 1x PBS for 
2hrs at room temperature with shaking and then incubated with BrdU primary antibody 
(G3G4: Developmental hybridoma bank, Iowa) diluted in 1.5% goat serum (Sigma) for 
1.5hr at room temperature with shaking.  Cells were washed with 1x PBS-T (0.5% 
Tween20) and incubated with anti-mouse secondary antibody conjugated to FITC 
(Sigma) diluted in 1.5% goat serum (Sigma) for 2hrs at room temperature with shaking.  
Cells were washed with 1x PBS-T (0.5% Tween20).  
 
Microscopy and Fluorescence     Fluorescence and phase contrast pictures were 
obtained using an epifluoresence microscope (Axiovert 35; Carl Zeiss MicroImaging), 
with appropriate phase and filter settings, and either 4X NA 0.10 or 10X NA 0.25 
Achrostigmat objective lenses.  Images were recorded with a digital camera (Canon, 
EOS D60).   
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Western blotting analysis     Total cellular protein extracts were prepared in NP-40 
lysis buffer (0.1 % NP-40, 150 mM NaCl, 1mM EDTA, 50 mM Tris-HCl  pH 8.0, 
1mM sodium vanadate, 1mM PMSF, supplemented with a protease inhibitor cocktail 
(Sigma, P-8340)).  Protein concentrations were determined by a standard Bradford 
assay (BioRad).  Equivalent amounts of protein were resolved by SDS-PAGE gels, 
followed by electrophoretic transfer to an Immobilon-P membrane (Millipore) as 
directed by the manufacturer (Millipore).  Blots were incubated with the indicated 
primary antibody in 5% milk in PBS or Tris buffered saline (TBS)-T (10mM Tris-HCl 
pH8.0, 150mM NaCl, 0.1% Tween-20) or 5% Bovine serum albumin (BSA) in TBS-T 
according to the manufacturer’s protocol at 4 °C overnight with gentle agitation.  After 
washing briefly, the blots were incubated with the appropriate HRP-conjugated 
secondary antibodies in 5% milk in PBS or TBS-T at room temperature according to 
the manufacturer’s protocols (Santa Cruz Biotechnology, Cell Signaling Technology). 
After washed three times with 1XPBS or 1XTBS (depending on the primary antibody) 
at room temperature, the blots were treated with the Enhanced chemiluminescence 
reagent (Amersham) to detect immuno-reactive proteins. The blots were exposed to 
Biomax film (Kodak) for visual representation.   
 
Transcription reporter gene assays     C2C12 myoblasts were transfected by a 
standard calcium phosphate-DNA precipitation method with the indicated reporter gene 
and expression constructs and pCMV-β-Galactosidase to monitor transfection 
efficiency.  After transfection, the cells were washed with PBS and maintained in GM 
and then treated as indicated. Total cellular protein was extracted with luciferase lysis 
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buffer (20mM Tris-HCl pH7.4, 0.1% Triton X-100). Luciferase and β-Galactosidase 
enzyme assays were performed according to the manufacturer’s protocol (Promega). 
Luciferase activity was quantified using a luminometer (Berthold Lumat, 9501) and 
standardized according to the β-Galactosidase activity. Relative Luciferase units 
normalized for the β-Galactosidase activity (Relative Luciferase Unit; RLU) were 
determined and plotted as an average of triplicate determinations and error bars 
represent standard deviations of the triplicate values. Each experiment was repeated at 
least three times. 
 
Semi-quantitative RT-PCR analysis   Total RNA was extracted from cells with 
TRIzol (invitrogen) according to manufacture’s protocol. cDNA was generated from 
the isolated total RNA (1μg) with SuperScript III (invitrogen) and oligo-dT (16)  primer 
(Sigma) by the protocol provided by the manufacturer. To amplify a target transcript, a 
pair of primers was designed that flanked an intron based on the mouse gene sequences. 
The target transcripts were amplified by taq DNA polymerase (New England Biolab) 
with gene specific primers. An amplified DNA was separated in an agarose gel and 
visualized by ethidium bromide (EtBr) (Sigma) staining and UV exposure. Detailed 
information about the primers is in supplement. 
 
Co-immunoprecipitation analysis     An equal amount of total cellular protein 
(250μg) was diluted with NP-40 lysis buffer to a final concentration of 1 μg/μl.  Protein 
complexes were immunoprecipitated with the indicated antibody and 25μl of protein G-
Plus Sepharose beads (50% slurry) (Santa Cruz Biotechnology) by incubation at 4°C 
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overnight on a rotating platform.  The beads were washed with three changes of NETN 
wash buffer (0.1% NP-40, 150mM NaCl, 1mM EDTA, and 50 mM Tris-HCl pH 8.0).  
Beads were boiled in SDS sample buffer, and protein complexes were resolved by 
SDS-PAGE and immuno-blotted as described above. 
 
CT-1 adenovirus    The CT-1 adenovirus was previously described (Bordet et al., 
1999). Briefly, full length murine CT-1 cDNA was isolated by PCR and the CT-1 
reading frame was fused with a 60 base pair pre-Nerve Growth Factor (NGF) leader 
sequence to promote secretion of the CT-1 protein.  The CT-1 cDNA was cloned in 
frame with the long terminal repeat of the Rous Sarcoma virus (RSV) (Bordet et al., 
1999). A LacZ containing adenovirus (CTRL) was used as a control for all injection 
experiments. This adenovirus was kindly provided by Dr. Robin Park at the Ottawa 
Health Research Institute, Ottawa, Canada.  
 
In vivo administration of CT-1: Muscle injury  To test CT-1 in vivo, B6C3F1 mice 
were subjected to systemic delivery of the CT-1 adenovirus.  Briefly, animals were 
anaesthetized with halothane. The injections were administered via intra-cardiac 
chamber delivery using a 29-gauge insulin needle (VWR) with 50µL of Ad-CT-1 at a 
concentration of 3.0 X 108 PFU/mL (n=3). A control group of B6C3F1 mice were 
injected with 50µL Ad-CTRL at a similar concentration (n=3). In a separate group of 
animals, cardiotoxin was used to induce muscle injury immediately prior to AdCT-1 
and Ad-CTRL injection (n=3 for each group). 25μl of 10μM cardiotoxin (Latoxan) was 
injected directly into the TA muscle using a 29G1/2 insulin syringe in halothane 
76 
 
anaesthetized mice (Asakura et al., 2002).  Post-recovery, mice were monitored closely 
for weight loss, dehydration and cardiac distress.   All injections were administered by 
a trained animal care technician according to the standards of the Animal Care 
Committee at the University of Ottawa, Ottawa, Canada.  
 
Immuno-histology  At 7days post-injection, skeletal muscle was excised and rinsed in 
cold 1XPBS. The muscle was fixed in 4% PFA in PBS for 2days then embedded in 
paraffin, sectioned at 10μM and counterstained with haematoxylin and eosin to 
visualize the nuclei and cytoplasm. Sections were dehydrated in a graded ethanol series 
ending in CitriSolv (Fisher Scientific). For immuno-histological, sections were treated 
with antigen unmasking solution (Vector Labs), blocked with 5% BSA, incubated 
overnight at 4˚C with a primary antibody, then incubated in donkey-anti-goat CY3 
antibody (Chemicon) and finally counterstained with DAPI (Sigma). 5 fields of view 
per section and 5 sections per TA muscle were analysed. The micrographs were 
representative views. 
 
Stem Cell/Progenitor Cell Isolation     Side population (muscle progenitor cells) were 
collected as previously described (Hierlihy et al., 2002). Contra lateral TA muscle was 
collected from Ad-CT-1 and Ad-CTRL mice and all visible connective tissue and blood 
vessels were removed by dissection.  Muscle was digested in collagenase B (10mg/mL) 
(Roche) plus dispase II (2units/mL) (Roche) for and the resulting single ell suspensions 
were then stained with Hoechst dye 33342 (5ug/mL) (Sigma-Aldrich) at 37°C for 90 
minutes.  As an SP control, the drug verapamil (50μM) (Sigma-Aldrich) was added to 
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an aliquot of cells simultaneously stained with Hoechst 33342.  Cells were finally re-
suspended in 500μL of Hanks Balanced Salt solution with 2% FBS and 10mM Hepes 
(HBSS+). The cells were filtered through a 50µM Cell Tric® (disposable filters made 
of monofil nylon material) (Partec GmbH) and remained on ice until FACS analysis 
(Hierlihy et al., 2002). Cell sorting was performed using a DakoCytomation MoFlo 
high-speed cell sorter (DakoCytomation) (Hierlihy et al., 2002). Forward and side 
scatter was measured at 488 nm (Spectraphysic Argon Laser). The Hoechst dye was 
excited at 359nm (I90C laser from Coherent). Blue emission was measured at 424nm 
(424/44 band pass filter) and red emission was above 675nm (675 AGLP long pass 
filter).  All data was collected and analyzed with SummitTM Data Acquisition and 
Analysis Software (DakoCytomation). 
 
Methylcellulose Stem Cell/Progenitor Cell Culture     2x104 Side population cells 
were re-suspended in 2.5mL of Methocult media GF3434 (Stem Cell Technologies) 
using a 5mL syringe and a 12 gauge needle (Hierlihy et al., 2002). Cells were then 
plated on 2cm plastic petri dishes and incubated in humidity chambers at 37°C and 5% 
CO2 for 14days. At 14days post plating, colonies were counted using a Zeiss inverted 
microscope. 
 
Statistical Analysis      Differences between Ad-CT-1 and Ad-CTRL injected samples 
were evaluated for statistical significance using one tailed, unpaired Student’s t test. 
Differences were considered statistically significant at a p value less than 0.05 
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Results 
CT-1 represses myogenic differentiation 
Major sites of CT-1 expression during embryonic development are heart and 
skeletal muscle (Sheng et al., 1996). While CT-1’s role in the cardiovascular system is 
being defined (Sheng et al., 1997), its role in skeletal muscle is not characterized. To 
begin to elucidate CT-1 function in skeletal muscle, we initially treated C2C12 cells 
chronically with CT-1 (10ng/ml, 0.5nM) and assessed muscle differentiation by the 
formation of multi-nucleated myotubes and accumulation of a skeletal muscle 
differentiation marker protein, MyHC. Solvent treated C2C12 cells began to exhibit 
multinucleated myotubes after 48hrs in DM. Thereafter, the control, solvent treated  
C2C12 cells developed MyHC-positive myotubes with large numbers of nuclei at later 
time points (figure 1A). In contrast, C2C12 cells in the CT-1 containing DM failed to 
form multinucleated myotubes at 48hrs. At later time points, some myogenesis 
occurred although the number and calibre of MyHC-positive myotubes were greatly 
reduced in the presence of CT-1 compared to the corresponding controls (figure 1A). In 
addition, the MCK promoter activity was strongly inhibited by CT-1 as indicated by the 
transfection of a  MCK promoter-reporter gene fused to enhanced signal Green 
Fluorescent Protein (EGFP) (pMCK-EGFP) (figure 1B). We also observed that CT-1 
did not affect the cellular proliferation rate of differentiating myoblasts in DM assessed 
by BrdU incorporation rate (figure 1C&D). Therefore, these data document that CT-1 
represses the skeletal muscle differentiation programme without affecting proliferation 
rate. 
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Figure 1. CT-1 represses myogenic differentiation. A) C2C12 cells were seeded onto cell 
culture plates at equal density and maintained in CT-1 (10ng/ml) or solvent containing 
growth medium (GM) or differentiation medium (DM) for the indicated time period. The 
cells were fixed and stained for muscle myosin heavy chain (MyHC) detection by 
immunochemistry. The photomicrographs are representative fields in each condition. B) 
C2C12 cells were plated at equal density and transfected with pCMV-deRed2 and pMCK-
eGFP constructs. The transfected cells were maintained in CT-1 (10ng/ml) or solvent 
containing DM for 72 hrs to induce myotube formation. The cell morphology was recorded 
by phase-contrast microscopy and transfected cells were monitored by the red fluorescence 
signal. MCK promoter activity was assessed by the green fluorescence signal. C) C2C12 
cells were maintained in DM for 72hrs and CT-1 (10ng/ml) or solvent was added every 
24hrs.  After 72hrs in low serum conditions cells were incubated with 100μM of BrdU for 
1hr.  Cells were then fixed with 70% ethanol and then incubated with 2N HCl to denature 
the DNA.  The cells were then blocked with 10% goat serum prior to incubation with BrdU 
primary antibody.  The cells were then washed with 1x PBS-T and incubated with 
secondary antibody conjugated to FITC.  The cells were washed with 1x PBS-T and 
mounted using fluorescence mounting media and viewed under a fluorescence microscope. 
D) The average of percentage of BrdU positive nuclei over total nuclei in 12 individual 
fields per condition was calculated and graphed. (error = standard variation)   
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CT-1 represses the expression of pro-differentiation transcriptional regulators 
(MyoG and MEF2A/D) 
 
To generate multi-nucleated myotubes from mono-nucleated myoblasts, the 
MRFs and MEF2s play an essential synergistic role at various stages of the 
differentiation programme (Kaushal et al., 1994). Therefore, we postulated that CT-1 
might interfere with muscle differentiation through the MRFs and/or MEF2. First, in 
order to establish that the repression of myogenesis by CT-1 was observed in this 
analysis the levels of MyHC, a structural marker of muscle differentiation were 
assessed. As we expected that MyHC accumulated in the solvent treated C2C12 cells at 
late time points. Conversely, this accumulation of MyHC was largely attenuated in 
C2C12 cells treated with CT-1 (figure 2). Having determined that myogenesis was 
repressed by CT-1 at the molecular level, we next assessed the levels of various muscle 
transcription factors. Under these conditions, the expression of MyoG, a key MRF 
required for differentiation (Myer et al., 1997) was repressed by CT-1 compared to the 
solvent treated cells, in which it was strongly induced (figure 2). In addition, MEF2A 
and MEF2D were also lower in the cells treated with CT-1 (figure 2). These data 
indicate that CT-1 inhibits myogenic differentiation by interfering with the up-
regulation of MyoG and MEF2 factors. Interestingly, MyoD and Myf5 protein levels 
were relatively not affected by CT-1 suggesting that the lesion in the hierarchical 
differentiation programme lies between the MRFs required for lineage commitment 
(MyoD and Myf5) and the pro-differentiation transcriptional regulators (MyoG and 
MEF2A and MEF2D).   
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Transcriptional induction of the myoG promoter by MyoD is repressed by CT-1 
signaling 
Since MyoD, along with Myf5, play an early ‘commitment’ role in the 
myogenic cascade and also play an important role in the induction of the myoG gene 
(de la Serna et al., 2005), we hypothesised that CT-1 might interfere with the trans-
activation properties of MyoD and therefore its ability to activate myoG transcription. 
To begin to address this hypothesis, we initially measured myoG promoter activity 
using reporter gene assays. In the absence of CT-1, the myoG promoter was activated in 
differentiating C2C12 cells in DM (figure 3). In the presence of CT-1, the activation of 
the myoG promoter was markedly inhibited in a dose dependent manner (figure 3). 
These data indicate that reduced MyoG levels observed with CT-1 (figure 2) result 
from a loss of transcriptional induction of the myoG locus.  
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Figure 2. CT-1 represses the expression of pro-differentiation transcriptional 
regulators (MyoG and MEF2A/D). C2C12 cells were induced to differentiate in DM with 
CT-1 (10ng/ml) or solvent. The cells were maintained in the indicated conditions for 
specific time periods. Total protein samples were extracted from the cells and equal 
amounts of total protein (20μg) were subjected to Western blotting analysis. The levels of 
indicated proteins were assessed by a standard immuno-blotting technique with a specific 
primary antibody. Actin indicates equal amounts of protein loading into each lane. 
 
 
Figure 3. Transcriptional induction of the myoG promoter by MyoD is repressed by 
CT-1. C2C12 cells were transfected with either pGL3 (empty control) or a Myogenin 
promoter-luciferase reporter gene construct (pMyoG-Luc), and to monitor transfection 
efficiency, pCMV-β-gal construct was included in each condition. The transfected cells 
were maintained for 16 hrs in the indicated concentration of CT-1 or its solvent in DM. 
Total protein samples were harvested with a luciferase lysis buffer. Luciferase activity in 
each condition was measured independently and normalized according to β-Galactosidase 
activity.  
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Trans-activation properties of the MRFs are repressed by CT-1 
 
Based on our observation that myoG gene transcription was attenuated by CT-1, 
we next focused on whether MyoD trans-activation properties might be altered by CT-
1 since MyoD expression levels remained unaffected with CT-1 treatment (figure 2).  
The trans-activation capacity of MyoD has already been documented to be a 
heavily regulated aspect of its function, both positively and negatively, by a variety of 
mechanisms (Kim et al., 2008; Polesskaya et al., 2001; Puri et al., 2001; Reynaud et al., 
2000). Bioinformatic analysis of MyoD interacting proteins revealed that MEK1 (Perry 
et al., 2001) and STAT3 (Kataoka et al., 2003) also share the property that they are 
known to be activated by phosphorylation in the presence of IL-6 family cytokines in 
different cell types. Therefore, we first confirmed that expression of CT-1 and its signal 
transduction receptors, Gp130 and LIFRβ in C2C12. Endogenous CT-1 and their 
receptor expression were confirmed by semi-quantitative RT-PCR analysis in the 
presence or absence of recombinant exogenous CT-1 in the media. We detected their 
transcripts in C2C12 cells, and their expression levels were not affected in the presence 
of CT-1 (figure 4A). We then surveyed these signaling molecules first by determining 
the phosphorylation levels of MEK1 and STAT3 in  C2C12 cells acutely (figure 4B) or 
chronically (figure 4C) treated with CT-1 by Western blotting analysis. Indeed, levels 
of phosphorylated MEK-1 and STAT3 proteins in C2C12 cells were elevated in the 
presence of CT-1 compared to those in solvent control cells (figure 4B and C).  A 
previous study indicated that MyoD’s transcriptional activation properties can be 
inhibited by a direct interaction with MEK1 (Perry et al., 2001). Therefore, we sought 
to test this interaction by co-immuno-precipitation analysis. These experiments 
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revealed that exogenous expression of an activated form of MEK1 (Act-MEK: MEK1 
R4F) and MyoD resulted in co-purification of the two molecules in the same complex, 
suggesting the possibility that this interaction can occur (figure 4D). In addition we 
observed that the typical activation of the myoG promoter (figure 4E) and MCK 
promoter (supplemental figure 1) by exogenously expressed MRFs was repressed by 
CT- 1 signaling (recombinant CT-1 or Act-MEK1) (figure 4E). These results further  
support the idea that MyoD trans-activation properties are repressed by CT-1 and 
that MEK activation is a key component of that repression.  
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Figure 4. Trans-activation properties of the MRFs are repressed by CT-1.  A) 
Total RNA was isolated from C2C12 cells in GM (lane 1), DM with solvent (48hrs) 
(lane 2), and DM with CT-1 (10ng/ml) (48hrs) (lane 3) and subjected to semi-
quantitative RT-RCP analysis with indicated gene specific primer pairs. RT-PCR 
amplified DNA was separated in a TAE/agarose-gel, and EtBr stained DNA was 
visualised by UV irradiation. GAPDH serves as an internal loading control. B) 
C2C12 cells were plated at equal density and kept in DM for 16hrs. CT-1 (10ng/ml) 
or equal volume of the solvent was added to the media. The cells were harvested 
after 20min of CT-1/solvent addition. Total protein samples were subjected to 
Western blotting analysis to estimate the levels of indicated proteins. C) Western 
blotting analysis was performed as described above. However, the cells were 
maintained in DM with CT-1 or solvent for indicated time periods. D) C3H10T1/2 
cells were transfected with combinations of the indicated constructs. Total protein 
samples were extracted from the cells maintained in DM. Exogenous-expression of 
MyoD and an activated form of MEK1 was confirmed by immuno-blotting (IB) 
(10μg loading) with the specific antibodies.  An immuno-precipitation (IP) analysis 
was performed with the total protein extract (250μg) with MyoD antibody (mouse) 
and proteinG conjugated beads. Precipitated immuno-complex were eluted off the 
proteinG beads and subjected for an immunoblotting with MEK antibody (Rabbit). 
Equal amount of IgG loading was monitored with MyoD immuno-blotting with 
MyoD specific antibody (Rabbit). E) C2C12 cells were transfected with the 
indicated expression constructs or its empty vector (1μg) and myoG promoter- 
(pMyoG-Luc) promoter-Luciferase reporter construct (0.5μg). In addition, an 
activated form of MEK1 expression vector (1μg) or its empty vector (for CT-1 and 
solvent) was included. To monitor transfection efficiency, a pCMV-β-Gal construct 
was also included (0.3μg). After transfection, the cells were maintained in DM 
containing CT-1 (10ng/ml) or its solvent for 16 hrs. The cells were harvested and 
subjected to luciferase assay and β-Galactosidase assay.  
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CT-1 inhibits the transcriptional properties of the MRFs through activation of MEK 
signaling  
To directly test the idea that CT-1 activation of MEK is responsible for MyoD 
trans-repression, we utilized MEK specific inhibitors, PD98056 and U0126. First, we 
reasoned that if MEK activation is absolutely required for CT-1 repression of 
myogenesis, then we should abrogate CT-1 effects on myogenesis by repression of 
MEK. In the absence of CT-1 (solvent), C2C12 cells formed multinucleated myotubes, 
and they accumulated MyHC proteins (brown colour) after 2days in DM (figure 5A). 
These morphological changes were not observed in the presence of CT-1. However, 
addition of MEK inhibitors neutralized the inhibitory effect of CT-1 on both myotube 
formation and MyHC accumulation in a dose dependent manner (3μM vs. 10μM) 
assessed by immunochemistry (figure 5A). Western blotting analysis of MyHC levels 
further confirmed the above observations (figure 5B). In agreement with this, a more 
detailed Western blotting analysis showed that MyoG protein levels were lower in the 
presence of CT-1, and this inhibitory effect was reversed by MEK inhibition 
(PD98059), which prevented CT-1 mediated induction of phosphorylation of ERK (a 
MEK activity indicator). It was noted that as previously reported in different systems 
(Chen and Sytkowski, 2004; Yip-Schneider et al., 2009), the MEK inhibitor caused 
hyper-phosphorylation of MEK. However, in the presence of PD98059 upregulation of 
phospho-ERK by CT-1 was clearly inhibited (figure 5C). Therefore, this MEK inhibitor 
prevents CT-1 mediated activation of MEK. We also noticed that the MEK inhibitor 
reversed these CT-1 effects without affecting the phosphorylation levels of STAT3 
(figure 5C, see below). Furthermore, luciferase reporter gene assays also showed that 
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myoG promoter activity driven by exogenously expressed MyoD was repressed by CT-
1. Furthermore, exogenous expression of an activated form of MEK1 or Raf 
(components of the MAPK signaling pathway), also repressed myoG activation and 
these effects were  reversed in a dose dependent manner by MEK inhibition (figure 
5D), and by  expression of dominant negative form of MEK1 or Raf1 (figure 5E). 
Therefore, these data indicate that MEK inhibition ‘rescues’ muscle differentiation 
from the inhibitory effect of CT-1, both morphologically and biochemically; and 
repression of MyoD’s trans-activation properties by CT-1 is also reversed by MEK 
inhibition. Taken together, CT-1 represses skeletal myogenic differentiation through 
interference of the transcriptional activity of MyoD by the activation of MEK signaling. 
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Figure 5. CT-1 inhibits the transcriptional activity of the MRFs through activation of 
MEK signaling. A) C2C12 cells were plated at equal density and induced differentiation 
transferred into DM upon about reaching confluence. The cells were maintained in 
indicated concentration of MEK inhibitor (PD98059, U0126, or DMSO; 3μM or 10μM) 
with without CT-1 (10ng/ml). After 2days in the indicated conditions, the cells were fixed 
and stained for MyHC detection by immunochemistry with MF-20 mouse monoclonal 
antibody. MyHC protein accumulation was indicated by brown color. The 
photomicrographs are representative fields. B&C) C2C12 cells were maintained in DM 
with CT-1 (10ng/ml) and or PD98059 (10μM), or their solvents for 2days (C) or 3days (B) 
to induce myotube formation. Total cellular proteins were extracted from the cells in each 
condition. The total protein lysate samples (20μg) were subjected to Western blotting 
analysis. Actin levels indicate loading of an equal amount of the total protein into each 
lane. D) C2C12 cells were transfected with a pMyoG-Luc (0.5μg), a MyoD expression 
vector (1μg), a pCMV-β-Gal (0.3μg), and also the indicated kinase expression vector 
(act.MEK1, act.Raf) or an empty vector (1μg). The transfected cells were maintained in 
DM containing CT-1 (10ng/ml) or solvent, and the indicated concentration of PD98059 
MEK inhibitors for 16hrs. The cells were harvested and subjected to Luciferase assay and 
β-Gal assay. Luciferase activity was normalized according to the β-galactosidase activity 
from a co-transfected pCMV-β-Gal expression construct by calculating the Relative 
Luciferase Unit (RLU) for each individual condition, and the fold-activation was calculated 
with respect to the average  RLU of the “empty vector + solvent” at the corresponding 
concentration of PD98059.  E) C2C12 cells were transfected with a pMyoG-Luc (0.5μg), a 
pCMV-β-Gal (0.3μg), and also the indicated kinase expression vector (DN-MEK1, DN-
Raf1) or an empty vector (1μg). The transfected cells were maintained in DM containing 
CT-1 (10ng/ml) or solvent for 16hrs. The cells were harvested and subjected to Luciferase 
assay and β-Gal assay. 
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STAT3 activation by CT-1 is not sufficient for inhibition of myogenesis 
We documented that STAT3 is highly phosphorylated at tyrosine 705 (Y705) 
and serine 727 (S727) in response to CT-1 treatment (figure 4A&B). The Y705 
phosphorylation is required for STAT3 dimer formation, nuclear translocation, and 
transcriptional regulatory activity of STAT3 (Bromberg et al., 1999; Wen et al., 1995; 
Yu et al., 1995). Since a previous study showed that activated STAT3 can inhibit the 
transcriptional properties of MyoD (Kataoka et al., 2003), we postulated that STAT3 
might also be involved in the repression of MyoD by CT-1 signaling. Western blotting 
analysis showed that the MEK inhibitor inhibited phospho-ERK1/2 (an indicator of 
MEK activity) activation by CT-1. However, MEK inhibition had no apparent effect on 
the phosphorylation levels of STAT3 at Y705 or S727 by acute or chronic CT-1 
treatment (figure 5C and 6A).  Since MEK inhibition rescues myogenic repression but 
does not alter STAT3 phosphorylation by CT-1, this indicates that STAT3 activation is 
not sufficient to inhibit myogenesis. To further address this issue, we next used a pan-
JAK kinase inhibitor, P6 (Pedranzini et al., 2006) since STAT3 is phosphorylated by 
the Gp130/LIFRβ associated JAK kinases. As previously observed, CT-1 inhibited 
myotube formation and MyHC accumulation in DM compared to controls (figure 6B). 
In assessing the dose dependency of the P6, we observed no effect on CT-1 mediated 
myogenic repression up to a concentration at 250nM. However, at 500nM, P6 clearly 
neutralised the inhibitory effect of CT-1. Since P6 inhibits tyrosine kinase activity of 
other kinases at high levels (Thompson et al., 2002), we assessed the inhibitory effect 
of P6 on the phosphorylation levels of, STAT3, MEK1/2, and ERK1/2 by Western 
blotting analysis. As is claimed for this inhibitor, increased phosphorylation of STAT3 
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(Y705 and S727) by CT-1 was inhibited by P6 in a dose dependent manner (figure 6C). 
However, at a high concentration (500nM), P6 also repressed phosphorylation of 
ERK1/2 in the presence of CT-1. Since significant repression of phosphorylation of 
STAT3 was seen with the P6 inhibitor at low concentrations (up to 250nM), but such 
concentrations had no effect in reversing CT-1 effects on myogenesis, we conclude that 
STAT3 activation by CT-1 is not sufficient to inhibit myogenesis. In agreement with 
the above results, MyoD driven myoG promoter activity was clearly inhibited in the 
presence of CT-1 (figure 6D). However, at any concentration tested, P6 had little effect 
on CT-1’s inhibitory effect. In addition, exogenous expression of constitutively active 
(A662C and N664C) (Bromberg et al., 1999),  phospho-mimetic mutant (Y705D and 
S727D) or dominant negative forms of STAT3 (S705F and S727A) (Kaptein et al., 
1996) had no apparent effect on myogenesis phenotypically and biochemically in the 
presence of CT-1.  Therefore, these results indicate that inhibition of MEK1/2 activity 
but not JAK activity is required for reversing the inhibitory effect of CT-1 on 
myogenesis. Taken together, we conclude that CT-1 inhibits skeletal muscle 
differentiation primarily through activation of MEK and, surprisingly, does not require 
STAT3 activation. 
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Figure 6. STAT3 activation by CT-1 is not sufficient for inhibition of myogenesis. A) 
C2C12 cells were plated at equal density maintained in DM. A MEK inhibitor (PD98059 
(10μM)) or DMSO was added 30min before the addition of CT-1 (10ng/ml) or its solvent. 
After 20 min of CT-1 or solvent treatment, the cells were harvested, and total protein 
samples were extracted for each condition. The protein samples (20μg) were subjected to 
Western blotting analysis. B) An equal number of C2C12 cells were plated and maintained 
in DM containing CT-1 (10ng/ml) or its solvent, in addition, the indicated concentration of 
pan-JAK kinase inhibitor, P6, was included in the DM. The cells were fixed after 
maintained in the DM for 3days, and accumulation of MyHC was visualized by 
immunochemistry. The brown color indicates MyHC accumulation in the cells. The 
photomicrographs are representative fields of each condition. C) C2C12 cells were plated at 
equal density and maintained in DM for 16 hrs. Thirty min before adding CT-1 (10ng/ml) 
or its solvent, the cells were treated with indicated concentration of P6 (pan-JAK kinase 
inhibitor). After 20 min of CT-1 or solvent addition to the media, the cells were harvested. 
Total protein samples were extracted from the cells in each condition, and equal amounts of 
the protein (20μg) was subjected for Western blotting analysis. D) C2C12 cells were 
transfected with an either pMyoG-Luc or pGL4-10 (0.5μg), and a MyoD expression vector 
(1μg), a pCMV-β-Gal (0.3μg). The transfected cells were maintained in DM containing 
CT-1 (10ng/ml) or solvent, and the indicated concentration of P6 pan-JAK inhibitor for 
16hrs. The cells were harvested and subjected to Luciferase assay and β-Gal assay. 
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CT-1 increases the number of muscle precursor cells and delays regeneration of 
damaged muscle in vivo 
To test the effect of CT-1 on in vivo skeletal muscle function, we utilized 
systemic delivery of a CT-1 expressing adenovirus, AdCT-1 (Bordet et al., 1999). 
AdCT-1 infection causes accumulation of CT-1 protein in cell-culture medium (figure 
7A), and AdCT-1 injection leads to accumulation of CT-1 in liver and skeletal muscle 
(figure 7B). Although it did not lead to gross morphologic alterations in skeletal muscle 
(figure 7C), we noted a significant increase in the number of DAPI positive nuclei per 
myofiber following exposure to AdCT-1 compared to control injected animals (Figure 
7C&D; P<0.05).   This observation suggested that CT-1 exposure represses 
differentiation leading to an increase in the number of undifferentiated myogenic 
precursors in vivo, similar to the effect elicited in C2C12 myoblast cell cultures.  To test 
the possibility that CT-1 elicited an expansion of the myoblast/muscle precursor cell 
population, we also investigated the impact of CT-1 administration on the endogenous 
skeletal muscle progenitor pool.  Skeletal muscle contains a population of cells that 
retain stem cell/progenitor like characteristics and these cells can be isolated based on 
Hoechst dye exclusion, referred to as side population (SP) cells (Asakura et al., 2002; 
Jackson et al., 2002; Muskiewicz et al., 2005). Skeletal muscle derived muscle 
progenitor cells from CT-1 injected animals were substantially increased compared to 
the number of progenitor cell colonies derived from control injected animals (10.6 vs 
1.0; P<0.05; n=7).   Based on our in vitro observations, we postulated that CT-1 
exposure might also limit the differentiation of myoblasts in vivo.  To test this 
supposition we induced muscle regeneration via cardiotoxin (CTX) injection in animals 
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that received either AdCT-1 or the control adenovirus.  CTX injury elicits a well 
defined response in which the myofibers are damaged, followed by expansion and 
differentiation of myogenic precursors to renew or replace the lost myofibers. 
Interestingly, CT-1 injected animals displayed a limited regeneration, exemplified by a 
marked reduction in the number of myofibers with centrally located nuclei and an 
expansion of mononucleated cells associated with regenerating myofibers compared to 
controls (Figure 7E).   These results suggest that CT-1 targets myoblasts/muscle 
progenitor cells in vivo and actively represses the differentiation program. Taken 
together, our results implicate a role for CT-1 in the maintenance of the undifferentiated 
state in muscle progenitor cells. 
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Figure 7. CT-1 delays regeneration of damaged skeletal muscle in vivo  A) Immunoblotting 
was used to verify the efficacy of Adenovirus CT-1 production. Recombinant CT-1 protein 
(100ng) was used as a positive control, as well as media from CT-1 adenovirus infected 
myocytes. At 72hrs post-infection, the media from the treated and untreated cells was collected 
and subjected to Western blotting analysis with a CT-1 antibody. B) At 7 days post-injection, 
skeletal muscle (sk.muscle) and liver samples were excised from adenovirus injected mice. 
Frozen tissue was homogenized and a total of 300μg of protein was electrophoresed on a 15% 
SDS-PAGE. An equal protein loading was verified by Western blotting analysis using β-tubulin 
specific antibody C) At 7days post-injection, skeletal muscle was excised, fixed then embedded 
in paraffin, and sectioned at 10μm. These sections were counterstained with haematoxylin and 
eosin to visualize the nuclei and cytoplasm. For immuno-histological detection of β-actinin, the 
sections were incubated with β-actinin antibody (Abcam), then incubated in donkey-anti-goat 
CY3 antibody (Chemicon) and finally counterstained with DAPI (Sigma). The micrographs were 
representative fields D) 5 fields of view per section and 5 sections per TA muscle were analysed. 
Differences between Ad-CT-1 and Ad-CTRL injected samples were evaluated for statistical 
significance using one tailed, unpaired Student’s t test. Differences were considered statistically 
significant at a p value less than 0.05. (n=3)  
 E) B6C3F1 mice were subject to systemic delivery of the CT-1 adenovirus. The injections were 
administered via intra-cardiac chamber delivery with 50µL of Ad-CT-1 at a concentration of 3.0 
X 108 PFU/mL (n=3). A control group of B6C3F1 mice were injected with 50 µL Ad-CTRL at a 
similar concentration (n=3). In a separate group of animals, cardiotoxin was used to induce 
muscle injury immediately prior to AdCT-1 and Ad-CTRL injection (n=3 for each group). 25μl 
of 10μM cardiotoxin (Latoxan) was injected directly into the TA muscle. 5 fields of view per 
section and 5 sections per TA muscle were analysed. The micrographs were representative views. 
During post-recovery, mice were monitored closely for weight loss, dehydration and cardiac 
distress.  
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Discussion 
In this study, we have characterised CT-1 as a potent inhibitory cytokine for the 
skeletal muscle differentiation program. We document that CT-1 activates MEK, which 
functionally abrogates the transcriptional activation properties of MyoD, a master regulator 
of myogenesis. Repression of this core muscle transcriptional network extinguishes induction 
of the myoG gene, an essential downstream regulator of the muscle differentiation program. 
Inhibition of muscle differentiation by CT-1 is MEK dependent since well-established MEK 
specific inhibitors, PD98059 and U0126 reverse CT-1’s inhibitory effects on myogenesis 
both biochemically and phenotypically. Conversely, even though STAT3 is highly 
phosphorylated in the presence of CT-1, our experiments indicate that the phosphorylated 
STAT3 at Y705 and S727 is not sufficient to inhibit myogenesis. Thus, we conclude that CT-
1 mediated inhibition of myogenesis requires MEK activation which subsequently interferes 
with the trans-activation properties of MyoD. This repression is independent of JAK-STAT 
signaling since pharmacological blockade of this pathway has no effect on the repression of 
myogenesis by CT-1. 
 
Is MEK-ERK signaling a convergent regulatory nexus for cytokine mediated myogenic 
repression? 
Several cytokines and growth factors such as FGF and EGF inhibit myogenesis 
through activation of MEK-ERK signaling. There are however some exceptions, such as IGF 
and Insulin, which activate MEK-ERK but paradoxically enhance muscle differentiation 
under some conditions. Since IGFs and Insulin also activate the Phosphatidy Inositol 3-
Kinase (PI3K)-Akt pathway, and inhibition of PI3K or Akt neutralises their effect on 
104 
 
myogenesis (Xu and Wu, 2000), it is likely that inhibition of differentiation is a “ground 
state” which can be overcome by pro-myogenic signals such as those mediated by Akt (Serra 
et al., 2007). This is essentially the sequence of events during ontogeny in which the muscle 
progenitor cells are held in an undifferentiated state until appropriate cues and conditions for 
differentiation are established. Thus, the dominance of pro-myogenic over inhibitory signals 
is a prerequisite for differentiation to occur. There is now substantial evidence suggesting 
that MEK activation is a point of convergence for several growth factors in repressing 
myogenesis (Page et al., 2004; Ramocki et al., 1997; Rommel et al., 1999). Evidence to date 
indicates that an activated nuclear MEK interacts with the MRFs and inhibits their 
transcriptional activation properties (Perry et al., 2001). The MRFs have consensus MAPK 
phosphorylation sites. However, MEK is capable of inhibiting the activity of a mutated form 
of Myf5, which does not have intact ERK phospho-acceptor sites. Therefore, the 
phosphorylation of the MRFs by MEK is not necessarily required for the repression (Winter 
and Arnold, 2000). Recently, transcriptional regulators have been found to recruit kinases in 
a stable manner to target promoters to phosphorylate other components at the transcriptional 
machinery (Puri et al., 2001). Therefore, it is possible that the recruitment of kinases to 
muscle promoters is required for the inhibitory effects on differentiation. This is consistent 
with our data which indicates that the physical association of MyoD with MEK is crucial for 
the anti-myogenic activity of CT-1.  
Interestingly, another member of the IL-6 cytokine family, LIF, was shown to inhibit 
skeletal myogenesis in vitro (Jo et al., 2005). In agreement with our observations, LIF 
mediated repression was also correlated with MEK-ERK pathway activation (Jo et al., 2005). 
LIF and CT-1 transduce signals in a similar manner through β-receptors such as Gp130 and 
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LIFRβ. Prior to binding to the β-receptors, at least some of the IL-6 family cytokines bind to 
ligand specific α-receptors, and expression levels of the α-receptor in some cell types is 
known to regulate the sensitivity of the responsiveness to the specific ligand. Although LIF 
appears to bind β-receptors directly, CT-1 forms a complex with an α-receptor (Heinrich et 
al., 2003). However, this receptor has so far not been fully characterized, so a tissue specific 
role of this receptor has yet to be determined. In C2C12 skeletal muscle cells, we have 
confirmed that Gp130 and LIFRβ are expressed, and further characterization of the CT-1 α-
receptor will delineate the precise receptor system. The convergence of LIF and CT-1 on 
MEK-ERK signaling suggests that this is a common nodal point for Gp130 linked cytokines. 
CT-1 was originally isolated as a hypertrophic factor for cardiomyocytes in vitro 
(Pennica et al., 1995). Chronic administration of CT-1 into the mouse, indeed, causes 
hypertrophic hearts and also increases the size of liver, kidney, and spleen. This is, at least 
partially, the result of induction of the Vascular Endothelial Growth Factor (VEGF) gene in 
cardiac myocytes through activation of the Gp130-JAK-STAT3 pathway (Jin et al., 1996). In 
addition, CT-1 activates MAPK pathways and the Akt-PI3 kinase pathway and protects 
cardiomyocytes from apoptosis (Brar et al., 2001; Liao et al., 2002; Sheng et al., 1997). One 
of the target genes of CT-1 in this cardio-protective role is the Small Proline-Rich Repeat 
protein-1A (SPRR1A) gene. CT-1 induces SPRR1A expression transcriptionally through 
activation of MEK-AP-1 and CCAAT/Enhancer-Binding Protein-β (C/EBPβ) pathways. This 
SPRR1A gene induction by CT-1 is independent of STAT3 activity but blunted by small 
chemical inhibitors of MEK activity, PD98059 and U0126 (Pradervand et al., 2004). 
Therefore, in other systems, CT-1 activates MEK kinases and regulates their down stream 
transcription factors. In C2C12 cells, we observed that the SPRR1A promoter was also up-
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regulated by CT-1 or an activated form of MEK, and this induction was dependent on MEK 
activation. However, SPRR1A over-expression does not inhibit myogenesis suggesting that 
this CT-1 target gene is not responsible for myogenic repression. Our observations are 
discordant with a previous study, in which it was shown that activated STAT3 and MyoD 
physically interact and functionally antagonise each other by competing for limited amounts 
of co-activators, such as P300 and PCAF (Kataoka et al., 2003). We document that the pan-
JAK inhibitor, P6, reduced the phosphorylation levels of STAT3 (Y705 and S727) by CT-1 
but had little effect on myotube formation or MyoD’s transcriptional activity at the 
concentration at which P6 inhibits phosphorylation of STAT3. Therefore, while we do not 
completely rule out the possibility that the inhibition of MyoD activity may be partly 
mediated by STAT3, we conclude that activation of MEK but not STAT3 is the primary 
molecular event responsible for CT-1’s inhibitory effect on myogenesis. Further support for 
this idea was recently provided by the observation that STAT3 and JAK2 were shown to be 
required for muscle differentiation C2C12 (Wang et al., 2008). Thus, the notion that STAT3 
also functions in an inhibitory manner is unlikely. In addition, we observed that a well 
established JAK2 inhibitor, AG490, inhibited muscle differentiation in a dose dependent 
manner as previously reported (supplemental figure 2A) (Wang et al., 2008). However, this 
JAK2 inhibitor surprisingly had no effect on phosphorylation of STAT3 by CT-1 
(supplemental figure 2B). Therefore, the JAK/STAT pathway does not appear to play a 
repressive role during myogenesis. 
Given the temporal and spatial patterns of CT-1 expression during myogenesis, a 
pervasive consideration is whether CT-1 plays a role in the maintenance of the 
undifferentiated state or even pluripotency of progenitor cells in an autocrine or paracrine 
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manner. Since CT-1 is expressed in skeletal muscle at key times during embryogenesis, and, 
as we observed, has a potent role in which it can reversibly repress myogenesis in vitro and 
delay regeneration in vivo. The observed in vitro and in vivo role of CT-1 in skeletal muscle 
cells defines it as a potential target of therapeutic interventions in which small molecule cell 
permeable inhibitors can be used to manipulate pro- and anti-differentiation pathways. 
Moreover, knowledge of these pathways could be instrumental in ex-vivo programming of 
progenitor cells which may have critical implications for a variety of cellular based muscle 
therapies. 
In summary, we have documented that the CT-1 cytokine has a potent repressive 
effect on skeletal myogenesis in vivo and in vitro. This effect, which is reversible, requires 
MEK-ERK signaling and, surprisingly, does not require STAT3 activation. The expression 
patterns of CT-1 and its in vivo and in vitro properties described here make it a viable 
candidate to play a role in the maintenance of the undifferentiated muscle progenitor cell 
state in embryonic and post-natal skeletal muscle. 
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Summary 
Activator protein 1 (AP-1) is a ubiquitous transcription factor that paradoxically 
also has some tissue specific functions. In skeletal muscle cells, we document that the 
AP-1 subunit, Fra-2, is expressed in the resident stem cells (Pax7 positive satellite 
cells) and also in the analogous undifferentiated “reserve” cell population in myogenic 
cultures, but not in differentiated myofibre nuclei.  Silencing of Fra-2 expression 
enhances the expression of differentiation markers such as muscle creatine kinase 
(MCK) and myosin heavy chain (MyHC) indicating a possible role of Fra-2 in 
undifferentiated myogenic progenitor cells.  We observed that Fra-2 is a target of 
cytokine mediated ERK 1/2 signalling in cultured muscle cells and extensive mass 
spectrometry and mutational analysis identified S320 and T322 as regulators of Fra-2 
protein stability.  Interestingly, Fra-2 S320 phosphorylation occurs transiently in 
activated satellite cells and is extinguished in Myogenin positive differentiating cells.  
Thus, cytokine mediated Fra-2 expression and stabilization is linked to regulation of 
myogenic progenitor cells having implications for the molecular regulation of adult 
muscle stem cells and skeletal muscle regeneration. 
 
Keywords 
Activator protein-1, Phosphorylation, myogenesis, satellite cells, ERK 1/2 signalling 
Abbreviations:  AP-1, activator protein-1; CT-1, cardiotropin-1; EDL, extensor 
digitorum longus; ERK 1/2, extracellular signal-regulated kinase; MAPK, mitogen 
activated protein kinase; MB, myoblast, MCK, muscle creatine kinase; MRF, myogenic 
regulatory factor; MT, myotube; MyHC, myosin heavy chain. 
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Introduction 
Skeletal muscle development (myogenesis) is a complex and crucial process in 
all metazoan embryonic development involving temporal and spatial coordination of a 
network of myogenic transcription factors (Buckingham et al., 2003).  In particular, 
members of the myogenic regulatory factor (MRF) family have a prominent role during 
myogenesis.  These transcription factors include commitment factors MyoD and Myf5, 
and differentiation markers MRF4 and Myogenin (Braun et al., 1994; Cossu et al., 
1996; Kablar et al., 1999; Wright et al., 1989).  Other transcription factors also play 
obligatory roles in regulating skeletal myogenesis such as members of the myocyte 
enhancer factor 2 (MEF2) (Edmondson et al., 1994; Novitch et al., 1999; Ornatsky et 
al., 1997; Wang et al., 2001), Six, and Smad families (Kollias et al., 2006; Miyake et 
al., 2010).  Along with the tissue restricted myogenic factors, contributions of more 
ubiquitous transcriptional regulators at muscle promoters also impinge on the precise 
combinatorial regulation required for orchestration of the myogenic program 
(Andreucci et al., 2002).  Previously we have implicated activator protein-1 (AP-1) as 
one example of this class of ubiquitous transcription factors that contribute, in concert 
with the MRFs, to the regulation of muscle gene expression.   
AP-1 is a transcription factor complex comprising of Jun (c-Jun, JunD, JunB) 
homodimers or Jun-Fos (Fra-1, Fra-2, c-fos, FosB) heterodimers.  AP-1 complexes 
have been classically associated with cancer progression and are characterized as proto-
oncogenes (Bossy-Wetzel et al., 1992; Lian et al., 1991).  However, they are 
ubiquitously expressed and have a wider role than initially anticipated in the control of 
tissue specific genes.  In myogenic cells, previous data has suggested that AP-1 is a 
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negative regulator of differentiation based on observations that c-Jun dimerizes with 
MyoD to inhibit its activity (Bengal et al., 1992) and also MyoD is required to down 
regulate c-Fos for differentiation to proceed (Trouche et al., 1993).  The AP-1 subunits 
are well defined nuclear targets of signalling pathways active in skeletal muscle such as 
mitogen activated protein kinases (MAPK) and ERK 1/2 is a known upstream kinase of 
Fos family members (Acquaviva et al., 2001; Gruda et al., 1994). 
The AP-1 complexes that bind DNA in skeletal muscle cells was previously 
examined by us and it was found that Fra-2 was a primary component of the myogenic 
AP-1 DNA binding complex (Andreucci et al., 2002).  Thus, we sought to assess the 
role of Fra-2 and determine the mechanism by which it is regulated during myogenesis. 
Cardiotrophin-1 (CT-1), is a cytokine that potently inhibits skeletal muscle 
differentiation by activating MEK 1/2 -ERK 1/2 signaling (Miyake et al., 2009).  Using 
a mass spectrometry based approach along with mutational analysis we report two 
regulatory ERK 1/2 MAPK phosphorylation sites on Fra-2 in response to CT-1- ERK 
signaling.  The two Fra-2 phosphorylation sites, S320 and T322, contribute to a 
potentiation in Fra-2 protein stabilization.  These sites are phosphorylated in response 
to growth factors such as CT-1. Stabilization of Fra-2 by phosphorylation results in an 
overall inhibition of differentiation while loss of function studies using Fra-2 siRNAs 
demonstrated that reduced Fra-2 levels potentiate expression of muscle specific marker 
genes such as muscle creatine kinase (MCK) and myosin heavy chain (MyHC).  
Interestingly, separation of reserve cells and myotubes (MT) in a differentiated culture 
revealed differential expression of Fra-2. Fra-2 expression was largely restricted to 
reserve cells during differentiation and further studies indicate that Fra-2 was expressed 
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and phosphorylated in activated muscle satellite cells, the adult muscle stem cell 
progenitor population. 
 
Materials and Methods 
 
Cell culture.  The C2C12 cell line was purchased from American Tissue Culture 
Collection (ATCC).  Cells were maintained in growth media (GM) consisting of 10% 
foetal calf serum (FBS) in Dulbecco modified eagles medium (DMEM) (Gibco) 
supplemented with 2mM L-glutamine (Invitrogen) and 100μg/ml 
penicillin/streptomycin (Invitrogen).  Cells were induced to differentiate at 80% 
confluency using differentiation media (DM) consisting of 2% horse serum in DMEM 
supplemented with 2mM L-glutamine (Invitrogen) and 100μg/ml 
penicillin/streptomycin (Invitrogen).   
 
Fractionation of Myotubes and Reserve cells.  C2C12 cells were allowed to 
differentiate for 96 to 144h in DM.  Media was removed from the plate and cells were 
washed twice with cold 1X PBS (phosphate buffered saline) followed by addition of 
1ml of 0.125% trypsin diluted in 1X PBS.  Cells were inspected using an Axiovert 25 
(Carl Ziess) light microscope for MT contraction.  On visual observation of MT 
contracture trypsin was removed and 1ml of cold 1X PBS was added.  The plate was 
gently swirled to dislodge MT which were then collected in a 1.5ml tube.  The plate 
was further washed with cold 1X PBS to remove residual MT after which the reserve 
cells (which remained on the plate) were scraped off into a 1.5ml tube.  
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Cloning and mutagenesis.  The Fra-2 ORF was cloned into the pGEX-4T vector, 
pcDNA3 (Invitrogen) or in frame downstream of an EGFP tag.  Site directed 
mutagenesis was carried out using the QuikChange Multi-site directed mutagenesis kit 
(Stratagene) for construction of the Fra-2 phospho-mutations, following manufacturers 
protocol. 
 
Antibodies and other reagents.  The following antibodies were purchased from 
SantaCruz: Fra-2 Q-20 (sc-604), Fra-2 L-15 (sc-171), c-Jun (H-79) (sc-1694), Actin (I-
19) (sc-1616-R), dsRed (C-20) (sc-33354), MyoD (M-318) (sc-760), ERK1 (C16) (sc-
93), donkey anti-goat IgG-HRP (sc-2020).  The following antibodies were obtained 
from Cell Signalling: MEK 1/2 (#9122), phospho-MEK 1/2 (#9121), phospho-p44/p42 
MAPK (Thr202/Tyr204) (#9106), phospho-Fra-1 (#3880), phospho-c-Jun (#9261). 
Myogenin (clone F5D) and MyHC (clone MF20) monoclonal antibodies were derived 
from hybridomas provided by the Developmental Studies Hybridoma Bank (DSHB).  
Goat anti-rabbit IgG-HRP (170-6515) and goat anti-mouse IgG-HRP (170-6516) were 
from BioRad Laboratories.  Lyophilized CT-1 (438-CT) was obtained from R and D 
systems.  PD98059 (#9900) was purchased from Cell signalling.  MG132 (C2211) was 
from Sigma-Aldrich. 
 
Transfection.  Myoblasts were seeded at a density of 12.5 x 103 cells/well for 6-well 
plates and 1.0 x 105 cells/plate for 100 mm plates.  Transfections were carried out using 
standard Hepes buffered saline (HEBS)-CaCl2-phosphate mediated transfection method 
using a total of 5μg of DNA for 6 well plates and 25μg for 100 mm plates.  Expression 
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vectors used included pcDNA3_Fra-2, pcDNA3_Fra-2 DEF, dsRed2, and Fra-2 
S120A, S230A, S320A, Fra-2 S120A, S200A, S230A, Fra-2 S120A, S200A, S230A, 
S320A, Fra-2 S320A, Fra-2 T322A, Fra-2 S320A T322A, Fra-2 S320D, Fra-2 T322D.  
Luciferase reporter constructs include pGL-4-10_luc, pGL4-10_myogenin_luc and 
pRL_Renilla (Promega).  Three siRNAs (Mission® siRNA ID’s: 
SASI_Mm01_00201000, SASI_Mm01_00201002, SASI_Mm01_00201004) targeting 
mouse Fra-2 were obtained from Sigma-Aldrich.  They were reconstituted in nuclease 
free water (Ambion) and 15nM of siRNA was transfected into cells using lipofectamin 
(Invitrogen) in serum-free media.  
 
Protein extraction.  For total cell lysate analysis, media was aspirated from plates and 
cells were washed twice with cold 1X PBS and scraped into 1.5 ml tubes.  Cells were 
pellet at 1.5 x1000g and resuspended in NP-40 lysis buffer (50 mM Tris, 150 mM 
NaCl, 0.5% Nonietp-40 (NP-40) 2 mM EDTA) 100 mM NaF and 10 mM Na 
pyrophosphate) supplemented with protease inhibitor cocktail (Sigma, P8340), 1mM 
NaV (Bioshop) and 1mM PMSF (Sigma).  Cytosolic and nuclear extraction was 
performed using a NE-PER nuclear protein extraction kit (Thermoscientific, #78833) 
Protein concentrations were determined using the Bradford protein assay (BioRad).  
 
Luciferase reporter gene assays.  Media was aspirated from cells grown in 6-well 
dishes and cells were washed twice with cold 1X PBS.  Cells were scraped in 
Luciferase lysis buffer (20mM Tris pH 7.4 0.1% TritonX) and lysate was transferred to 
1.5ml tubes.  Samples were briefly vortexed and spun at maximum speed for 15 min at 
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4°C.  Samples were aliquoted into tubes and Luciferase assay substrate (E1501) or 
Renilla assay substrate (E2820), purchased from Promega, was added and Luciferase 
and Renilla enzymatic activity was measured on a luminometer. 
 
IP and CIP treatment.  Immunoprecipitation was carried out using the ExactaCruz F 
kit (SantaCruz, sc-45043) according to manufactures’ protocol.  Briefly, 40μl of IP 
matrix was incubated overnight with 5μg of Fra-2 primary antibody.  The IP matrix-
antibody complex was washed three times with cold 1X PBS and incubated overnight 
with 120μg of total cell lysate.  IP matrix-antibody-protein complex was washed three 
times with cold 1X PBS supplemented with protease inhibitor cocktail (Sigma, P8340), 
1mM NaV (Bioshop) and 1mM PMSF (Sigma), before incubation with CIP (NEB, 
M0290S) or its buffer.  2X SDS sample buffer was added and samples were boiled and 
loaded on a 10% SDS page gel and analyzed by Western blotting.  
 
Western blotting.  A total of 20μg of total lysate was resolved on 10% (or 8%) SDS-
PAGE gels and transferred onto Imobolion-P or Immobilon-FL PVDF membranes 
(Millipore).  Membranes were blocked using 5% milk in 1X PBS or 1X Tris buffer 
saline (TBS) containing 0.05% tween20 (TBS-T) and incubated with primary 
antibodies overnight at 4°C.  Membranes were washed with 1X PBS or 1X TBS-T and 
incubated with secondary antibody then washed with 1 X PBS or 1X TBS-T.  
Immunoreactive bands were detected using ECL Chemiluminescence reagent (GE 
Healthcare). 
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GST-purification.  Human full length ORF of Fra-2 was cloned in frame into a pGEX 
4T-1 vector, which contains glutathione S-transferase (GST) to generate a GST-Fra-2 
fusion protein.  GST-Fra-2 was transformed in BL-21 competent E. coli cells.  
Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Bioshop, IPT001) was used to 
induce expression of the fusion protein.  Cells were harvested and the fusion protein 
was purified via affinity binding on GST beads (Sigma, G4510). 
 
In vitro kinase assay.  Bacterial expressed purified GST (2μg), GST-Fra-2 (2μg), or 
MBP (NEB, P6021S) (2μg) were incubated with radioactive γ32P-ATP (Amersham) 
with or without purified ERK2 (20ng) kinase (NEB, P6080S).  Samples were incubated 
at 30°C for 40 min before addition of 4x SDS sample buffer and boiled for 5 min.  
Samples were resolved on an 8 % SDS-PAGE gel which was Coomassie stained to 
visualize bands.  The gel was dried and exposed to film to capture light emitted by γ32P-
ATP-labelled proteins. 
 
In-gel digestion and mass spectrometry analysis.  The kinase assay as indicated above 
was repeated, replacing the radiolabelled γ32P-ATP with unlabelled ATP (NEB, 
P0756S), and the band shift was observed once again in a Coomassie blue stained gel 
when GST-Fra-2 was incubated with ERK2, however, an 8% SDS-PAGE gel was run 
to achieve greater resolution of the bands.  The lower mobility phosphorylated GST-
Fra-2 band was excised along with the un-phosphorylated GST Fra-2 band.  These 
bands were digested with trypsin overnight at 37°C.  Tryptic peptides were loaded onto 
a HPLC Chip (160 nl high capacity sample enrichment column and 75-μm x 150 mm 
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SB-C18 separation column, Agilent Technologies, Santa Clara, CA, USA) and 
separated by flow rate at 300 nL per minute, with solvent A (0.2(v/v)% formic acid in 
water) and solvent B (100 % acetonitrile) and the following gradients: at 0, 50, 54, 56 
minute after injection with 3%, 35%, 80%, 100% solvent B, respectively.  The LC-
MS/MS analysis was carried out using an Agilent 1100 HPLC-chip and 6340 ion trap 
system with MS scan range from 300 to 1,300 m/z and back-to-back CID/ETD 
(collision-induced-dissociation/electron transfer dissociation).  30 seconds dynamic 
exclusion was applied to the precursor previously selected for MS/MS twice.  Raw data 
files from LC-MS/MS were searched against a custom protein sequence representing 
GST-Fra-2 using Spectrum Mill MS Proteomics Workbench (v03.03.084, Agilent 
Technologies).  The Data Extractor utility program detected peaks, assigned precursor 
charges where possible (for those not successfully determined, 2+ to 5+ were 
considered), filtered MS/MS spectra by quality (spectra with peak number > 4 and 
sequence tag length > 2 were kept for MS/MS search), centroided the MS/MS spectra, 
merged nearby MS/MS spectra from the same precursor by default MS/MS similarity 
criteria and generated peak lists.  Peak lists were searched by the following criteria: two 
missed trypsin cleavages, fixed modification (carbamidomethylation on cysteine), 
variable modifications (oxidized mthionine, pyro-glutamic acid modification at N-
terminal glutamines, phosphorylated-serine, -threonine, and -tyrosine), precursor mass 
tolerance +/- 2.5 Da, product mass tolerance +/- 0.7 Da.    The spectra identified by 
Spectrum Mill to be phopshorylated were manually verified and reported. 
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Immunocytochemistry.  Cells were grown to the desired state and media was removed.  
Cells were washed with 1X PBS and fixed with 70% methanol.  Cells were blocked in 
5% milk in 1X PBS and incubated with MyHC primary antibody.  Primary antibody 
was removed and cells were washed with 1X PBS and incubated with anti-mouse 
secondary antibody HRP-conjugated.  A final concentration of 10mg/ml of DAB 
(Sigma, D8001) and 3% hydrogen peroxide (Sigma, 216763) were used as a substrate 
and the nuclei were stained with haematoxylin (Sigma, H3136). 
 
Limited proteolytic cleavage.  In vitro kinase was preformed as described above and 
the reaction products incubated with trypsin (Roche) at 16°C for the indicated times.  
At each time point 4X SDS loading buffer was added to stop cleavage.  Samples were 
boiled and analyzed by Western blotting. 
 
Primary skeletal muscle fibre isolation and immunoflourescence analysis.  Myofibres 
were isolated from the muscle of 4- extensor digitorum longus (EDL) month-old female 
C57Bl/6 mice as described in detail by Otto et al (2008). Briefly, undamaged EDL 
muscles were dissected with both tendons intact and the single fibres liberated through 
digestion with 0.1% type I Collagenase in DMEM at 37ºC 5% CO2.  Heat flame tapered 
glass pipettes were used to plate isolated single fibres into floating culture wells 
containing DMEM supplemented with 10% horse serum and 0.5% chick embryo 
extract for up to 72h. For immunocytochemistry, myofibres were fixed in 2% 
Paraformaldehyde in PBS for 10 minutes and washed 3 times in PBS. Myofibres were 
permeabilised in a solution of 20 mM Hepes, 300 mM sucrose, 50 mM NaCl, 3 mM 
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MgCl2 and 0.5% Triton-X100 (pH7) at 4°C for 15 minutes and incubated in blocking 
wash buffer (5% newborn calf serum in PBS containing 0.01% triton X-100) for 30 
minutes prior to antibody incubation. Antibodies were diluted and pre-blocked in wash 
buffer for 30 minutes prior to addition to the myofibres. Primary antibodies used were: 
Monoclonal mouse anti-Pax7 and anti-Myogenin (clone F5D) both from (DSHB) 1:1, 
Fra-2 (SantaCruz Q-20) 1:2000 and phospho Fra-1 (Cell Signalling Technology #3880) 
1:1000.  All primary antibodies were incubated with fibres overnight at 4°C. Primary 
antibodies were visualised using the following secondary antibodies: Alexa Fluor goat 
anti-mouse 594 (A11032 Molecular probes), Alexa Fluor goat anti-rabbit 488 (A11034 
Molecular probes). Secondary antibodies were used at 1:200 and incubated at room 
temperature for 45 minutes.  All myofibres were mounted in Fluorescent mounting 
medium (DAKO cytomation) containing 7.5mg/ml DAPI for nuclear visualisation. 
Mounted myofibres were analysed using a Zeiss Axioscope fluorescence microscope 
and images captured using an Axiocam digital camera system and Axiovision image 
analysis software (version 4.7). 
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Results 
Fra-2 is a downstream target of cytokine activated cellular signalling pathways 
that inhibit myogenic differentiation 
Expression of the AP-1 transcription factors has been observed in differentiating 
myogenic (C2C12) cells even though exogenous expression of c-Jun has been shown to 
repress myogenesis (Thinakaran et al., 1993).  We previously determined that Fra-2 is 
the main Fos related subunit of the AP-1 DNA binding complex in myogenic cells and 
its regulation may be mediated by phosphorylation (Andreucci et al., 2002).  Fra-2 is 
know to be a ERK 1/2 MAPK target (Eriksson and Leppa, 2002; Murakami et al., 
1997) and the ERK 1/2 MAPK pathway is active in proliferating MB cells and in later 
stages of differentiation where it is critical for MB fusion (Li and Johnson, 2006).  
Growth factors that suppress differentiation are involved with the maintenance of the 
undifferentiated state such as CT-1 (Miyake et al., 2009).  These growth factors, 
specifically CT-1 have also been shown to activate ERK 1/2 and we therefore 
postulated that Fra-2 may be a downstream target in myogenic cells. When MB in 
serum reduced conditions were treated with CT-1 (10ng/ml) we observed an increase in 
P-ERK 1/2 10 to 30min post treatment (see supplementary figure S1).  Concurrently we 
observed a low mobility Fra-2 band which was correlated with the activation of ERK 
1/2 in CT-1 treated cells (see supplementary figure S1).  Our data indicate that CT-1 
was able to activate the MEK 1/2-ERK 1/2 MAPK pathway and target Fra-2 by 
inducing a slower migrating Fra-2 band in C2C12 cells (figure 1A).  To test whether 
the lower mobility Fra-2 band was ERK 1/2 dependent we used an inhibitor of 
activated MEK 1/2 (PD 98059) to block ERK 1/2 activation.  Figure 1B indicates that 
123 
 
the slower mobility Fra-2 band seen with CT-1 (10ng/ml) treatment was reduced by the 
addition of the MEK 1/2 inhibitor PD 98059 
and was correlated with reduced P-ERK 1/2 levels.  Thus, repression of ERK 1/2 
activation by pharmacological inhibition of MEK 1/2 resulted in a loss of the modified 
form of Fra-2 in C2C12 cells.  These data implicate ERK 1/2 activation by CT-1 with 
changes in the mobility of Fra-2 and repression of myogenesis.  
To directly test whether the change in Fra-2 mobility with CT-1 was due to 
direct phosphorylation we analyzed mobility changes of endogenous and exogenously 
expressed Fra-2 in the presence or absence of CT-1 in C2C12 MB cells (figure 1C).  
Fra-2 was immunoprecipitated from MB and treated with calf intestinal phosphatase 
(CIP) which resulted in the loss of the slower mobility Fra-2 band (figure 1D).  
Interestingly, in addition to loss of the higher mobility Fra-2 band we observed 
enhanced mobility of all the immunoreactive Fra-2 after CIP treatment suggesting that 
Fra-2 exists in various states of phosphorylation (figure 1D).   
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Figure 1.  Fra-2 is a downstream target of the MEK 1/2 -ERK 1/2 MAPK pathway.  (A) 
C2C12 MB were serum starved for 8 h prior to treatment with Cardiotrophin-1 (10ng/ml) or 
solvent control.  Cells were harvested after 20min of CT-1 treatment and Fra-2 expression was 
assessed by Western blotting.  (B) Proliferating MB following serum withdrawal for 8 h were 
pre-treated with PD98059 1 h prior to CT-1 (10ng/ml) treatment.  Cells were harvested 20 min 
after CT-1 treatment and analyzed for Fra-2 expression by Western blotting.  (C) Western blot 
of exogenously expressed Fra-2 in cells treated with CT-1 (10ng/ml).  C2C12 MB expressing 
exogenous Fra-2 were incubated with CT-1 (10ng/ml) for 20min prior to harvesting.  Total cell 
lysates were prepared and Fra-2 was IP from cells.  (D) The Immunoprecipitated samples were 
treated with calf intestinal phosphatase (CIP) or its buffer before Western blotting.   
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Identification and characterization of ERK 1/2 specific Fra-2 phosphorylation 
sites 
Since there is always some ambiguity as to the true identity of kinase-substrate 
interactions in cell lysates, we performed an in vitro kinase assay to assess if Fra-2 was 
directly phosphorylated by activated ERK 1/2.  Figure 2A (first panel) shows that when 
GST-Fra-2 was incubated with activated ERK 2 and γ-32P-ATP a change in mobility of 
the GST-Fra-2 protein was seen in the Coomassie blue stained gel  (as marked by 
asterisks in the first panel) in agreement with the cell based studies.  In addition, the 
slower mobility complex was hyperphosphorylated as indicated by γ-32P-ATP 
radioactive incorporation into the Fra-2 protein when the gel was exposed by 
autoradiography (figure 2A second panel), thus, directly showing that Fra-2 was 
phosphorylated by ERK 2. 
   To begin to define the effects of ERK 1/2 on Fra-2 we mapped the specific 
phosphorylation sites on Fra-2 by ERK2 using mass spectrometric methods.  We 
performed an in vitro kinase assay using GST-Fra-2 as substrate and ERK2 as kinase 
and processed the Coomassie blue stained Fra-2 protein bands for mass spectrometric 
analysis.  Using this methodology, four phosphorylated peptides were detected (boxed 
in figure 2B) containing four proline directed phosphorylated residues: S120, S200, 
S230, S320 and one potential non-proline directed site T322 (bold in figure 2B) were 
identified.  These phosphopeptides were selected and fragmented by tandem MS.  
Figure 2C (first panel) shows an ETD MS/MS spectrum of a precursor peptide (m/z 
1023.5 doubly charged) which corresponds to amino acids 317-326 of Fra-2 with an 
extra 80 Da.  Note that in the ETD spectrum, fragments from the N terminus give C ion 
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series and fragments from the C terminus give Z ion series and the peptide bond N-
terminal to a proline residue does not break.  The observed C ion series (C10, C12, 
C13, C15, C17, C18, and C19) supported the identity of the peptide (317- 
SSSSGDQSSDSLNSPTLLAL-326).  In addition, though fragment C14 was not 
expected due to the nature of a proline residue in the ETD spectrum, the difference 
between the C13 (1269.7 m/z) and C15 (1534.8 m/z) fragment ions is 265.1 Da which 
is equal to a combination of theoretical mass of serine and proline and an extra 80 Da.  
Thus, it is clear that S320 was phosphorylated in this ETD spectrum. Similarly in figure 
2C (second panel) the C13 ion had a m/z of 1269.6 Da and C16 of 1634.7 Da.  The 
difference between the two ion fragments is 365.1 Da which the mass of serine, 
threonine and proline.  The theoretical mass of serine, threonine and proline is 285.31 
Da and since the difference between the observed (365.1 Da) and the actual (285.31 
Da) fragment mass was 80 Da we can conclude that the serine or threonine is 
phoshorylated.  Thus, these data support phosphorylation at S320 and T322 on Fra-2. 
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Figure 2.  Identification of Fra-2 phospho-acceptor sites using phospho-peptide mass 
spectrometry analysis.  (A) Purified GST, GST-Fra-2, or MBP were incubated with γ-32P-ATP 
and activated ERK 2 or its buffer in vitro.  The samples were run on an 8% SDS-PAGE gel 
which was Coomassie stained (panel A), dried and exposed to film (panel B).  GST alone was 
used as a negative control and MBP was used as a positive control.  (B)  Linear Fra-2 amino 
acid sequence.  The In vitro kinase assay was repeated with GST-Fra-2, activated ERK 2 and 
unlabeled ATP.  Samples were resolved on an 8% SDS-PAGE gel and the unphosphorylated 
and phosphorylated GST-Fra-2 bands were excised, digested by trypsin and the resultant 
peptides were analyzed by mass spectrometry.  The results from the mass spectrometry analysis 
are summarized:  where phospho-peptides detected by mass spectrometry are boxed, DEF 
domain (282-285) is underlined and ERK 2 phosphorylated residues (120, 200, 230, 320, 322) 
are in bold.  (C) Spectra for S320 (first panel). C13 ion has a m/z of 1269.7 and C15 ion 1534.8 
and a difference of 265.1.  The C13 ion is composed of S and P which have masses of 87.08 
and 97.12 respectively, added together to give 184.2.  The difference between 265.1 and 184.2 
is 80.90 which corresponds to a addition of a phosphate group.  The spectra for T322 (second 
panel) has a C13 of 1269.6 and C16 1634.7 has a difference of 365.1.  The C16 ion corresponds 
to S, P, T, which m/z of 87.08, 97.12, and 101.11 respectively added together gives 285.31.  
The difference gives 79.79 corresponding to an addition of a phosphate group. 
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Mutational analysis of Fra-2 specific phosphorylation sites 
We next sought to determine the function of the Fra-2 phosphorylation sites 
identified by mass spectrometry.  To address this, a series of combinatorial Fra-2 
phospho acceptor site mutations were generated by site-directed mutagenesis.  Some 
interesting observations were made when the combinatorial mutations were expressed 
in C2C12 cells.  Fra-2 phospho-mutations containing S320A and/or the T322A 
mutation altered the Fra-2 protein mobility pattern compared to wild-type Fra-2 which 
was similar to Fra-2 DEF which contains a mutation in the ERK 1/2 docking site.  Fra-
2 containing S320A and/or T322A had an observable loss of the slower migrating 
hyperphosphorylated Fra-2 band while mutations not containing S320A or T322A did 
not (see supplementary figure S2).  Interestingly, expression levels of Fra-2 containing 
S320A and/or T322A mutations were expressed at lower levels in addition to the loss 
of the slower mobility (High Mr) band (figure 3A).  Initial mutational data suggested 
that S320 and T322 might be important phosphorylation sites for Fra-2 stability.  
Interestingly, S320 is a conserved phosphorylation site on Fra-1 and a similar 
observation was previously reported (Basbous et al., 2008), however, the T322 site has 
not been examined in any Fos family member.  In order to assess the function of these 
sites, single neutralizing mutation of S320 and T322 to alanine were generated and 
expressed in C2C12 cells.  Neutralization of S320 or T322 alone resulted in loss of the 
slower mobility band and reduced notably expression of Fra-2 (figure 3B).  The double 
mutation: both S320A and T322A had similar effects to the single mutations.  These 
results suggest that S320 and T322 are responsible for hyperphosphorylation of Fra-2; 
moreover lack of phosphorylation at these sites contributes to a marked decrease in Fra-
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2 protein levels compared to wild-type Fra-2.  Interestingly, we noticed that 
neutralization of S320 and T322 to alanine causes Fra-2 to become considerably less 
stable than wild-type Fra-2 (figure 3B) and we therefore postulated that phospho-
mimetic mutation would result in the opposite effect.  Expression of S320D and T322D 
mutants reconstituted Fra-2 stability similar to wild-type Fra-2 (figure 3B) suggesting 
that phosphorylation at S320 and T322 is required for Fra-2 protein stability.  To 
confirm phosphorylation of Fra-2 on S320 we used a phospho-Fra-1 antibody that 
reacts with the conserved peptide containing phospho-S320 of Fra-2.  Wild-type Fra-2 
when phosphorylated at S320 could be detected at high levels using the phospho-
specific antibody indicating its efficacy (figure 3B). As expected Fra-2 S320D was 
undetectable with the phospho-specific antibody but unexpectedly cells expressing Fra-
2 T322D did not have a high level of phosphorylated S320 (figure 3B).  Moreover, we 
observed a reduction in phospho-S320 in Fra-2 when only T322 was mutated 
suggesting that T322 may be required for efficient phosphorylation of S320. 
 
Fra-2 phosphorylation at S320 and T322 regulates protein stability 
Since our earlier experiments suggested that Fra-2 phosphorylation might alter 
its function in myogenic cells, the Fra-2 phospho-mutations were tested in MBs.  We 
expressed the phospho-mutations S320A and T322A in MB and MT and observed 
reduced expression of the mutated versions compared to wild-type Fra-2 in MB and 72 
h MT (see supplementary figure S3) suggesting that S320 and/or T322 are important 
sites for stabilizing Fra-2 throughout differentiation.  Loss of phosphorylation at S320 
and T322 destabilized Fra-2, possibly targeting it to the proteosome for degradation.  
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To address this further we treated C2C12 expressing the mutated Fra2 variants with the 
proteosome inhibitor MG132.  When MG132 was included we noticed that the 
expression of the phospho-neutralizing mutations increased as well as wild-type Fra-2 
and Fra-2 DEF (figure 3C).  Thus, Fra-2 targeted proteosomal degradation is resisted by 
S320 and T322 phosphorylation.  Our data suggest that CT-1 can activate the ERK 1/2 
MAPK pathway which phosphorylates Fra-2 at S320 and T322 affecting protein 
stability.   
Phosphorylation can result in conformational changes in protein structure with, 
in many cases, subsequent effects on function.  Fra-2 protein is stabilized when 
phosphorylated by ERK 1/2 and we postulated that its conformation in the 
phosphorylated and unphosphorylated states may differ.  When unphosphorylated at 
S320 and T322, Fra-2 is unstable.  To determine if the phosphorylated form of Fra-2 is 
in a different conformation to the unphosphorylated protein we performed a limited 
proteolytic digestion assay.  The idea of this assay is that if a protein is in an altered 
conformational state then its susceptibility to limited proteolytic digestion may be 
altered.  After incubating GST-Fra-2 with activated ERK 2 kinase we observe a 
phosphorylated high mobility Fra-2 band (figure 3D).  When digested for short time 
periods with trypsin we observe different patterns of peptide accumulation for the 
unphosphorylated and phosphorylated forms of GST-Fra-2 indicative of a change in 
conformation (figure 3D).  This analysis provides initial structural evidence that ERK 
1/2 phosphorylated Fra-2 is in an altered conformation compared to the 
unphosphorylated Fra-2.  Further NMR and crystallography based studies will be 
required to fully characterize the ERK 1/2 dependent conformational changes in Fra-2. 
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Stability of Fra-2 is potently enhanced by phosphorylation at S320 and T322 
and the next question concerns how this affects its function.  Therefore, we investigated 
whether stability affected Fra-2 function during myogenesis.  The Myogenin promoter 
is active in differentiation conditions and its activity is regulated by MyoD.  Using 
Myogenin as a marker for skeletal muscle differentiation we found that wild type Fra-2 
inhibited the induction of the Myogenin promoter and Fra-2 S320D and T322D 
mutations further blocked this activity (figure 3E) compared to the control.  Thus, 
suggesting that stability of Fra-2 by phosphorylation may impede myogenesis. 
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Figure 3.  Expression and stability of Fra-2 phospho-mutants in myogenic cells.  
(A) Western blot analysis showing the expression of Fra-2 (wild-type), Fra-2 DEF and 
mutated proteins:  Fra-2 S120A, S230A, S320A, Fra-2 S120A, S200A, S230A, Fra-2 
S120A, S200A, S230A, S320A, T322A.  (B) Western blot analysis showing expression 
of Fra-2 (wild-type), Fra-2 DEF,  Fra-2 S320A, Fra-2 T322A, Fra-2 S320A/T322A, 
Fra-2 S320D and Fra-2 T322D in myogenic cells.  (C) C2C12 cells treated with 
MG132 (5μM) for 5 h.  Cells were harvested and expression of wild-type and mutated 
Fra-2 were analyzed by Western blotting.  Actin was used as a loading control and 
dsRed as a marking of transfection efficiency.  (D)  Limited proteolytic digestion of 
GST-Fra-2.  An in vitro kinase assay using 10μg of GST-Fra-2 and 2ng of activated 
ERK 2 was performed.  The reaction was divided into seven tubes and trypsin was 
added at a ratio of 100:1 and incubated for the indicated times.  Samples were run on a 
10% SDS page gel and Fra-2 was detected by Western blotting.  (E) C2C12 cells were 
transfected with wild-type Fra-2 or Fra-2 S320D or T322D and a myogenin promoter 
reporter gene (pGL4-10-myogenin-luc).  Cells were maintained in DM conditions for 
24 h prior to harvesting.  Luciferase values were normalized to Renilla.  Luciferase and 
Renilla values represent an average of three independent samples. 
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Loss of Fra-2 expression enhances myogenesis 
In an initial attempt to assess the functional role for Fra-2 in skeletal 
myogenesis, we silenced its expression using siRNA technology.  Initially, three 
siRNAs targeting Fra-2 were characterized for their efficacy.  All three siRNAs reduced 
Fra-2 protein level when compared to cells transfected with a negative control siRNA 
and untransfected cells, however siRNA2 gave the most optimal reduction (figure 4A).  
Fra-2 suppression in differentiating MB cultures resulted in no change in Fra-1 or c-Jun 
expression (figure 4B) during a time course of skeletal muscle differentiation.  In 
conditions where Fra-2 was reduced, we observed an increase in late differentiation 
marker proteins MCK and MyHC compared to control conditions (figure 4B).  Thus, a 
reduction of Fra-2 protein levels resulted in an observable increase in the expression of 
muscle specific differentiation markers.   
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Figure 4.  Knock down of Fra-2 enhances differentiation.  (A) Three independent siRNAs 
targeting Fra-2 were transfected in proliferating C2C12 cells.  Western blot analysis was 
performed to determine level of Fra-2 knock down.  Actin was used as a loading control and 
dsRed as a marker for transfection efficiency.  (B)  Knock down of Fra-2 was assessed during a 
time course of C2C12 differentiation by Western blotting.  Protein levels of some AP-1 
components and myogenic markers were also analyzed. 
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Fra-2 expression in reserve and primary satellite cells 
In a differentiated culture of C2C12 cells as shown in figure 5A there is a bi-
modal population of cells: multi-nucleated myotubes (indicated by an arrow) and mono 
nucleated “reserve cells” (as seen boxed).  The establishment of the reserve population 
is a stochastic event since this is a clonal cell line in which all cells have the same 
potential when seeded, but yet some form MT while others remain quiescent and 
undifferentiated.  Reserve cells and MT in a differentiated culture can be separated to 
assess differential gene expression (Cao et al., 2003; Stuelsatz et al., 2010; Sun et al., 
2008).  When separated the reserve cells and MT revealed differential expression of 
AP-1.  Protein analysis in figure 5B shows that Fra-2 was expressed in proliferating 
MB in GM and in total differentiated lysate (includes MT and reserve cells).  However, 
when MT and reserve cells were fractionated from a differentiated culture and western 
blotting performed we noticed that Fra-2 (along with c-Jun) was greatly reduced in MT 
while their expression was maintained in the reserve cells (figure 5B). Interestingly, 
Fra-1 expression was detected in only MB cells ruling out its involvement during 
differentiation.  Since Fra-2 is not expressed in MT we attributed potentiation of 
differentiation to a reduction of the reserve cell population suggesting that Fra-2 
ordinarily holds the cells in an undifferentiated state and, when its expression is 
extinguished, leads these cells to differentiate.  
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Figure 5.  Expression and localization of Fra-2 in myogenic cells.    (A) A 96h culture of 
differentiated C2C12 cells under phase contrast microscopy.  The boxed cells are 
mononucleated reserved cells and the arrows indicate multinucleated myotubes.  First panel 
depicts cells in culture maintained in DM and the second panel shows fixed cells immuno-
stained for MyHC, a marker of differentiation, the nuclei were stained with haemotoxylin.  (B) 
Western blot analysis was performed on proliferating C2C12 cells in GM conditions and 
differentiated cultures maintained in DM.  The differentiated cultures were analyzed by total 
(T) which included all cells in a differentiated culture, myotube (MT), the fraction enriched for 
MT, and the reserve (R) fraction of mononucleated cells.   
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Reserve cells have been described as analogous to satellite cells, which lie within the 
basal lamina of muscle fibres and are activated after muscle injury.  We performed 
immunostaining for Fra-2 and P-Fra-2 on primary muscle fibres at various time points 
and stained for Pax7 and Myogenin (figure 6A, B).  In view of the analogy between 
reserve cells and satellite cells, we postulated that Fra-2 might play a role in satellite 
cells.  To address this we used primary single fibre cultures in which myofibres are 
cultured with their associated satellite cells.  In these cultures satellite cell activation 
and differentiation occurs in a manner similar to their activation in vivo.  Fra-2 and its 
phosphorylated form were expressed at 48h in Pax7 positive cells and was not 
expressed in the myonuclei of the myofibre consistent with our idea that Fra-2, along 
with Pax7,  marks satellite cells (figure 6A).  At 72h myogenin expression was 
observed in cells that co-expressed Fra-2 (figure 6B).  Interestingly, the Myogenin 
expressing cells did not co-express the phosphorylated form of Fra-2 (figure 6B). These 
data indicated that Fra-2 is expressed in both Pax7 and Myogenin positive satellite 
cells, while phospho-Fra-2 was only observed in cells expressing Pax7 but not 
Myogenin (figure 6C).  Together, these data suggest that Fra-2 phosphorylation only  
marks activated satellite cells and the phosphorylation is extinguished in Myogenin 
positive differentiating cells. 
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Figure 6.  Fra-2 expression in satellite cells.  Myofibers were dissected from EDL muscle of 
adult mice and cultured in a dish for the indicated times (48h and 72h) (A) Fibres were 
immunostained for Fra-2 (green) or P-Fra-2 (green), and Pax7 (red) at 48h in culture.  Nuclei 
were stained with DAPI (blue).  (B) Fibres were immunostained for Fra-2 (green) or P-Fra-2 
(green), and Myogenin (red) at 72h in culture.  Nuclei were stained with DAPI (blue).  (C) 
Schematic representation of Fra-2, P-Fra-2, Pax7 and myogenin expression in satellite cells 
(SC) in single fibre cultures. Dark blue circles represent myonuclei, and light blue satellite cells 
that reside within the basal lamina (BL) and sarcolemma (SL). 
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ERK 1/2 inhibition modulates satellite cell differentiation and Fra-2 
phosphorylation.   
 
In 48h primary single fibre cultures P-Fra-2 is expressed in Pax7 positive 
satellite cells but myogenin expression does not appear until 72h in culture and is not 
co-expressed with P-Fra-2.  When 50µM of the MEK 1/2 inhibitor, PD 98059 was 
added to 48h primary culture fibres, P-Fra-2 levels decrease due to ERK 1/2 activation 
being inhibited (figure 7).  In addition, Myogenin expression appeared precociously at 
48h in fibres treated with PD 98059 compared to control treated fibres (figure 7). Taken 
together, these experiments are consistent with the idea that ERK phosphorylation and 
Fra-2 stabilization are congruous with the undifferentiated state in myoblasts and 
satellite cells. Conversely, repression of ERK signalling and concomitant 
hypophosphorylation and destabilization of Fra-2 result in enhanced myogenic 
differentiation (Figure 8). The identification of Fra-2 expression in both “reserve” and 
satellite cells may have important implications for a role in muscle maintenance and 
regeneration. 
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Figure 7.  MEK 1/2 inhibition activates satellite cell differentiation in primary muscle 
fibres.  Satellite cells in primary single muscle fibres from the EDL muscle were isolated from 
adult mice.  After 48h in culture, fibres that were previously incubated with 50µM of the MEK 
1/2 inhibitor PD 98059 or its control (DMSO) were immunostained for Myogenin (green) or P-
Fra-2 (red).  DAPI (blue) was used to mark nuclei. 
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Figure 8.  Fra-2 phosphorylation may regulate muscle gene induction in C2C12 cells.  Fra-
2 is phosphorylated at S320 and T322 by ERK 1/2 resulting in protein stabilization which leads 
to inhibition of muscle-specific gene expression and differentiation. 
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Discussion 
In this study, we report a novel regulation of the AP-1 subunit Fra-2 in skeletal 
myogenesis.  We have demonstrated that Fra-2’s expression is restricted to mono-
nucleated “reserve cells” in a differentiated culture suggesting a possible role in 
maintaining the undifferentiated state.  Additionally, we have identified an important 
level of regulation for AP-1 complex composition by identifying S320 and T322 as 
ERK 1/2 dependent phosphorylation sites on Fra-2 in skeletal muscle. These phospho-
acceptor sites determine the contribution of Fra-2 to the AP-1 complex by potently 
stabilizing Fra-2 protein levels.  Neutralization of one or both of these sites destabilizes 
Fra-2 making it susceptible to proteosomal degradation.  Conversely, phospho-mimetic 
mutation of S320 and T322 facilitate stabilization of the protein.  Stabilization of Fra-2 
contributes to the ensemble of gene expression leading to skeletal muscle 
differentiation. 
 
Regulation and expression of Fra-2 in skeletal muscle differentiation.   
Fra-2 is expressed in cultured skeletal muscle cells and satellite cells indicating 
that it may be important for skeletal muscle gene expression.  ERK 1/2 signalling has 
also previously been implicated as playing a complex bi-phasic role in skeletal muscle 
differentiation (Bennett and Tonks, 1997). Here, we show that Fra-2 is a primary ERK 
substrate in response to cytokine signalling in myogenic cells.  We previously reported 
CT-1 as an inhibitor of differentiation and have implicated this cytokine as maintaining 
the undifferentiated state in myoblasts (Miyake et al., 2009).  CT-1 is an activator of the 
ERK 1/2 pathway and we now report that it targets Fra-2 indicating the possibility that 
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AP-1 might be involved in maintenance of the undifferentiated state in myogenic cells.  
AP-1 expression is maintained in the “reserve population” in a differentiated C2C12 
culture. These reserve cells are stochastically determined as cells that remain in a 
quiescent undifferentiated state despite the surrounding clonally equivalent cells 
forming differentiated myotubes (Kuang et al., 2007). In addition, our observations that 
Fra-2 is expressed in Pax7 positive satellite cells and not in the differentiated myonuclei 
supports a possible role in adult muscle progenitor cells.  These preliminary data imply 
a previously unexplored role for AP-1 in regulating the reserve population (mono-
nucleated cells in differentiation conditions) in an undifferentiated state and also 
satellite cells in mature muscle.  Consistent with our data, AP-1 may be down regulated 
in MT as multinucleated cells become unresponsive to ERK 1/2 signalling.   Also, it is 
possible that  secreted factors from MT impede differentiation of  adjacent myoblasts 
which establishes the reserve population by activating a paracrine signal pathway (Chan 
et al., 2007).  If the cells become differentially responsive to ERK 1/2 signalling then 
Fra-2 would be unphosphorylated at S320 and T322 in differentiating myotubes when 
ERK signalling is down regulated which could be a mechanism to destabilize Fra-2 
protein and promote its proteosomal degradation. Our observation that Fra-2 levels are 
reduced in differentiating cells and maintained in quiescent undifferentiated cells and 
satellite cells is consistent with this idea.   
 
S320 mediated Fra-2 protein stability is dependent on T322 phosphorylation.  
Interestingly, other Fos family members such as c-Fos and Fra-1 have a 
conserved serine at the site corresponding to S320 of Fra-2 in their C-terminus 
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(Acquaviva et al., 2001).  Moreover the site corresponding to T322 of Fra-2 is also 
conserved on c-Fos and Fra-1 but has not been reported to influence the stability of 
these proteins.  Here, we show that T322 of Fra-2 is vital for efficient phosphorylation 
and stabilization of Fra-2 primarily through its effect on S320 phosphorylation.  Our 
data suggest that this site may function as a  priming site for S320 phosphorylation 
however more detailed structural studies are required to further investigate the role of 
T322 (or its analogous residue in the other Fos proteins) in tandem with S320 for Fra-2 
stabilization. 
 
AP-1 as a direct regulator of a variety of muscle specific genes. 
Recently Cao et al., reported that a large subset of genes regulated by MyoD in 
skeletal muscle cells are enriched with AP-1 sites (Cao et al., 2010).  These data 
suggest that AP-1, similar to MyoD, may regulate a number of genes in the muscle 
lineage. Many of these genes prove to be down-regulated during myogenesis.  These 
differential effects of AP-1 at different gene loci reflects a common theme of modern 
transcription factor biology in which the effect of a particular factor on a target gene is 
dependent on the combinatorial influence of co-factors and other transcription factors at 
any given promoter/enhancer, as well as the myriad post translational events that 
converge on each transcriptosome. There are still a number of important paradoxes to 
explain with regard to AP-1 and its role in a variety of cellular contexts and processes. 
Part of the answer may lie in the promiscuous nature of AP-1 in its ability to interact 
with a diverse network of factors that may lead to complex transcriptional outcomes 
that are dependent on higher order transcriptosome network dynamics.  
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Fra-2 as part of the AP-1 complex.   
The variation in AP-1 complex composition can dictate how it will function 
(Andreucci et al., 2002).  Fra-2 is one component of a functional AP-1 complex which 
can also comprise of Jun-Jun, Jun-Fos or Jun-ATF2 dimers (Daury et al., 2001).  In 
differentiating skeletal muscle, our data demonstrate that Fra-2 is the primary AP-1 
subunit binding DNA which dimerizes with either c-Jun or JunD (Andreucci et al., 
2002).   This suggests that Fra-2 is the major regulator in AP-1 complexes formed in 
myogenic cells.  Thus, establishing a role for Fra-2-c-Jun and Fra-2-JunD complexes 
could provide insight into differential gene regulation by AP-1 complexes.  In other 
systems it has been determined that AP-1 function differs depending on its dimer 
composition (Abell et al., 2009).  Differential subunit recruitment of co-factors is also a 
factor that might influence AP-1 specificity.  For, example Trip6, a LIM domain 
protein, was found to interact with Fos family members but not Jun proteins 
(Diefenbacher et al., 2008) which illustrates an additional level of regulation for Fos 
proteins possibly including Fra-2. 
 
Functional specificity and redundancy for AP-1 components.  
In an attempt to characterize the role of individual AP-1 subunits some groups 
have generated and analyzed AP-1 knockout mice.  Deletion of c-jun, junB, or fra-1 are 
found to be embryonic lethal, while mice lacking jund, c-fos, or fra-2 have specific 
organ defects (Jochum et al., 2001).  To date no skeletal muscle defects have been 
reported for any of the AP-1 subunits.  Interestingly, the fra-2 homozygous null mouse 
dies within one week of birth and is runted implicating a possible lack of postnatal 
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muscle growth based on the fact that skeletal muscle constitutes the heaviest 
contributor to body mass.  Conditional knockouts have provided more information on 
the role of individual AP-1 proteins in specific tissue types.  For example c-Jun, when 
deleted in hepatocytes, impairs liver regeneration.  Interestingly, some studies have 
analyzed the possible redundancy of AP-1 protein function by “knock in” strategies.  
For example JunB was knocked into the c-Jun locus and was found to largely rescue the 
embryonic lethality of c-Jun homozygous deletion (Passegue et al., 2002).  Also, Fra-1 
was knocked into c-Fos deficient mice and found to rescue c-Fos knockout defects 
(Fleischmann et al., 2000).  Contrary to the gene targeting data that suggests specific 
functions of different AP-1 components in different tissue or cell types, the “knock in” 
data suggest that, to some degree, the specificity of AP-1 subunits may be more closely 
related to their spatial and temporal pattern of expression than differences in the 
properties of the individual subunits. This is indeed a controversial idea in view of the 
many studies that have shown unique properties of distinct AP-1 components, 
necessitating further clarification.  
In summary, we have observed restricted expression of Fra-2 in the reserve and 
satellite cell populations in skeletal muscle.  SiRNA mediated reduction of Fra-2 
increases the commitment of cells to the differentiation program suggesting a possible 
role for Fra-2 in satellite cells.  Additionally, we have identified and characterized two 
phosphorylation sites on Fra-2 that are targeted by ERK 1/2 signalling that potently 
regulate Fra-2 stability in skeletal muscle.  Fra-2 expression is restricted to cells that are 
maintained in the undifferentiated state suggesting that the signal dependent 
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stabilization of Fra-2 and its contribution to the AP-1 complex may be an important 
contributor to satellite cell function in response to a variety of cytokines. 
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S1.  CT-1 transiently activates Fra-2 in C2C12 cells.   
C2C12 cells were serum starved for 8h followed by treatment with CT-1 
(10ng/ml) and harvested at the indicated time points.  Western blot analysis 
was performed to determine CT-1 effect on Fra-2 protein levels. 
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S2.  ERK 1/2 targets S320 and T322 are regulated sites on Fra-2.  
Combinatorial mutation for Fra-2 phospho-sites were generated and 
transfected into C2C12 cells.  Western blotting was used to determine 
expression of the mutated Fra-2 constructs.  Actin was used as a loading 
control and dsRed as a marker for transfection efficiency. 
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S3.  Neutralization of S320 and T322 on Fra-2 decreases protein 
expression.   
C2C12 cells were transfected with wild-type Fra-2, Fra-2 DEF, or 
neutralization mutation for S320 and T322. Expression of Fra-2 and its 
mutation were assessed by Western blotting in MB and MT.  Actin was used 
as loading control and dsRed as a marker for transfection efficiency. 
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Chapter V: Summary and conclusion 
The processes that encompass skeletal muscle development such as 
determination, proliferation and differentiation as well as maintenance and regeneration 
are regulated by MRFs and MEF2 family of transcription factors (Naya and Olson, 
1999; Tapscott and Weintraub, 1991).  While transcriptional control of these processes 
is established the upstream signaling events regulating MRFs and MEF2 are not well 
understood.  The cytokine, CT-1, is a known cardiomyocyte hypertrophic factor that is 
also expressed in skeletal muscle.  Activation of the MEK1/2/ERK1/2 and JAK/STAT 
pathways is initiated by CT-1 in skeletal muscle.  However, MEK1/2, but not 
JAK/STAT, when activated by CT-1, was determined to be inhibitory to differentiation.  
Activation of MEK1/2 by CT-1 promoted interaction with MyoD repressing its 
transcriptional activity leading to inhibition of muscle gene expression (Miyake et al., 
2009).  Thus, a direct role for MEK1/2 in myogenesis was demonstrated in this work.  
Additionally, MEK1/2 is the upstream kinase of ERK1/2 which has a role in 
proliferation and maintenance of skeletal muscle. However, direct targets of ERK1/2 
are not fully characterized in skeletal muscle. 
Other transcription factors such as AP-1 augment gene expression in skeletal 
muscle contributing to the processes involved in myogenesis.  AP-1 is known to 
activate proliferative genes in MB and also to inhibit differentiation.  Studies reported 
here have expanded the putative role of AP-1 in myogenesis to  maintenance and 
regeneration in adult muscle (Alli et al., 2013).  Fos family members including Fra-2 
are known to be regulated by phosphorylation by the ERK1/2 kinase which is also 
important in regulating skeletal muscle proliferation and quiescence.  Previously, CT-1 
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was determined to maintain undifferentiated myogenic cells via MEK 1/2 signaling 
(Miyake et al., 2009).  Using CT-1 it was observed that MEK1/2 activated ERK 1/2, a 
kinase that phosphorylates the AP-1 subunit, Fra-2.  Consequently, it was determined 
that in skeletal muscle Fra-2 is phosphorylated on S320 by ERK1/2 resulting in a 
change in Fra2 protein stability.  Stabilization of Fra-2 when phosphorylated on S320 
negatively impacts differentiation possibly by maintenance of quiescence.  A novel 
biological role for Fra-2 is proposed base on its restricted expression in reserve cells in 
a differentiated culture of C2C12 cells that includes myotubes.  Moreover, differential 
expression of Fra-2 in satellite cells not in mature myocytes provides further evidence 
of a putative role in maintaining the undifferentiated state (Alli et al., 2013).  Based on 
these studies, Fra-2 is now an established activated satellite cell marker that may also 
be required for progenitor cell maintenance. 
In summary, inhibitory cytokines such as CT-1 repress skeletal muscle 
differentiation by MEK1/2 activation.  Once activated MEK1/2 may directly repress 
expression of muscle specific genes by inhibiting MyoD activity or by activation of 
ERK1/2.  Activation of ERK 1/2 leads to the phosphorylation of Fra-2 which maintains 
its stability repressing the differentiation program.  AP-1 target genes are largely 
unidentified but mustn1 is an AP-1 target gene in skeletal muscle and its mechanism of 
regulation and role has yet to be determined (figure 23). 
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Figure 25. Summary of AP-1’s role and regulation in skeletal muscle 
development. 
In proliferating myoblast, Fra-2 is phosphorylated by ERK1/2 on S320, 
mediating protein stability.  Stabilized Fra-2 leads to inhibition of muscle 
specific genes, while loss of Fra-2 expression upregulated muscle genes.  In 
differentiated muscle, Fra-2 expression is reduced in myotubes and in 
myonuclei of muscle fibres.  Fra-2 expression is elevated in mononucleated 
reserve cells and satellite cells of the muscle fibre. 
Myoblast Myofibre 
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Skeletal muscle specific target genes regulated by AP-1 are uncharacterized.  
Analysis of MyoD and MEF2 binding sites obtained from ChIP experiments may prove 
useful in identifying muscle specific AP-1 targets, as they are enriched for TREs (Cao 
et al., 2010).  Exploring such target genes may provide further insight into a mechanism 
for AP-1 target gene regulation in skeletal muscle either enhancing or repressing 
muscle specific genes.  An AP-1 ChIP sequencing study in C2C12 cells or satellite 
cells to determine target genes would provide a global profile of gene regulation in 
skeletal muscle.  Although, AP-1 gene targets in skeletal muscle remain largely 
unknown, the mustn1 gene may be a useful candidate for AP-1 regulation in 
myogenesis.  The mustn1gene contain MyoD binding sites and is enriched for AP-1 
sites (see Appendix A, figure 1).  The expression profile for the mustn1gene shows that 
it is expressed in proliferating cells, and levels increase in differentiating C2C12 cell 
(see Appendix A, figures 2).  In addition, Fra-2 was found to bind to the endogenous 
mustn1 promoter in differentiating C2C12 cells (see Appendix A, figure 3).  More 
recently, mustn1 was found in satellite cells (Krause et al., 2013), which leads to the 
possibility that Fra-2 may regulate its expression in regeneration. 
The regulation of Fra-2 and other AP-1 proteins is crucial to its function in 
skeletal muscle.  The role of posttranslational modification is complex since Fra-2 is 
highly phosphorylated possibly by other unidentified kinases, as well as ERK1/2 
described here.  Whether, Fra-2 requires additional phosphorylation for dimerization or 
DNA binding has yet to be determined.  It remains unclear what interacting partners 
mediate AP-1 activity.  Therefore, knowledge of dimerization partners and co-factors 
that enhance or repress AP-1 protein activity would also be useful in understanding its 
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regulation.  Studies focused on AP-1 gene regulation require identification of targets 
that mediate skeletal muscle development.  Large scale studies such as AP-1 ChIP 
sequencing would identify genes bound by AP-1 which could be classified based on 
function.  Such studies would provide insight into the different subset of genes 
regulated by AP-1. 
Loss of function experiments in primary single fibres would be valuable to 
understand AP-1’s role in satellite cells.  Manipulation of AP-1 by siRNA in single 
muscle fibres followed by analysis of Pax7+ cells would help determine the role of AP-
1 in satellite cells.  Gene targeting in mice provides a useful model for analyzing 
development effects in loss of function or gain of function studies.  Fra-2 transgenic 
and conditional knockout mice would assist in investigating skeletal muscle phenotype 
and satellite cell regeneration in an in vivo model.  Such experiments would test 
whether AP-1 is required for satellite cell activation and maintenance.   
Examining the role of AP-1 in maintaining quiescence in other systems may be 
of interest.  Rhabdomyoscaroma cells, which express muscle specific genes such as 
MyoD and Myogenin but do not differentiate into multi nucleated myotubes (Tonin et 
al., 1991), could be used as a model to investigate AP-1 regulation of undifferentiated 
cells.  Somitic mesodermal cells that have the potential to commit to different cell 
lineages and it would be of interest if AP-1 was involved in keeping other cell types in 
an undifferentiated state.  Treatment of C2C12 cells with some growth factors can 
redirect muscle to other phenotypes such as osteogenic or adipogenic (Fux et al., 2004).  
Since AP-1 is involved in maintaining quiescence these transcription factors may have 
roles in transdifferentiation processes allowing one cell type to change phenotype to 
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another.  A novel role for AP-1 in pluripotency could be developed as well as potential 
use in stem cell therapies. 
Molecular studies on skeletal muscle development involving AP-1and CT-1 
may be relevant clinically.  Muscular dystrophies are characterized by loss of muscle 
mass or chronic muscle weakness.  Cachexia and sarcopenia are also characterized by 
irreversible muscle loss.  Given that these diseases are all characterized by muscle loss, 
studies directed at muscle regeneration are required.  Since satellite cells are resident 
muscle stem cells, AP-1 could be a target for maintaining these cells.  Stem cell and 
muscle precursor cells have been utilized in transplantations in attempts to restore 
muscle.  However, satellite cell transplantations are not widely used due to the low 
yield after isolation.  Regulation and activation of satellite cells in culture are currently 
being studied.  Propagation of satellite cells in culture to generate higher yields could 
allow use for transplantation.  Interestingly, it has been demonstrated that fibrosis 
reduces muscle regeneration.  Using extracellular signaling molecules such as TGF-β 
and myostatin inhibitors have been shown to reverse fibrotic deposition.  Since CT-1 is 
an inhibitory cytokine that activates similar downstream effectors as TGF-β it may be 
used as an anti-fibrotic drug.  Additionally, CT-1 maintains undifferentiated muscle, 
thus it may have another role in maintaining satellite cells.  
In this thesis, the molecular role of an AP-1 subunit (Fra-2) has been studied 
and linked to cellular signalling pathways.  The identification of Fra-2 as a new marker 
and also potential regulator of satellite stem cells in mature skeletal muscle offers new 
insight and possibilities for muscle maintenance and regeneration in the physiology and 
pathophysiology of the muscular system.
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Summary 
Satellite cells are the adult muscle stem cells and are marked by the expression 
of Pax7 and Myf5 transcription factors.  Previously, the AP-1 subunit Fra-2 was shown 
to be co-expressed in Pax7 positive satellite cells of single primary muscle fibres 
indicating a possible role for AP-1 in muscle regeneration.  The genes targeted by AP-1 
in skeletal muscle regeneration are of interest but are currently unknown.  In this study 
we demonstrate that Fra-2 regulates mustn1, a MyoD and AP-1 target gene expressed in 
skeletal muscle and satellite cells. 
 
Introduction 
The events that comprise skeletal myogenesis are commitment, differentiation 
and regeneration.  Skeletal myogenesis is regulated by the myogenic regulatory factors 
(MRFs), which are a family of skeletal muscle specific transcription factors (Molkentin 
and Olson, 1996b).  The MRF are basic helix loop helix proteins that along with 
myocyte enhancer factor 2 (MEF2) transcription factors regulate gene expression 
required for in skeletal muscle development (Molkentin and Olson, 1996a; Pownall et 
al., 2002; Puri and Sartorelli, 2000).  Myogenic cells are specified in mesodermal cells 
of the somites by Pax3 and Pax7 transcription factors.  Pax3 and Pax7 regulate 
expression of Myf5 and MyoD which are commitment factors of myoblasts.  MyoD 
along with MEF2 proteins regulate expression of muscle differentiation factors such as 
Myogenin and muscle creatine kinase (MCK) (Qin et al., 1998).  Injured skeletal 
muscle fibres are capable of repairing as they possess adult muscle stem cells termed 
satellite cells (Bischoff, 1975).  Satellite cells are located within the basal lamina and 
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scaroplasma of the fibre and express Myf5 and Pax7 (Kuang et al., 2007).  Activated 
satellite cells proliferate and undergo differentiation or self-renewal.  Satellite cells can 
self-renew in which case they express Pax7 or they can differentiate in which case they 
upregulate myogenic factors MyoD and Myogenin forming a cluster of clonogenic, 
myogenic cells that will form a new fibre or contribute to an existing one (Buckingham 
and Montarras, 2008). 
Activator protein-1 (AP-1) is a transcription factor complex that is composed of 
Jun and Fos proteins that have implications for skeletal myogenesis.  The Jun proteins 
include c-Jun, JunB and JunD and can homodimerize or heterodimerize with Fos 
proteins, c-Fos, FosB, Fra-1 and Fra-2 (Angel and Karin, 1991).  AP-1 research has 
evolved since the early nineties following its discovery. Overall, AP-1 is a negative 
regulator of skeletal muscle differentiation suggested by the data in the literature to date 
(Alli et al., 2013; Bengal et al., 1992; Thinakaran et al., 1993).  The transcription factor 
complex has defined roles in proliferation mediating the activation of cell cycle 
progression genes (Schreiber et al., 1999) and repression of myogenic factors, 
specifically MyoD (Bengal et al., 1992).  The AP-1 proteins can also bind DNA in 
differentiating myoblast cells (Andreucci et al., 2002) but the muscle specific genes 
regulated remain largely unknown.  More recently, a regenerative role for the AP-1 
subunit Fra-2 has been proposed (Alli et al., 2013).  Expression data suggests that AP-1 
may have a role in regulating quiescence and activation of satellite cells (Alli et al., 
2013).  AP-1 already has been shown to activate proliferation in stem cells in other 
lineages (Biteau and Jasper, 2011; Kook et al., 2013) and may be a regulator of muscle 
stem cell function. 
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A less characterized AP-1 target gene in skeletal muscle is mustn1.  Mustn1 was 
originally identified in a bone fracture screen and has been reported to be regulated by 
AP-1 (Liu and Hadjiargyrou, 2006; Lombardo et al., 2004).  Furthermore, AP-1 
complexes were reported to activate a mustn1 driven luciferase reporter (Liu and 
Hadjiargyrou, 2006).  More recently, GFP expression when driven by the mustn1 
promoter was detected in Pax7 positive satellite cells in muscle fibres (Krause et al., 
2013).  These data suggest that mustn1 may have a role in skeletal muscle regeneration 
and its regulation may be influenced by AP-1. 
In this study, we evaluate a subset of MyoD target genes that are enriched for 
AP-1 binding sites.  We show that one of these genes, mustn1, is expressed in skeletal 
muscle cells.  We also demonstrate that the AP-1 subunit, Fra-2, targets the mustn1 
gene in skeletal muscle. 
 
Materials and Methods 
 
Cell culture.  The C2C12 cell line was purchased from American Tissue Culture 
Collection (ATCC).  Cells were maintained in growth media (GM) consisting of 10% 
foetal calf serum (FBS) in Dulbecco modified eagles medium (DMEM) (Gibco) 
supplemented with 2mM L-glutamine and 100μg/ml penicillin/streptomycin 
(Invitrogen).  Cells were induced to differentiate at 80% confluency using 
differentiation media (DM) consisting of 2% horse serum in DMEM supplemented 
with 2mM L-glutamine and 100μg/ml penicillin/streptomycin (Invitrogen).   
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ChIP and qPCR.  Plates were washed once with 1X PBS (4°C) to remove media.  Cells 
were incubated with 1% formaldehyde for 15 min at RT after which 0.125 M of glycine 
was added.  Liquid was removed and cells were washed three times with 1X PBS 
(4°C).  Cells were scraped in 1 ml of 1X PBS and protease and phosphatase inhibitors 
(4°C) and centrifuged for 5 min at 5000 rpm at 4°C to pellet cells.  Supernatant were 
removed and cells resuspended with 1 ml of Wash buffer I (10mM HEPES pH 6.5, 0.5 
mM EGTA, 10mM EDTA, 0.25% Triton X-100, protease and phosphatase inhibitors) 
and Incubated on ice for 5 min.  Lysate was centrifuged for 5 min at 3000 rpm at 4°C, 
supernatant was removed and nuclei were resuspended in 1 ml of Wash buffer 2 
(10mM, HEPES pH 6.5, 0.5mM EGTA, 1mM EDTA, 200mM NaCl, protease and 
phosphatase inhibitors) and incubate for 10 min on ice followed by centrifugation at 
5000 rpm for 5 min at 4° and removal of supernatant.  To lyse nuclei, 250 μl of SDS 
lysis buffer (50mM Tris-HCl ph 8.1, 1mM EDTA, 1% SDS, protease and phosphatase 
inhibitors, prepare fresh) was added to nuclei.  DNA was sonicated to approximately 
250-600 bp fragments.  Samples were centrifuge at max speed for 15 min at 4°C to 
remove insoluble materials.  Supernatant, containing sheared DNA, were transferred to 
a clean tube.  Protein G dynal magnetic beads were blocked using salmon sperm DNA 
while   1μg of Fra-2 (SantaCruz Q-20) primary antibody was incubated with sheared 
DNA overnight at 4°C.  Pre-blocked protein G dynal magnetic beads were added to the 
IP reaction and incubated for 1h at 4°C. The magnetic beads were washed with low salt 
wash buffer (20mM Tris pH 8.1, 2mM EDTA, 150mM NaCl, 1% Triton-X 100, 0.1% 
SDS) followed by washing in high salt buffer (20mM Tris pH 8.1, 2mM EDTA, 
500mM NaCl, 1% Triton-X 100, 0.1% SDS.  Beads were then washed twice with Tris-
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EDTA.  Protein-DNA complex were eluted from beads by incubating with elution 
buffer (0.1M NaHCO3, 1% SDS) for 30min at room temperature.  Collect supernatant 
in clean tubes and incubate with 5M NaCl overnight at 65°C.  Isolated DNA was 
purified using the Qiagen PCR clean up kit, as per manufactures instructions.  Samples 
were analyzed using the Applied biosystems 7500 real time PCR system. 
 
qRT-PCR.  RNA was isolated from C2C12 cells using the RNeasy kit (Qiagen) 
following manufactures protocol.  Isolated RNA was converted to cDNA using 
superscript II (Invitrogen) following manufactures protocol.  Specific primers for 
mustn1 were use to amplify the cDNA template.  Samples were run on a 1.2% agarose 
gel containing ethidium bromide.  Bands on the agarose gel were visualized using an 
imager.  
 
Results and Discussion 
 
 
The MyoD target Mustn1 contains AP-1 DNA binding sites 
Genes regulated by AP-1 in skeletal muscle differentiation and regeneration are 
largely unknown but large scale studies of MyoD ChIP-sequencing and MEF2 ChIP-
exonuclease from our group (Stephanie Wales, unpublished observations) have 
revealed that their respective binding sites, CANNTG and AT rich sites such as 
5’C/TTA(AT)4TAG/A’, are enriched with 12-O-tetradecanolyphorbol 13-acetate (TPA) 
responsive elements (TRE’s) (Angel et al., 1987; Lamph et al., 1988), which are 
identified by its 5’ TGAC/GTCA 3’ consensus sequence TRE’s (Cao et al., 2010).  
These data support the hypothesis that AP-1 may also contribute to the control of 
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muscle specific gene expression in skeletal muscle.  A genome wide MyoD ChIP-
sequence performed in Stephen J. Tapscotts lab (Cao et al., 2010) analyzed MyoD 
binding in target promoters in myoblast and myotube cultures.  The group also assessed 
changes in expression of these genes using an array study (Cao et al., 2010).  Using a 
motif search it was predicted that many promoters (approximately 839) where MyoD 
binding occurred were also enriched for AP-1 sites (data provided by S.J. Tapscott, 
based on paper by Cao et al (Cao et al., 2010).  Of the MyoD bound genes, 43% did not 
change in expression while 4% did have changes in expression during differentiation 
(figure 1A).  A total of 35 genes that were enriched for AP-1 binding sites had changes 
in expression (figure 1B).  Of the 35 genes 14 had increased expression and 21 had 
decreased expression during differentiation relative to proliferation (figure 1C).  Further 
analysis was done and it was determined that 3 of the 35 genes contained AP-1 binding 
sites that were less than 2.0 kb from the transcriptional start, thus in the regulatory 
regions (figure 1C).  These genes were mustn1, F2r, and Tpbg (figure 1C).  Although, 
these genes have MyoD regulatory sites and AP-1 binding regions, only the mustn1 
genes was expressed in adult skeletal muscle (Lombardo et al., 2004) and has been 
reported to be required for MT fusion (Liu et al., 2010).  The MyoD binding region is 
on the mustn1 promoter shown in figure 1D.  These data suggest that AP-1 may 
regulate a subset of MyoD target genes and could participate in an antagonistic role in 
their expression.     
 
 
 
13 19 3 
mustn1 
F2r 
Tpbg 
< 2.0 Kb  
from  
TSS 
Pattern Gene Distance to TSS 
Array fold 
change 
TGACTCA Plf -25708 -5.594 
TGACTCA Dermo1 15286 -2.452 
TGACTCA Arl7 62629 -2.232 
TGACTCA Pdk4 66621 -2.022 
TGACTCA Pdk4 66621 -2.022 
TGACTCA Id1 -9370 -1.844 
TGACTCA Tsp2 34215 -1.659 
TGACTCA Osbp2 -7684 -1.651 
TGACTCA Aqp1 -15318 -1.428 
TGACTCA Tpbg -284 -1.426 
TGACTCA Abcc4 24946 -1.413 
TGACTCA Chc1 4005 -1.399 
TGACTCA Tuba6 985 -1.338 
TGACTCA Htra1 25259 -1.298 
TGACTCA Igfbp2 -40976 -1.275 
TGACTCA F2r -164 -1.206 
TGACTCA Cis3 36790 -1.182 
TGACTCA Q9CZZ8 -9789 -1.172 
TGACTCA Vps37b -20156 -1.125 
TGACTCA Ica1 -2318 -1.049 
TGACTCA Rbpms2 6483 -1.04 
TGACTCA Il33 -7575 1.044 
TGACTCA Il33 -7575 1.044 
TGACTCA Insig1 -34103 1.15 
TGACTCA Q3UR46 19367 1.453 
TGACTCA Il12a -6835 1.478 
TGACTCA Vdu2 -2632 1.508 
TGACTCA Mustn1 -1522 1.573 
TGACTCA Kremen -3836 1.596 
TGACTCA Baiap2l1 -14230 1.642 
TGACTCA Baiap2l1 73317 1.642 
TGACTCA Klhl30 1429 1.736 
TGACTCA Nrap 22081 1.744 
TGACTCA Mmp15 33907 2.518 
TGACTCA Dcn 34243 3.526 
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Figure 1.  MyoD ChIP data analysis of potential AP-1 target genes. 
(A) Pie chart showing that 4% of genes that had changes in expression 
contained MyoD and AP-1 binding sites, while 43% of genes did not.  These 
was no expression date for 53% of these genes.  (B)  List of genes and fold 
change in expression from proliferation to differentiation that contain MyoD 
and AP-1 binding sites.  (C) Venn diagram showing 3 of the 35 genes with 
changes in expression had MyoD and AP-1 binding sites in regulator regions in 
their promoters. 
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Figure 1.  MyoD ChIP data analysis of potential AP-1 target genes. 
(D) Screen shot from genome browser showing location of MyoD binding in 
the mustn1 promoter. 209 
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Mustn1 is expressed in skeletal muscle and satellite cells 
To determine if mustn1 was expressed in the C2C12 cell line, a model for 
skeletal muscle differentiation we assessed its gene expression using RT-PCR.  The 
mustn1 transcript was detected in both proliferation (using GM) and differentiation 
(using DM) conditions (figure 2A).  Interestingly, levels of mustn1 seemed higher in 
differentiation conditions compared to proliferative conditions (figure 2A).  Since RT-
PCR is semi-quantitative, qRT-PCR was employed to determine if there were changes 
in levels of mustn1 from proliferative to differentiation.  Figure 2B shows that mustn1 
expression was 8-fold greater in differentiation verses proliferative.  These results 
demonstrate that mustn1 is expressed in C2C12 cells and that expression is higher 
under differentiating conditions. 
However, recent expression data demonstrates that AP-1 is differentially 
expressed in a culture of differentiated C2C12 cells.  A differentiated culture contains 
terminally differentiated MT and quiescent mononucleated cells and AP-1 proteins are 
exclusively expressed in mononucleated cells (Alli et al., 2013).  Furthermore, Fra-2 
expression was detected in satellite cells of primary single muscle fibres, not in the 
myocyte (Alli et al., 2013).   
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Figure 2. mustn1 expression is increased in differentiating skeletal muscle.   
(A) RNA was isolated from C2C12 cells and RT-PCR of mustn1 expression in 
growth (growth media; GM) and  differentiation (differentiation media; DM) 
condition was performed. Gapdh was used as an internal control.  The first 
panel is a 60 sec exposure of the agarose gel to ultra violet light and the second 
panel is a 15 exposure (B) RNA was isolated from C2C12 cells and qRT-PCR 
of mustn1 expression in growth and differentiation condition was preformed.  
GM and DM samples were analyzed in triplicate and are relative to gapdh 
expression. 
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 AP-1 and MyoD both bind to mustn1 
Studies using luciferase assays have demonstrated that AP-1 transcription 
factors can regulate an exogenously expressed mustn1 promoter (Liu and Hadjiargyrou, 
2006).  The mustn1 promoter has multiple AP-1 sites but by using the mustn1 promoter 
fused to luciferase the regulated site was determined (Liu and Hadjiargyrou, 2006).  A 
Fra-2 ChIP was performed to further investigate AP-1 binding to the mustn1 promoter. 
Using ChIP we observed direct binding Fra-2 to endogenous mustn1 promoter in 
skeletal muscle (figure 3).  Altogether, these preliminary, novel data implicate mustn1 
as a Fra-2 target gene in differentiating skeletal muscle and regeneration. 
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Figure 3. Fra-2 binds to the endogenous mustn1 promoter in skeletal 
muscle. 
Chromatin was isolated and sheared from C2C12 cells, 72h in differentiation 
conditions.  Chromatin was immunoprecipitated using a Fra-2 antibody or 
rabbit IgG contol.  qPCR was performed on the isolated DNA fragments using 
mustn1 specific primers flanking the AP-1 site.  Samples immunoprecipitated 
with IgG or Fra-2 were analyzed in triplicate.  Fold change was calculated 
relative to input samples. 213 
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Appendix B:  Methods 
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Appendix B:  Methods 
 
Cell Culture 
 
Reagents:  
 
DMEM (supplemented with 1% Penicillin-Streptomycin (Gibco) and 1% L-glutamine 
(Gibco) added as required) 
 
1X Dulbecco's PBS  
 
Versene (VE) (0.2g of EDTA in 1L 1X PBS),  
 
0.125% trypsin in VE (Gibco) 
 
Freezing medium ((Growth media (GM) supplemented with 10% DMSO); sterilize the 
freezing medium by passing through a 0.2um filter), FBS (heat inactivated at 56°C for 
30 min), HS (heat inactivated at 56°C for 30 min). 
 
1% gelatin for coating plates 
 
 
Cell passaging 
 
1. Aspirate media. 
2. Rinse cells with 5 ml of VE.  
3. Remove VE and add 1 ml of 0.125% trypsin solution. 
4. Pipette the trypsin solution. 
5. Using a light microscope check if cells are detaching 
6. Add 10 ml of GM and resuspend cells  
7. Plate cells accordingly. 
 
 
Inducing Muscle Cell Differentiation 
 
1. At  approximately 80% confluence, wash cells twice with 1X PBS 
2. Add 10 ml of DM. 
3. Change media to new DM every 48h 
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Transfection 
 
Calcium chloride mediated transfection of mammalian cells 
 
Reagents:  
 
2x HEBS (2.8 M NaCl, 15mM Na2HPO4, 50mM HEPESpH to 7.15, filter sterilize)   
2.5 M CaCl2 (filter sterilize) 
 
Calcium-phosphate transfection 
 
1. Plate cells one day before transfection for 30-50% confluent (1.0 x 105 cells/ml 
for 100 mm plates and 12.5 x 103 cells/ml for 6 well plates). 
2. Change to fresh GM 3 h prior to transfecting. 
3. Add 500μl of 2X HEBS to a 10ml conical tube. 
4. Prepare DNA-CaCl2 solution as follows, add 25μg DNA and bring up to a final 
volume of 450μl with ddH2O. Mix. 
5. Add 50μl of 2.5 M CaCl2. Mix. 
6. Add DNA-CaCl2 solution drop-wise to the 2X HEBS while gently vortexing 
7. Add DNA mix drop-wise to plates while moving palate back and forth to mix. 
8. Incubate cells with transfection mixture for 16h. 
9. Wash cells twice with 1X PBS 
10.  Add 10ml of fresh GM. 
11. Recover for at least 6-8h 
 
 
Lipofectamine transfection for C2C12 cells 
 
See manufactures protocol for details 
 
1. Prepare DNA-lipofectamine mixture.   
2. Add a total of 5μg of DNA to 1 ml of DMEM (no antibiotic and serum for 
lipofectamine – Invirotgen) and 35 μl of Lipofectamine reagent to 1ml of 
DMEM for 100mm plates.  Use a total of 1μg of DNA and 7μl of 
lipofectamine/well for 6 well plates.  Incubate for 5 min at RT 
3. Add DNA mixture to lipofectamine mixture and incubate for 20-40 min at RT 
4. During incubation wash cells twice with 1X PBS and add 4 ml of DMEM to 
plate 
5. Add 2 ml of DMEM to DNA-lipefectamine mixture for a total of 4 ml and mix 
6. Add DNA-lipofectamine mixture (4ml) drop wise to plate  
7. Incubate cells with DNA-lipofectamine mixture for 5 h 
8. Add 2 ml of FBS to plates to stop transfection or wash plates twice with 1X 
PBS and add 10 ml of 20% FBS in DMEM to plate 
9. Recover O/N and harvest at desired time point. 
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Luciferase Assay 
 
Reagents: Luciferase assay Lysis buffer (20 mM Tris, pH 7.4, 0.1% Triton-X 100), 
Luciferase substrate (Promega), Renilla substrate (Promega) 
 
1. Following transfection protocol and harvest using the following. 
2. Wash adherent cells twice with 1XPBS (4°C). 
3. Add 300μl of Luciferase lysis buffer per well (35mm) 
4. Scrape cells in each well and collect in 1.5ml eppendorph tubes 
5. Vortex cells in tube and spin 16.1 X 1000 G for 10min. 
6. Transfer 20μl – 100μl of supernatant to Luciferase assay tube. 
7. Read sample using a luminomitor that injects luciferase substrate 
8. If using Renilla as an internal control.  Add supernatant to another assay tube 
and using Renilla substrate read samples using liminomintor. 
 
 
β-Galactosidase Assay 
 
Reagents: ONPG (4 mg/ml in ddH2O), Z buffer (60 mM Na2HPO4,  40mM NaH2PO4, 
10mM KCl, 1mM MgSO4), 1 M Na2CO3 
 
1. Prepare reaction mixture.  For one sample add 500µl Z buffer, 100µl ONPG, 
2.74µl β- mercaptoethanol (one extra for control). 
2. Add 600μl of β-gal reaction mixture to a clean 1.5ml eppendorph tube 
3. Add 10μl-30μl of supernatant from samples 
4. Incubate at 37°C (incubator or water bath) until light yellow colour develops 
5. Add 400µl of 1M Na2CO3 to each tube to stop reaction. 
6. Measure absorbance of samples at 420nm. 
 
Reconstitute CT-1 
Prepare 25 ml of 4 mM HCl, 0.1 % BSA to resuspend CT-1 
 
1. In a 50 ml falcon tube dissolve 0.025 g of BSA in 24.13 ml of ddH2O, add 847 
µl of 118 mM HCl.  Mix solution and filter (0.22 µm pore size) into a new 50 
ml falcon tube under sterile conditions. 
2. Cool the 4 mM HCl, 0.1% BSA solution (solvent) on ice along with twenty-1.5 
ml eppendorph tubes (ten tubes for the solvent and ten for reconstituted CT-1) 
for 30 min. 
3. Add 500 µl of the 4mM, 0.1 % BSA solution to 10 µg of CT-1 (R&D systems, 
Cat# 438-CT) to obtain a concentration of 20 ng/µl and keep on ice.  Allow CT-
1 to be completely resuspended in the solvent.                                                                                                                        
4. Aliquot 50 µl of resuspended CT-1 (20 ng/µl) into ten-1.5 ml eppendorph tubes 
and 50 µl of solvent into the other ten tubes. Store at -80°C for approximately 3 
months or at 4°C for 1 month. 
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ChIP assay and qRT-PCR 
Adaption of EZ ChIP protocol, (Andy Sharocks Lab, modified by Catherine Chan, 
modified by Stephanie Wales). 
 
Day 1 
 
 Preparation of cross-linked cells, isolation of nuclei, chromatin preparation 
 
1. Wash plate once with 1X PBS (4°C) 
2. Add 10 ml of 1X PBS (4°C) followed by 270 μl of 37% formaldehyde (final 
1%) 
3. Incubate for 15 min at RT 
4. Add 1.25 M glycine (10X stock of glycine) drop wise to plate (final 
concentration of 0.125 M) 
5. Place dishes on ice and remove liquid 
6. Wash three times with 1X PBS (4°C), aspirate last wash to remove 1X PBS 
(4°C) 
7. Scrape cells in 1 ml of 1X PBS + inhibitors (4°C) 
8. Pellet cells by centrifugation for 5 min at 5000 rpm at 4°C 
9. Remove supernatants and resuspend cells with 1 ml of Wash buffer I (10mM 
HEPES pH 6.5, 0.5 mM EGTA, 10mM EDTA, 0.25% Triton X-100, protease 
and phosphatase inhibitors) 
10. Incubate on ice for 5 min 
11. Centrifuge for 5 min at 3000 rpm at 4°C 
12. Remove supernatant and resuspend nuclei in 1 ml of Wash buffer 2 (10mM, 
HEPES pH 6.5, 0.5mM EGTA, 1mM EDTA, 200mM NaCl, protease and 
phosphatase inhibitors) 
13. Incubate for 10 min on ice 
14. Centrifuge at 5000 rpm for 5 min at 4° 
15. Remove supernatant.  Continue to day 2 or nuclei can be frozen at -80°C 
Day 2 
 
A. Nuclear lysis 
 
1. Add 250 μl of SDS lysis buffer (50mM Tris-HCl ph 8.1, 1mM EDTA, 1% SDS, 
protease and phosphatase inhibitors, prepare fresh) to nuclei 
2. Sonicate DNA to approximately 250-600 bp fragments 
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3. Centrifuge samples at max speed for 15 min at 4°C to remove insoluble 
materials 
4. Transfer supernatant to clean tube 
a. 200 μl aliquot for IP 
b. Each 400 μl aliquot should have 1 x 106 cells 
c. 2 x 20 μl aliquots for gel and input samples 
 
B. Pre-Block Protein G Beads 
 
1. Incubate 15 μl of protein G dynal beads with 20 μg of salmon sperm DNA for 
each IP in IP dilution buffer 
2. 15 μl of beads + 135 μl IP dilution buffer + 20 μg (2 μl of 10 mg/ml) salmon 
sperm per IP 
3. Make 1 extra IP 
 
C. Lysate-antibody incubation 
 
1. Once the DNA concentration is known, 25μg per IP is recommended 
2. Dilute sample 1:10 with IP dilution buffer (0.01% SDS, 1.1% Triton-X 100, 
1.2mM EDTA, 16.7mM Tris-HCl pH 8.1, 167mM NaCl) to 2ml  
3. Add 1-2μg of Antibody.  Use equivalent amount of IgG control. 
4. Rotate at 4°C overnight. 
Day 3 
 
Incubation with Dynalbeads and recovering bound DNA 
 
1. Add 152μl of pre-blocked beads to each IP reaction.  Rotate at 4°C for 1h 
2. Using magnet, remove supernatant 
3. Wash beads with 1ml of cold IP low salt immune complex wash buffer I 
(20mM Tris pH 8.1, 2mM EDTA, 150mM NaCl, 1% Triton-X 100, 0.1% SDS) 
4. Rotate at 4°C for 5-10min 
5. Using magnet, remove supernatant  
6. Wash beads with 1ml of cold IP high salt immune complex wash buffer 2 
(20mM Tris pH 8.1, 2mM EDTA, 500mM NaCl, 1% Triton-X 100, 0.1% SDS) 
7. Rotate at 4°C for 5-10min 
8. Using magnet, remove supernatant 
9. Elute Protein-DNA complex by adding 300μl of freshly made elution buffer 
(0.1M NaCO3, 1% SDS) 
10. Incubate for 30min at room temperature 
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11. Using a magnet, collect the supernatant in a clean tube 
12. To the recovered IP complexes, add 12μl of 5M NaCl 
13. Incubate at 65°C overnight 
Day 4 
  
DNA purification 
 
1. Use the qiagen PCR clean up kit, as per manufactures directions 
2. The purified DNA can be analyzed or stored at -20°C 
 
Protein Extracts 
 
Reagents: 1XPBS (4°C), Lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM 
Sodium vanadate, 1 mM PMSF, protease inhibitor cocktail,  Sigma-Aldrich, P-8340), 
2X SDS sample buffer (BioRad) (supplemented with β-mercaptoethanol) 
1. Pour off media from plates 
2. Wash cells 2X with 1X PBS (4°C). 
3. Add 700μl of 1X PBS (4°C) and scrape cells in plate. 
4. Transfer cell suspension into a 1.5ml eppendorph tube 
5. Centrifuge at 1.5 X 1000 G for 5 min at 4°C. 
6. Aspirate PBS, and resuspend the pellet with five times (vol/vol) the volume of 
lysis buffer. 
7. Vortex cells briefly, and place on ice, repeat every 5 min for 15 min. 
8. Centrifuge cell lysate at 16.1 X 1000 G for 15 min at 4°C, and transfer 
supernatant to clean 1.5 ml eppendorph tube. 
9. Determine protein concentration by Bradford assay. 
 
Harvesting cells 
 
1. Remove cells from the 37°C incubator and place on ice. 
2. Pour off media and wash plates with 10 ml of ice-cold 1x PBS. 
3. Add 200- 300 µl of cold 1x PBS each plate and scrape cells from the plates 
using a rubber scraper.  Collect cells (suspended in 1x PBS) into 1.5 ml 
eppendorph tubes.   
4. Spin cells at 4°C at a force of 1500 G for 5 min to pellet the cells.  Aspirate the 
supernatant.   
5. Lyse cells using NP-40 lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% NP-40), 
containing 0.1 M phenlymethylsulfonyl fluoride (PMSF), phosphatase inhibitor 
cocktail 1 (Sigma, Cat# P 2850) and protease inhibitor cocktail (Sigma, Cat# P 
8340) at 1/100 of the total volume.  
6. Add NP-40 lysis buffer including inhibitors to each tube at a volume 5x that of 
the pelleted cells. 
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7. Vortex cells and place on ice.  Repeated three times (once every 5 min for 15 
min). 
8. Spin lysed cell debris at 4°C at a force of 16 100 G for 15 min.  Collect the 
supernatant into a new 1.5 ml eppendorph tube and stored at -80°C. 
 
 
Bradford Assay 
After collecting the cell lysate, the protein concentration can be determined by the 
Bradford Assay. 
 
1. Thaw bovine serum album (BSA, 1µg/µl) and protein samples on ice. 
2. Label 1.5 ml eppendorph tubes 0, 1, 2, 4, 6, 8 µg/µl for increasing 
concentrations of BSA and with appropriate sample name. 
3. Add 800 µl of ddH20 to the 1.5 ml eppendorph tubes. 
4. Add the appropriate volume of BSA for the above concentrations to the proper 
tube and add 2 µl of cell lysate for each sample to the ddH20 followed by 200 µl 
of Bradford reagent (BioRad).   
5. Invert tubes to mix the contents and incubate for 5 min at room temperature. 
6. Determine optical density (OD) at 595nm for each sample using a 
spectrophotometer. 
7. Generate a standard curve, to determine the sample concentrations. 
8. Determine the appropriate volume for 15-20 µg of protein and the correct 
volumes of 4x sample buffer NP-40 lysis buffer. 
 
MF-20 staining for α-MHC 
Fixing the Cells 
 
1. Aspirate the media from a 35 mm – 6 well plate.   
2. Wash cells three times using 3 ml of 1x PBS at room temperature.   
3. Incubate cells with 2 ml of ice-cold 90% methanol in ddH2O for 6 min at -20°C.   
4. Wash cells three times with 3 ml of 1x PBS at room temperature and store at 
4°C in 3 ml of 1x PBS.   
Primary and Secondary Antibody Incubation 
 
5. Aspirate the 1x PBS from the wells and blocked cells in 2 ml of 5% non-fat 
skim milk in 1x PBS for 5 min on the shaker at room temperature followed by 
30 min at 37°C.   
6. Incubate cells with 1 ml of MF-20 primary antibody diluted 1:20, in 5% non-fat 
skim milk for 2 h on the shaker at room temperature.   
7. Wash cells three times (once every 5 min for 15 min) with 3 ml of 1x PBS with 
gentle shaking.   
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8. Incubate cells with the secondary antibody, goat-anti-mouse IgG (H+L)-HRP 
conjugate (BioRad), diluted 1:1000 in 5% non-fat skim milk in 1x PBS for 1 hr 
on the shaker at room temperature.   
9. Wash cells three times (once every 5 min for 15 min) with 3 ml of 1x PBS.   
 
Preparation of diaminobenzidine (DAB) and staining MHC 
 
10. Prepare 6 mg of DAB in 10 ml of 1x PBS.  Add 30% hydrogen peroxide at 
1/1000 of the total volume. 
11. Incubate cells with the DAB containing solution for 30 min at room temperature 
with gentle shaking. 
12. Wash cells three times (once every 5 min for 15 min) with 3 ml of 1x PBS, and 
twice (once every 5 min for 10 min) with 3 ml of distilled water. 
 
Counter-staining Nuclei 
 
13. Add 1 ml of haematoxylin to each well for 2 min. 
14. Wash cells three times (once every 5 min for 15 min) with 3 ml of distilled 
water. 
15. Store cells in 3 ml of distilled water at 4°C. 
 
 
Nuclear and Cytoplasmic Protein Extracts (NE-PER kit, Pierce) 
 
 
1. As per manufactures instructions 
2. Scrape cells and pellet by centrifugation at 1 500XG for 5 min at 4 °C. 
3. Remove supernatant and add 200 µl of ice-cold CER I to the cell pellet. 
4. Vortex the tube for 15 sec and then incubate tube on ice for 10 min. 
5. Add 11 µl of ice-cold CER II to the tube. 
6. Vortex the tube for 5 sec on the highest setting and then incubate tube on ice for 
1 min. 
7. Vortex the tube for 5 more sec and then centrifuge at 13 000xg for 5 min at 4°C. 
8. Immediately transfer the supernatant (cytoplasmic extract) fraction to a clean 
pre-chilled tube. Place this tube on ice until use or storage. 
9. Re-suspend the insoluble pellet fraction from step 7 in 100 µl of ice-cold NER. 
10. Vortex on the highest setting for 15 sec every 10 min for 40 min. 
11. Centrifuge the tube at 13 000XG for 10 min at 4 °C and then transfer 
supernatant to new tube. 
12. Determine protein concentration by Bradford assay and analyze samples by 
Western analysis. 
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SDS-PAGE 
 
Reagents: 1.5M Tris pH 8.8, 30% acrylamide mix, 10% SDS, 10% APS, TEMED, 1X 
Laemmli buffer. 
1. Prepare resolving gel mixture and pour into gel caster 
2. After polymerization pour stacking gel and insert combs 
3. Fill bottom and centre well of mini-gel apparatus with 1X Laemmli buffer. 
4. Load samples on a gel. 
5. Run a gel at 100-150 V. 
 
Western blotting 
 
1. Transfer protein from a gel to Immobilon-P (Millipore) membrane by wet 
transfer at 20 V for 16 hrs or 100 V for 1h (use ice pack). 
2. Block membrane with 5 % (w/v) milk in 1X PBS/TBS-T (blocking solution). 
3. Incubate membrane with primary antibody diluted in blocking solution for 16 
hrs at 4 °C with rocking. 
4. Wash membrane with 1X PBS/TBST (3 X 5min each) with rocking. 
5. Incubate membrane with secondary antibody in blocking solution for 1-2 hrs at 
room temperature (RT) with rocking. 
6. Wash membrane with PBS/TBST (3 X 5 min each) with rocking. 
7. Mix chemiluminescence reagents and add to memebrane 
8. Incubate for 1min and expose blot to film. 
9. Develop (manually or using an automated developer) 
 
Immunoprecipitation 
 
1. Prepare cell lysates as described in protein extracts section. 
2. Dilute protein sample in lysis buffer. 
3. Incubate 40μl of ImmunoCruz beads with 1-5μg of primary antibody O/N at 
4°C with rocking. 
4. Spin antibody-matrix complex at max speed for 30sec at 4°C. 
5. Remove supernatant 
6. Add 1ml of 1X PBS (4°C) 
7. Repeat twice more 
8. Add 1ml of cell lysate (250-1000µg total protein, make up volume with lysis 
buffer and inhibitors) to antibody-matrix complex and incubate O/N at 4°C. 
9. Pellet immuno-complex by centrifugation at 1000XG for 30 sec 
10. Remove supernatant. 
11. Wash pellet with 1ml of 1X PBS (4°). 
12. Repeat steps 5 and 6 twice more. 
13. Re-suspend pellet in 40 µl of 2X SDS sample buffer and boil for 3 min, 
14. Load supernatant onto gel (do not transfer beads) 
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CIP treatment 
 
1. Follow IP protocol until washing 
2. Wash with 1X CIP buffer and incubate at  
3. Add 1X CIP buffer to tube or 4μl CIP 
4. Incubate at 37°C for 30min 
5. Wash with 1X CIP buffer 
6. Add 4X SDS loading dye 
7. Boil at 95°C for 3 min 
8. Load sample on SDS-PAGE gel 
9. Proceed with Western blotting 
 
 
In vitro kinase assay 
 
Kinase Assay:  Phosphorylation of GST-Fra-2 by p42 MAP Kinase (ERK2) 
p42 MAP kinase (ERK2) (NEB, Cat# P6080S) 100U/µl 
p42 MAP kinase reaction buffer (10X) (50mM Tris-HCl, 10mM MgCl2, 2mM DDT, 
1mM EGTA, 0.01% Brij 35 (non-ionic detergent). pH 7.5 @ 25˚C) 
ATP (10mM) 
[γ32-P]ATP 
Myelin Basic Protein (0.5mg/ml) – positive control 
pGEX-4T1 (2T) (GST) – negative control 
pGEX-4T1-Fra-2 (GST-Fra-2) 
 
1. Dilute 10x kinase reaction buffer to 1x 
2. Supplement 1x kinase reaction buffer with 200µM ATP and [γ-32P]ATP to a 
final specific activity of 100-500 µCi/µmol 
3. Add 2µl (20ng) of purified activated p42 MAP kinase to 8µg of protein 
4. Add 10µl of ATP to rxn mixture and mix 
5. Incubate reaction mixture for 30 min at 30˚C (water bath) 
6. Add 2x sample buffer and boil for 5 min 
7. Resolve on a 10% SDS-PAGE gel 
8. Coomassie stain gel, take pic 
9. Dry gel, expose and develop 
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Immunohistochemistry  
 
Reagents: Fixative (90% ice-cold methanol), Blocking reagent (5 % skim-milk 
in 1XPBS). 
1. Wash cells and fix and permeabilize with 90 % methanol for 10 min at -20°C. 
2. Block with 5 % skim-milk in 1XPBS at 37 °C for 30 min. 
3. Incubate cells with primary antibody for 1 hr in 5 % skim-milk. 
4. Incubate cells with Horseradish peroxidase (HRP)-conjugated secondary 
antibody, 1 hr in 5 % skim-milk 1XPBS. 
5. Wash cells three times with 1XPBS and incubated in developer (0.6 mg/ml 
DAB, 0.1 % H2O2 in 1XPBS).  
6. Counter-stain nuclei with haematoxylin.  
7. Wash several times in ddH20. 
8. Mounting cells with mounting media and cover-slip. 
 
 
RNA Isolation 
As per Qiagen RNeasy kit.  See manufactures protocol. 
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Primary single fibre isolation 
 
Stock solutions for fibre culture and staining 
 
Collagenase I solution (make fresh), heat to 37°C 
 
0.02g collagenase I (sigma)/10ml DMEM+ 
2ml per mice (2 muscles) 
 
Fibre isolation media (use at 37°C, keep warm) 
 
DMEM + 
20% FBS 
 
Fibre growth media 
 
DMEM+ 
20% FBS 
1% Chick embryo extract (CEE) 
 
Fibre Differentiation media 
 
DMEM+ 
10% HS 
 
 
Solutions for Fibre Staining 
 
Fixation solution 
 
2% PFA in 1X PBS 
 
Blocking buffer 
 
1X PBS 
5% HS or Goat serum 
1% BSA 
0.5% Triton X-100 
0.01% NaAzide 
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Primary EDL fibre isolation protocol 
 
1. Sacrifice 6-8 week old male mice (resting or injured) 
2. Remove skin from hind limbs 
3. Remove the fascia around the hind limb muscle 
a. cut skin around ankle and cut skin up to knee on the inside and peel up 
4. Identify the tendons attaching the TA and EDL to the ankle  
5. Cut the tendon from the TA muscle and lift the TA away from the EDL with 
tweezers 
6. Cut the TA proximally near the knee parallel to the EDL to find the other 
tendon attaching the EDL to the knee joint 
7. Cut this tendon to separate the EDL away from the knee 
8.  Cut the tendon attaching the EDL to the ankle and lift the EDL out of the leg 
9.  Place the EDL in collagenase I solution and incubate at 37°C for 1h with 
shaking (until fibres become loose) 
a. Use a 15ml tube 
10. Using flamed-polished wide bore glass pipettes, titurate the muscle until the 
fibres come loose from the tendon 
11.  Remove the tendons physically with a narrow opening glass pipette 
a. Place in 1 well of a 12 well plate (coated with HS) 
b. Remove chunks of fibres 
12. Wash 3 times with warm fibre isolation media (fill the well, wait for fibres to 
settle, then aspirate the supernatant with the narrow pipette) 
a. Let fibres settle then pipette from the surface 
13.  Dispense isolated fibres into HS-coated culture dishes (12-24 well plates) 
a. 20-30 fibres per well 
14. Incubate at 37°C  in plates for 20-30min to screen kinks 
15. Culture for 42h to observe first division 
 72h to observe transition into myocytes (Myogenin activation) 
 4-5 days for differentiation  
 
 
Staining fibres 
 
1. Remove GM and add 1X PBX then Fix in 2% PFA (pre-warmed at 37°C) 
a. Can store in 1X PBS at 4°C 
b. Can transfer fibres into clean HS coated plate (can be uncoated) 
2. Block using blocking buffer O/N at 4°C or 45min – 1h at RT, with shaking 
3. Primary antibody incubation, dilute in blocking buffer, incubate 2h at RT or 
O/N at 4°C with shaking (300μl/well) 
a. Pax7 1:2 
b. Fra-2 1:500 
c. P-Fra-2 1:200 
d. C-Jun 1:500 
4. Wash with 1X PBS (1-3X) 
228 
 
5. Secondary antibody 1:1000, 1h at RT with shaking (300μl/well) 
6. Wash with 1X PBS (1-3X) 
7. Dapi, 1:50 000 in PBS for 8 min at RT 
8. Wash with 1X PBS (1-3X) 
9. Mount onto slides 
Mounting onto slides 
 
Use Superfrost Plus slides (fisher) microscope slides white 
Glass covers (22X50) 
 
Hydrophobic pen 
 
1. Mark border of pen with PAP 
2. Place all fibres on slide using a wide bore pipette 
3. Remove all liquid using a small bore pipette 
4. Add 2 drops of Permaflour (Thermo) 
5. Remove bubbles 
6. Spread out fibres with tweezers 
7. Remove excess mounting media 
8. Cover slip 
 
